US8999982B2 - Pharmaceutically active compounds as Axl inhibitors - Google Patents

Pharmaceutically active compounds as Axl inhibitors Download PDF

Info

Publication number
US8999982B2
US8999982B2 US13/819,560 US201113819560A US8999982B2 US 8999982 B2 US8999982 B2 US 8999982B2 US 201113819560 A US201113819560 A US 201113819560A US 8999982 B2 US8999982 B2 US 8999982B2
Authority
US
United States
Prior art keywords
oxy
phenyl
carboxamide
fluoro
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US13/819,560
Other versions
US20140018365A1 (en
Inventor
Carsten Schultz-Fademrecht
Bert Klebl
Axel Choidas
Uwe Koch
Jan Eickhoff
Alexander Wolf
Axel Ullrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Lead Discovery Center GmbH
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Lead Discovery Center GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV, Lead Discovery Center GmbH filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority to US13/819,560 priority Critical patent/US8999982B2/en
Assigned to MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V., LEAD DISCOVERY CENTER GMBH reassignment MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHOIDAS, AXEL, EICKHOFF, JAN, KLEBL, BERT, KOCH, UWE, SCHULTZ-FADEMRECHT, CARSTEN, ULLRICH, AXEL, WOLF, ALEXANDER
Publication of US20140018365A1 publication Critical patent/US20140018365A1/en
Application granted granted Critical
Publication of US8999982B2 publication Critical patent/US8999982B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to novel compounds which are inhibitors of Axl receptor tyrosine kinase subfamily which comprises Axl, Mer and Tyro3. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the Axl family.
  • the compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.
  • Receptor tyrosine kinases are cell surface receptors that transmit signals from the extracellular environment to control growth, differentiation and survival of cells. Deregulated expression of protein kinases by gene deletion, -mutation or amplification has been found to be important for tumor initiation and progression, involving cancer cell proliferation, -survival, -motility and -invasivity as well tumor angiogenesis and chemotherapy resistance. Because of the advanced understanding of their critical role, protein kinases are important targets for novel therapies, especially for cancer (Hananhan et al., 2000; Blume-Jensen et al., 2001).
  • Axl is a member of the TAM (Tyro-Axl-Mer) receptor tyrosine kinases. This family is characterised by an extracellular domain, consisting of two immunoglobulin-like domains followed by two fibronectin type 3-like domains.
  • the activation of the Axl RTK subfamily occurs by its cognate protein ligand, growth arrest specific 6 (Gas6).
  • the affinity of Gas6 is highest for Axl, followed by Tyro3, and finally Mer, and thereby activates the three proteins to varying degrees.
  • Gas6 is a member of the vitamin K-dependent family and shows a 43% sequence identity to and the same domain organisation as the protein S, a serum protein (Hafizi et al., 2006).
  • Axl is ubiquitously expressed at low levels and is detectable in a variety of organs. Expression patterns of the other two family members differ from that of Axl. Expression of Tyro3 is predominantly in the brain and CNS (central nervous system), while expression of Mer is almost exclusively in the monocyte cell lineage (Rescigno et al. 1991, Mark et al., 1994, Graham et al., 1994).
  • TAM family RTKs regulate a diverse range of cellular responses, including cell survival, proliferation, migration and adhesion (Hafizi et al., 2006).
  • TAM receptor signalling has been shown to regulate vascular smooth muscle homeostasis (Korshunov et al., 2007), platelet function, thrombus stabilization (Angelillo-Scherrer et al., 2001; Gould et al., 2005), and erythropoiesis (Angelillo-Scherrer et al., 2008).
  • TAM receptors are implicated in the control of oligodendrocyte cell survival (Shankar et al., 2006) and the regulation of osteoclast function (Katagiri et al., 2001).
  • the TAM receptors play pivotal roles in innate immunity (Lemke et al., 2008) and in inflammation (Sharif et al., 2006; Rothlin et al., 2007).
  • the TAM family promotes the phagocytosis of apoptotic cells (Prasas et al., 2006) and stimulates the differentiation of natural killer cells (Park et al., 2009; Caraux et al., 2006).
  • Axl activation is linked to several signal transduction pathways, including Akt, MAP kinases, NF- ⁇ B, STAT signal transduction pathways and others (Hafizi et al., 2006).
  • the compounds of the present invention are efficient inhibitors of TAM family RTKs and thus, are suitable for the treatment of disorders associated with, accompanied by and/or caused by TAM family RTKs hyperfunction, and thereby having an effect on cell survival, proliferation, autophagy, vascular smooth muscle homeostasis, migration, adhesion, angiogenesis, platelet aggregation, thrombus stabilization, erythropoiesis, oligodendrocyte cell survival, osteoclast function, innate immunity, inflammation, phagocytosis of apoptotic cells and/or natural killer cell differentiation.
  • the invention provides efficient inhibitors of Axl receptor tyrosine kinase which are suitable for the treatment of hyperproliferative disorders associated with, accompanied by and/or caused by Axl hyperfunction, particularly Axl receptor tyrosine kinase induced hyperproliferative disorders.
  • the compounds of the invention are capable of inhibiting cell proliferation and thus, are suitable for the treatment and/or prevention of Axl receptor tyrosine kinase induced hyperproliferative disorders, particularly selected from the group comprising cancer and primary tumor metastases.
  • the Axl receptor tyrosine kinase induced disorders are associated with Axl receptor tyrosine kinase receptor overexpression and/or hyperactivity, e.g. an increased degree of autophosphorylation compared to normal tissue.
  • the disorders may be selected from breast cancer, colon cancer, prostate cancer, lung cancer, gastric cancer, ovarian cancer, endometrial cancer, renal cancer, hepatocellular cancer, thyroid cancer, uterine cancer, esophagus cancer, squamous cell cancer, leukemia, osteosarcoma, melanoma, glioblastoma and neuroblastoma.
  • the disorders are selected from breast cancer, glioblastoma, renal cancer, non-small cell lung cancer (NSCLC), and melanoma.
  • NSCLC non-small cell lung cancer
  • the compounds are also suitable for the prevention and/or treatment of other hyperproliferative disorders, particulary benign hyperproliferative disorders such as benign prostate hyperplasia.
  • disorders associated with, accompanied by and/or caused by Axl hyperfunction are acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, aids-related cancers, aids-related lymphoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, osteosarcoma and malignant fibrous histiocytoma, brain stem glioma, brain tumor, central nervous system atypical teratoid/rhabdoid tumor, astrocytomas, craniopharyngioma, ependymoblastoma, ependymoma, medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate differentiation, supratentorial primitive neuroectodermal tumors and pineoblastoma, brain and spinal cord tumors
  • the preferred Axl receptor tyrosine kinase induced disorders are selected from adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, desmoid tumor, bladder cancer, bronchial carcinoma, breast cancer, Burkitt's lymphoma, corpus cancer, CUP-syndrome (carcinoma of unknown primary origin), colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors, gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, cervix, glioblastomas, gynecologic tumors, ear tumors, nose tumors and throat tumors, hematologic ne
  • the compounds of the present invention are efficient inhibitors of TAM family RTKs.
  • the inventive compounds are suitable for the use as a pharmaceutically active agent.
  • the inventive compounds are suitable for the treatment of disorders associated with, accompanied by and/or caused by TAM family RTKs hyperfunction.
  • the inventive compounds are suitable for the treatment and/or prevention of Axl receptor tyrosine induced disorders.
  • inventive compounds are used in the manufacture of a medicament or of a pharmaceutical composition for the treatment of disorders associated with, accompanied by and/or caused by TAM family RTKs hyperfunction.
  • inventive compounds are further used in the manufacture of a medicament or of a pharmaceutical composition for the treatment and/or prevention of Axl receptor tyrosine induced disorders.
  • the Axl receptor tyrosine kinase induced disorders are disorders caused by, associated with and/or accomplied by Axl kinase hyperfunction.
  • the Axl receptor tyrosine kinase induced disorders are selected from a group comprising hyperproliferative disorders.
  • the Axl receptor tyrosine kinase induced disorders are selected from the group comprising cancer and primary tumor metastases.
  • R 73 -R 84 independently of each other represent —H, —OH, —F, —Cl, —Br, —I, —R 85 ;
  • R 12 and R 13 when R 12 and R 13 represent alkenylene groups, R 12 and R 13 may combine to form a condensed aromatic ring together with the atoms of residue D to which R 12 and R 13 are attached in order to form a bicyclic group with residue D;
  • R 21 and R 98 represent independently of each other —CR 22 R 23 R 24 , —CR 23 R 24 —CR 25 R 26 R 22 , —CR 23 R 23 R 24 —CR 25 R 26 —CR 27 R 28 R 22 , —CR 23 R 24 —CR 25 R 26 —CR 27 R 28 —CR 29 R 30 R 22 , —CR 23 R 24 —CR 25 R 26 —CR 27 R 28 —CR 29 R 30 —CR 31 R 32 R 22 , —CR 23 R 24 —CR 25 R 26 —CR 27 R 28 —CR 29 R 30 —CR 31 R 32 —CR 33 R 34 R 22 ;
  • R 22 -R 34 independently of each other represent —H, —F, —Cl, —Br, —I, —CH 3 , —CF 3 , —OCH 3 , —OCF 3 , —C 3 H 7 ;
  • R 35 and R 99 represent independently of each other —O—CR 22 R 23 R 24 , —O—CR 23 R 24 —CR 25 R 26 R 22 , —O—CR 23 R 24 —CR 25 R 26 —CR 27 R 28 R 22 , —O—R 23 R 24 —CR 25 R 26 —CR 27 R 28 —CR 29 R 30 R 22 , —O—CR 23 R 24 —CR 25 R 26 —CR 27 R 28 —CR 29 R 30 —CR 31 R 32 R 22 , —O—CR 23 R 24 —CR 25 R 26 —CR 27 R 28 —CR 29 R 30 —CR 31 R 32 —CR 33 R 34 R 22 ;
  • R 36 , R 72 , R 87 , R 96 , R 105 , R 120 , R 132 and R 136 represent independently of each other —CR 23 R 24 —XH, —X—CR 22 R 23 R 24 —X—CR 23 R 24 —CR 25 R 26 R 22 , —CR 23 R 24 —X—CR 25 R 26 R 22 , —CR 23 R 24 —CR 25 R 26 —XH, —X—CR 23 R 24 —CR 25 R 26 —CR 27 R 28 R 22 , —CR 23 R 24 —X—CR 25 R 26 —R 27 R 28 R 22 , —CR 23 R 24 —CR 25 R 26 —X—CR 27 R 28 R 22 , —CR 23 R 24 —CR 25 R 26 —X—CR 27 R 28 R 22 , —CR 23 R 24 —CR 25 R 26 —X—CR 27 R 28 R 22 , —CR 23 R 24 —CR 25 R 26 —CR 27 R 28 —X
  • X represents —O—, —CO—, —O—CO—
  • R 37 , R 38 , R 93 and R 101 represent independently of each other —CR 40 R 41 —YH, —Y—CR 39 R 40 R 41 , —Y—CR 40 R 41 —CR 42 R 43 R 39 , —CR 40 R 41 —Y—CR 42 R 43 R 39 , —CR 40 R 41 —CR 42 R 43 —YH, —Y—CR 40 R 41 —CR 42 R 43 —CR 44 R 45 R 39 , —CR 40 R 41 —Y—CR 42 R 43 —CR 44 R 45 R 39 , —CR 40 R 41 —Y—CR 42 R 43 —CR 44 R 45 R 39 , —CR 40 R 41 —CR 42 R 43 —Y—CR 44 R 45 R 39 , —CR 40 R 41 —CR 42 R 43 —CR 44 R 45 —YH, —Y—CR 40 R 41 —CR 42 R 43 —CR 44 R 45 —CR 46 R 47 R 39 , —CR 40 R 41 —Y—
  • R 39 —R 53 represent independently of each other —H, —CH 3 , —C 2 H 5 , —C 3 H 7 ;
  • Y represents —NR 52 —CO—, —CO—NR 13 —;
  • R 54 , R 55 and R 102 represent independently of each other
  • R 56 , R 57 , R 94 and R 103 represent independently of each other —CR 58 R 16 R 17 , —CR 58 R 59 R 60 —CR 16 R 17 —CR 61 R 62 R 58 , —CR 59 R 60 —CR 61 R 62 R 58 , —CR 59 R 60 —CR 16 R 17 R 58 , —CR 16 R 17 —CR 61 R 62 —CR 63 R 64 R 58 , —CR 59 R 60 —CR 61 R 62 —CR 63 R 64 R 58 , —CR 59 R 60 —CR 16 R 17 —CR 63 R 64 R 58 , —CR 59 R 60 —CR 16 R 17 —CR 63 R 64 R 58 , —CR 59 R 60 —CR 16 R 17 —CR 63 R 64 R 58 , —CR 59 R 60 —CR 16 R 17 —CR 63 R 64 R 58 , —
  • R 58 -R 70 represent independently of each other —H, —NH 2 , —OH, —F, —Cl, —Br, —I, —R 71 , —O—R 71 , —R 72 , —O—R 95 , —R 96 , —O—R 104 , —R 105 , —COOH, —COOCH 3 , —COOC 2 H 5 , —COOC 3 H 7 , —COOCH(CH 3 ) 2 , —COOC(CH 3 ) 3 , —(C ⁇ O)—NR 16 R 17 , —SO 2 —NR 16 R 17 , —SO m —R 16 R 17 , —CR 16 R 17 H, —NR 16 R 17 ;
  • R 108 , R 117 and R 129 represent independently of each other —CH ⁇ CH 2 , —CH 2 —CH ⁇ CH 2 , —H, —C(CH 3 ) ⁇ CH 2 , —CH ⁇ CH—CH 3 , —C 2 H 4 —CH ⁇ CH 2 , —CH 2 —CH ⁇ CH—CH 3 , —CH ⁇ CH—C 2 H 5 , —CH 2 —C(CH 3 ) ⁇ CH 2 , —CH(CH 3 )—CH ⁇ CH, —CH ⁇ C(CH 3 ) 2 , —C(CH 3 ) ⁇ CH—CH 3 , —CH ⁇ CH—CH ⁇ CH 2 , —C 3 H 6 —CH ⁇ CH 2 , —C 2 H 4 —CH ⁇ CH—CH 3 , —CH 2 —CH ⁇ CH—C 2 H 5 , —CH ⁇ CH—C 3 H 7 , —CH 2 —CH ⁇ CH—CH ⁇ CH 2 , —CH ⁇ CH—
  • R 109 , R 118 and R 130 represent independently of each other —H, —C ⁇ CH, —C ⁇ C—CH 3 , —CH 2 —C ⁇ CH, —C 2 H 4 —C ⁇ CH, —CH 2 —C ⁇ C—CH 3 , —C ⁇ C—C 2 H 5 , —C 3 H 6 —C ⁇ CH, —C 2 H 4 —C ⁇ C—CH 3 , —CH 2 —C ⁇ C—C 2 H 5 , —C ⁇ C—C 3 H 7 , —CH(CH 3 )—C ⁇ CH, CH(CH 3 )—C ⁇ CH, —CH(CH 3 )—CH 2 —C ⁇ CH, —CH(CH 3 )—C ⁇ C—CH 3 , —C 4 H 8 —C ⁇ CH, —C 3 H 6 —C ⁇ C—CH 3 , —C 2 H 4 —C ⁇ C—C 2 H 5 , —CH 2 —C ⁇ C—
  • R 113 , R 115 , R 121 , R 124 , R 126 , R 127 , R 133 , R 135 , R 137 and R 138 independently of each other represent
  • R 114 represents
  • prodrug is defined as a substance, which is applied in an inactive or significantly less active form. Once applied and incorporated, the prodrug is metabolized in the body in vivo into the active compound. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example in “Design of Prodrugs”, ed. H. B. Bundgaard, Elsevier, 1985.
  • the residue D contains at least one nitrogen atom.
  • Said residue may contain one oxygen atom or one sulfur atom in addition to said one nitrogen atom. If no oxygen and no sulfur atom is present, said residue may contain one, two or three additional nitrogen atoms so that said residue contains in total one, two, three or four nitrogen atoms.
  • the position of the nitrogen atom in residue D is essential to the activity of the compound. It is important that this nitrogen atom is in ⁇ position to the carbonyl group and that the ring D which is most preferably aromatic forms a conjugated system with the attached carbonyl group or that at least the ring nitrogen in ⁇ position together with the alpha carbon atom and the attached carbonyl group form a conjugated system.
  • residues D pyrazoles, imidazoles, oxazoles, isoxazoles, thiazoles, isothiazoles, triazoles, and tetrazoles are preferred.
  • the heterocyclic ring D contains a nitrogen atom next to the carbon atom through which the ring D is connected to the amid bond.
  • pyrazoles, imidazoles, triazoles, and tetrazoles are more preferred than oxazoles
  • isoxazoles, thiazoles, and isothiazoles and pyrazoles are more preferred than triazoles, and tetrazoles which are again more preferred than imidazoles.
  • isoxazoles and isothiazoles are more preferred than oxazoles and thiazoles.
  • isoxazole residues as substituent D it is important that the isoxazole residue is linked through the 3-yl-carbon atom to the amide group and not through the 4-yl-carbon atom or the 5-yl-carbon atom.
  • an oxazole group as substituent D it is important that the oxazole group is linked to the amide group through 2-yl-carbon atom or the 4-yl-carbon atom but not through the 5-yl-carbon atom.
  • a pyrazole residue should be linked to the amide group through the 3-yl-carbon atom and not through the 4-yl-carbon atom or the through the 5-yl-carbon atom.
  • Thiazole residues as substituent D are linked to the amide group through the 2-yl-carbon atom or the 4-yl-carbon atom, but not through the 5-yl-carbon atom.
  • Similiar, isothiazoles are linked through the 3-yl carbon atom, but not through the 4-yl-carbon atom or 5-yl-carbon atom.
  • Imidazoles are linked through the 2-yl-carbon or 4-yl-carbon atom, but not through the 5-yl-carbon position.
  • residue D is directly connected to the amide group and not through a linker such as a methylene or ethylene linker so that the carbonyl function of the amide group can be in conjugation with the preferably aromatic ring D.
  • ring D need to be an aromatic 5-membered heterocyclic ring with at least one nitrogen atom attached to the carbon atom of the aromatic ring which is attached to the amide group. Moreover it seems advantageous that the ring D is linked through a carbon atom to the amide group.
  • the nitrogen atom of the amide group may be substituted by alkyl and substituted alkyl residues.
  • the aromatic 5-membered ring D has to have a specific substitution pattern in order to provide active compounds for the uses disclosed herein. Said specific substitution pattern requires that substituent R 13 is only a small group such as hydrogen, methyl, trifluoromethyl, fluoro, ethyl, otherwise the activity drops.
  • R 2 and R 3 can be modified in a broard range.
  • the sort of residue R 2 and R 3 is not important for the activity so that R 2 and R 3 can be hydrogen, smaller groups such as methyl or methoxy as well as longer residues with a carbon chain containing optionally oxygen, nitrogen or saturated, unsaturated carbocyclic or heterocyclic rings.
  • residue D is a substituted or unsubstituted pyrazole ring.
  • group A and group B are carbon atoms or wherein group A is a carbon atom and group B is a nitrogen atom, respectively.
  • R 1 , R 4 , R 5 and R 6 are selected from hydrogen or C 1-6 alkyl, particularly from hydrogen.
  • non of both or only one of both represents N.
  • Substituents R 1 , R 4 , R 5 , and R 6 are preferably hydrogen.
  • Substituents R 2 and R 3 are preferably selected independently of each other from:
  • R 73 — R 84 independently of each other represent —H, —OH, —F, —Cl, —Br, —I, —CH 3 , —CF 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CH 2 —CH(CH 3 ) 2 , —CH(CH 3 )—C 2 H 5 , —C(CH 3 ) 3 , —C 5 H 11 , —CH(CH 3 )—C 3 H 7 , —CH 2 —CH(CH 3 )—C 2 H 5 , —CH(CH 3 )—CH(CH 3 ) 2 , —C(CH 3 ) 2 —C 2 H 5 , —CH 2 —C(CH 3 ) 3 , —CH(C 2 H 5 , —C 2 H 4 —CH(CH 3 ) 2 , —C 6
  • R 86 represents —CH 3 , —CF 3 , —H, —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CH 2 —CH(CH 3 ) 2 , —CH(CH 3 )—C 2 H 5 , —C(CH 3 ) 3 , —C 5 H 11 , —CH(CH 3 )—C 3 H 7 , —CH 2 —CH(CH 3 )—C 2 H 5 , —CH(CH 3 )—CH(CH 3 ) 2 , —C(CH 3 ) 2 —C 2 H 5 , —CH 2 —C(CH 3 ) 3 , —CH(C 2 H 5 ) 2 , —C 2 H 4 —CH(CH 3 ) 2 , —C 6 H 13 , —C 3 H 6 —CH(CH 3 ) 2 , —C 2 H 4 —CH(CH
  • R 16 and R 17 represent independently of each other —CH 3 , —CF 3 , —H, —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CH 2 —CH(CH 3 ) 2 , —CH(CH 3 )—C 2 H 5 , —C(CH 3 ) 3 , —C 5 H 11 , —CH(CH 3 )—C 3 H 7 , —CH 2 —CH(CH 3 )—C 2 H 5 , —CH(CH 3 )—CH(CH 3 ) 2 , —C(CH 3 ) 2 —C 2 H 5 , —CH 2 —C(CH 3 ) 3 , —CH(C 2 H 5 ) 2 , —C 2 H 4 —CH(CH 3 ) 2 , —C 6 H 13 , —C 3 H 6 —CH(CH 3 ) 2 , —C 2 H
  • the residue —NR 16 R 17 may represent a nitrogen heterocyclic group selected from
  • the residue —CR 16 R 17 H may represent a carbocyclic or heterocyclic group selected from
  • Substituents R 7 and R 8 are preferably selected independently of each other from:
  • R 7 and R 8 represents hydrogen.
  • a and B represent preferably independently of each other C—H, C—F, C—Cl, C—Br, C—CN, C—CH 3 , C—C 2 H 5 , C—C 3 H 7 , C—CH(CH 3 ) 2 , C-cyclo-C 3 H 5 , C—CH ⁇ CH 2 , C—CH 2 —CH ⁇ CH 2 , C—CH ⁇ CH—CH 3 , C—C ⁇ CH, C—C ⁇ C—CH 3 , C—CH 2 —C ⁇ CH, C—OCH 3 , C—OH, C—OC 2 H 5 , C—OC 3 H 7 , C—OCH(CH 3 ) 2 , C—OC 4 H 9 , C—OCH 2 —CH(CH 3 ) 2 , C—OCH(CH 3 )—C 2 H 5 , C—OC(CH 3 ) 3 , C—OC 5 H 11 , N.
  • a and B represents C—H.
  • only one of A and B represents N.
  • a and B represent independently of each other C—H, C—F, C—Cl, C—Br, C—CH 3 , C—C 2 H 5 , C—C 3 H 7 , C—CH(CH 3 ) 2 , C-cyclo-C 3 H 5 , C—CH ⁇ CH 2 , C—CH 2 —CH ⁇ CH 2 , C—C ⁇ CH, C—OCH 3 , C—OH, C—OC 2 H 5 , C—OC 3 H 7 , C—OCH(CH 3 ) 2 , N; still more preferably C—H, C—F, C—Cl, C—CH 3 , C—C 2 H 5 , C—C 3 H 7 , C—CH 2 —CH ⁇ CH 2 , C—OCH 3 , C—OH, C—OC 2 H 5 , C—OC 3 H 7 , N; and most preferably
  • R 9 represents preferably hydrogen.
  • R 14 represents preferably —H, —OH, —F, —Cl, —Br, —I, —NO 2 , —CN, —NH 2 , —R 100 , —R 101 , —R 102 , —O—R 102 , —R 103 , —O—R 103 , —R 136 , or —R 113 , wherein the saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system represented by —R 113 is optionally mono- or polysubstituted by —F, —Cl, —Br, —I, —OH, —NO 2 , —NH 2 , —C 2 H 4 —N(CH 3 ) 2 , —CN, —CF 3 , ⁇ O, —R 16 , —R 17 , —R 106 , —O—R 107 , —R 108 ,
  • R 14 represents —Cl, —Br, —CH 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CH 2 —CH(CH 3 ) 2 , —CH(CH 3 )—C 2 H 5 , —C(CH 3 ) 3 , —R 103 , —R 136 , and —R 113 , wherein the saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system represented by —R 113 is optionally mono- or polysubstituted by —F, —Cl, —Br, —OH, —NO 2 , —NH 2 , —C 2 H 4 —N(CH 3 ) 2 , —R 16 , —R 106 , —O—R 107 , —R 108 , —R 109 ;
  • R 103 represents preferably —CR 58 R 16 R 17 , —CR 59 R 60 —CR 16 R 17 R 58 , —CR 59 R 60 —CR 61 R 62 —CR 16 R 17 R 58 , —CR 59 R 60 —CR 61 R 62 —CR 63 R 64 —CR 16 R 17 R 58 , —CR 59 R 60 —CR 61 R 62 —CR 63 R 64 —CR 65 R 66 —CR 16 R 17 R 58 , —CR 59 R 60 —CR 61 R 62 —CR 63 R 64 —CR 65 R 66 —CR 67 R 68 —CR 16 R 17 R 58 , —CR 58 R 59 R 60 , CR 59 R 60 —CR 61 R 62 R 58 , CR 59 R 60 —CR 61 R 62 58 , CR 59 R 60 —CR 61 R 62 58 , CR 59 R
  • R 58 -R 68 represent independently of each other —H, —NH 2 , —OH, —F, —Cl, —Br, —I, —OCH 3 , —OCF 3 , —OC 2 H 5 , —CH 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CF 3 , —C(CH 3 ) 3 , —CR 16 R 17 H, —NR 16 R 17 ; wherein R 16 and R 17 have the meanings as disclosed herein.
  • R 103 represents —CR 68 R 69 R 60 , —CR 59 R 60 —CR 61 R 62 R 58 , —CR 59 R 60 —CR 61 R 62 —CR 63 R 64 R 58 , —CR 59 R 60 —CR 61 R 62 —CR 63 R 64 —CR 65 R 66 R 58 , —CR 59 R 60 —CR 61 R 62 —CR 63 R 64 —CR 65 R 66 —CR 67 R 68 R 58 , and R 58 represents —CR 16 R 17 H or —NR 18 R 17 ; and
  • R 59 -R 68 represent independently of each other —H, —NH 2 , —OH, —F, —Cl, —Br, —I, —OCH 3 , —OC 2 H 5 , —CH 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CF 3 , —C(CH 3 ) 3 ; and R 16 and R 17 represent independently of each other —H, —CH 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CH 2 —CH(CH 3 ) 2 , —CH(CH 3 )—C 2 H 5 , —C 5 H 11 , —CF 3 , -Ph, —CH 2 -Ph, or represent together with the atom to which they are attached a saturated or unsaturated three- to
  • R 103 represents —CR 58 R 59 R 60 , —CR 59 R 60 —CR 61 R 62 R 58 , —CR 59 R 60 —CR 61 R 62 —CR 63 R 64 R 58 , —CR 59 R 60 —CR 61 R 62 —CR 63 R 64 —CR 65 R 66 R 58 , —CR 59 R 60 —CR 61 R 62 —CR 63 R 64 —CR 65 R 66 —CR 67 R 68 R 58 , and R 58 represents
  • R 59 -R 68 represent independently of each other —H, —CH 3 , —C 2 H 5 , —CF 3 .
  • R 103 represents —CH 2 R 58 , —CH 2 —CH 2 R 58 , —CH 2 —CH 2 —CH 2 R 58 , —CH 2 —CH 2 —CH 2 R 58 , CH 2 —CH 2 —CH 2 —CH 2 R 58 , and R 58 represents
  • R 103 represents —CH 2 R 58 , —CH 2 —CH 2 R 58 , —CH 2 —CH 2 —CH 2 R 58 , —CH 2 —CH 2 —CH 2 —CH 2 R 58 , and R 58 represents
  • R 136 represents —CR 23 R 24 —X—CR 25 R 26 R 22 , —CR 23 R 24 —X—CR 25 R 26 —CR 27 R 28 R 22 , —CR 23 R 24 —CR 25 R 26 —X—CR 27 R 28 R 22 , —CR 23 R 24 —X—CR 25 R 26 —CR 27 R 28 —CR 29 R 30 R 22 , —CR 23 R 24 —CR 25 R 26 —X—CR 27 R 28 —CR 29 R 30 R 22 , —CR 23 R 24 —CR 25 R 26 —CR 27 R 28 —X—CR 29 R 30 R 22 , —CR 23 R 24 —X—CR 25 R 26 —CR 27 R 28 —CR 29 R 30 —CR 31 R 32 R 22 , —CR 23 R 24 —CR 25 R 26 —X—CR 27 R 28 —CR 29 R 30 —CR 31 R 32 R 22 , —CR 23 R 24 —CR 25 R 26 —X—CR 27 R 28 —
  • R 136 represents —CR 23 R 24 —X—CR 25 R 26 R 22 , —CR 23 R 24 —X—CR 25 R 26 —CR 27 R 28 R 22 , —CR 23 R 24 —CR 25 R 26 —X—CR 27 R 28 R 22 , —CR 23 R 24 —X—CR 25 R 26 —CR 27 R 28 —CR 29 R 30 R 22 , —CR 23 R 24 —CR 25 R 26 —X—CR 27 R 28 —CR 29 R 30 R 22 , —CR 23 R 24 —CR 25 R 26 —CR 27 R 28 —X—CR 29 R 30 R 22 , —CR 23 R 24 —X—CR 25 R 26 —CR 27 R 28 —CR 29 R 30 —CR 31 R 32 R 22 , —CR 23 R 24 —CR 25 R 26 —X—CR 27 R 28 —CR 29 R 30 —CR 31 R 32 R 22 , —CR 23 R 24 —CR 25 R 26 —X—CR 27 R 28 —
  • R 136 represents —CH 2 —O—CH 2 R 22 , —CH 2 —O—CH 2 —CH 2 R 22 , —CH 2 —CH 2 —O—CH 2 R 22 , —CH 2 —O—CH 2 —CH 2 —CH 2 R 22 , —CH 2 —C 2 —CH—O—CH 2 —CH 2 R 22 , —CH 2 —CH 2 —CH 2 —O—CH 2 R 22 , —CH 2 —O—CH 2 —H 2 —CH 2 —CH 2 —CH 2 R 22 , —CH 2 —CH 2 —O—CH 2 —CH 2 —CH 2 R 22 , —CH 2 —CH 2 —CH 2 —O—CH 2 —CH 2 R 22 , —CH 2 —CH 2 —CH 2 —O—CH 2 —CH 2 R 22 , —CH 2 —CH 2 —CH 2 —CH 2 —O—CH 2 —
  • R 136 represents —CH 2 —O—CH 2 R 22 , —CH 2 —O—CH 2 —CH 2 R 22 , —CH 2 —CH 2 —O—CH 2 R 22 , —CH 2 —O—CH 2 —CH 2 —CH 2 R 22 , —CH 2 —CH 2 —O—CH 2 —CH 2 R 22 ; and R 22 represents —H, —CH 3 , —CF 3 , —C 2 H 5 .
  • R 136 represents —CH 2 —O—CH 2 CF 3 , —CH 2 —O—CH 2 —CH 2 CF 3 , —CH 2 —CH 2 —O—CH 2 CF 3 .
  • R 113 represents preferably
  • R 113 can be substituted by one or more substituents selected from —F, —Cl, —Br, —I, —OH, —NO 2 , —NH 2 , —C 2 H 4 —N(CH 3 ) 2 , —CN, —CF 3 , ⁇ O, —R 16 , —R 17 , —R 106 , —O—R 107 , —R 108 , —R 109 , and wherein R 16 , R 17 , R 100 , R 101 , R 102 , R 103 , R 106 , R 107 , R 108 , R 109 , R 113 , and R 136 have the meanings as disclosed herein.
  • R 113 represents
  • R 113 can be substituted by one or more substituents selected from —F, —Cl, —Br, —I, —OH, —NO 2 , —NH 2 , —C 2 H 4 —N(CH 3 ) 2 , —CN, —CF 3 , ⁇ O, —R 16 , —R 17 , —R 106 , —O—R 107 , —R 108 , —R 109 , and wherein R 16 , R 17 , R 100 , R 101 , R 102 , R 103 , R 106 , R 107 , R 108 , R 109 , R 113 , and R 136 have the meanings as disclosed herein.
  • R 113 represents
  • R 15 , R 15* , R 16 , R 106 , R 107 , R 108 , and R 109 have the meanings as disclosed herein and more preferably R 109 represent —H, —C ⁇ CH, or —CH 2 —C ⁇ CH; and R 108 represent —H, —CH ⁇ CH 2 , or —CH 2 —CH ⁇ CH 2 ; and
  • R 16 , R 106 and R 107 represent independently of each other —H, —CH 3 , —CF 3 , -Ph, —CH 2 -Ph, —O 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CH 2 —CH(CH 3 ) 2 , —CH(CH 3 )—C 2 H 5 , —C(CH 3 ) 3 , —C 5 H 11 , —CH(CH 3 )—C 3 H 7 , —CH 2 —CH(CH 3 )—C 2 H 5 , —CH(CH 3 )—CH(CH 3 ) 2 , —C(CH 3 ) 2 —C 2 H 5 , —CH 2 —C(CH 3 ) 3 , —CH(C 2 H 5 , —C 2 H 4 —CH(CH 3 ) 2 , —C 6 H 13 , —C
  • R 15 and R 15* represent independently of each other —H, —F, —Cl, —Br, —I, —OH, —NO 2 , —NH 2 , —C 2 H 4 —N(CH 3 ) 2 , —CN, —CF 3 , ⁇ O;
  • R 15 and R 15* represent independently of each other —H, —F, —Cl, —Br, —OH, —NO 2 , —NH 2 , —C 2 H 4 —N(CH 3 ) 2
  • R 16 represents —H, —CH 3 , —CF 3 , —C 2 H 5
  • R 106 represents more preferably —H, —CH 3 , —CF 3 , —C 2 H 5
  • R 107 represents more preferably —H, —CH 3 , —CF 3 , -Ph, —CH 2 -Ph, —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 ;
  • R 113 represents
  • Residues for R 14 proved by examples and thus preferred resudes are: —H, —Br, —CH 3 , —C 3 H 7 , —C(CH 3 ) 3 , -Ph, —CH 2 —O—CH 2 —CF 3
  • R 14 is attached to a nitrogen atom, R 14 does not represent —Br.
  • R 13 represents —H, —OH, —F, —Cl, —Br, —NO 2 , —CH 3 , —CF 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CH ⁇ CH 2 , —CH 2 —CH ⁇ CH 2 , —CH ⁇ CH—CH 3 , —C ⁇ CH, —C ⁇ C—CH 3 , —CH 2 —C ⁇ CH, cyclo-C 3 H 5 , —OCH 3 , —OCF 3 , —OC 2 H 5 , —OC 3 H 7 , —OCH(CH 3 ) 2 , or —OC 4 H 9 ;
  • R 13 represents —H, —OH, —F, —Cl, —NO 2 , —CH 3 , —CF 3 , —C 2 H 5 , —C 3 H 7 , —CH ⁇ CH 2 , —CH 2 —CH ⁇ CH 2 , —C ⁇ CH, —CH 2 —C ⁇ CH, cyclo-C 3 H 5 , —OCH 3 , —OCF 3 , —OC 2 H 5 , or —OC 3 H 7 .
  • R 13 represents —H, —OH, —F, —CH 3 , —CF 3 , —C 2 H 5 , —CH ⁇ CH 2 , —C ⁇ CH, —OCH 3 , —OCF 3 , or —OC 2 H 5 .
  • R 13 represents —H, —F, —CH 3 , —CF 3 , or —C 2 H 5 .
  • R 12 represents —H, —F, —Cl, —Br, —I, —OH, —NH 2 , —NHR 19 , —NR 19 R 20 , —OCH 3 , —OCF 3 , —OC 2 F 5 , —OC 2 H 5 , —OC 3 H 7 , —O-cyclo-C 3 H 5 , —OCH 2 -cyclo-C 3 H 5 , —O—C 2 H 4 -cyclo-C 3 H 5 , —O—C 3 H 5 -cyclo-C 3 H 5 , —OCH(CH 3 ) 2 , —OC(CH 3 ) 3 , —OC 4 H 9 , —OPh, —NO 2 , —R 94 , —OR 94 , —NHCH 3 , —NHC 2 H 5 , —NHC 3 H 7 , —NHCH(CH 3 ) 2 , —NHC
  • R 94 represents preferably —CR 58 R 16 R 17 , —CR 59 R 69 —CR 16 R 17 R 58 , —CR 59 R 69 —CR 61 R 62 —CR 16 R 17 R 68 , —CR 59 R 66 —CR 61 R 62 —CR 63 R 64 —CR 16 R 17 R 68 , —CR 59 R 69 —CR 61 R 62 —CR 63 R 64 —CR 66 R 66 —CR 16 R 17 R 68 , —CR 59 R 60 —CR 61 R 62 —CR 63 R 64 —CR 65 R 66 —CR 67 R 68 —CR 16 R 17 R 58 , —CR 58 R 59 R 69 , —CR 59 R 69 —CR 61 R 62 R 58 , —CR 59 R 69 , —CR 59 R 69 —CR 61 R 62 R 58 , —
  • R 16 , R 17 , R 19 , R 20 , R 71 , R 72 , R 95 , R 96 , R 104 , and R 105 have the meanings as disclosed herein.
  • R 12 represents —H, —F, —Cl, —Br, —I, —OH, —NH 2 , —CH 2 F, —CF 3 , —CH 2 —CH 2 F, —CH 2 —CF 3 , cyclo-C 3 H 5 , —CH 2 -cyclo-C 3 H 5 , —CH 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CH 2 —CH(CH 3 ) 2 , —CH(CH 3 )—C 2 H 5 , —C(CH 3 ) 3 , —C 6 H 11 , —C 6 H 13 , —CH ⁇ CH 2 , —CH 2 —CH ⁇ CH 2 , —C(CH 3 ) ⁇ CH 2 , —CH ⁇ CH—CH 3 , —C 2 H 4 —CH ⁇ CH 2 , —CH 2 —CH
  • R 94 represents preferably —CR 58 R 59 R 69 , —CR 59 R 69 —CR 61 R 62 R 58 —CR 59 R 69 —CR 61 R 62 —CR 63 R 64 R 68 , —CR 59 R 69 —CR 61 R 62 —CR 63 R 64 —CR 65 R 66 R 58 , —CR 59 R 69 —CR 61 R 62 —CR 63 R 64 —CR 65 R 66 R 58 , —CR 59 R 69 —CR 61 R 62 —CR 63 R 64 —CR 65 R 66 —CR 67 R 68 R 58 ,
  • R 59 -R 68 represent independently of each other —H, —NH 2 , —OH, —F, —Cl, —Br, —I, —OCH 3 , —OCF 3 , —OC 2 H 5 , —CH 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CF 3 , —C(CH 3 ) 3 ;
  • R 58 represents preferably —CH 3 , —CF 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CH 2 —CH(CH 3 ) 2 , —CH(CH 3 )—C 2 H 5 , —C(CH 3 ) 3 , —C 5 H 11 , —CH(CH 3 )—C 3 H 7 , —CH 2 —CH(CH 3 )—C 2 H 5 , —CH(CH 3 )—CH(CH 3 ) 2 , —C(CH 3 ) 2 —C 2 H 5 , —CH 2 —C(CH 3 ) 3 , —CH(C 2 H 5 ) 2 , —C 2 H 4 —CH(CH 3 ) 2 , —C 6 H 13 , —C 3 H 6 —CH(CH 3 ) 2 , —C 2 H 4 —CH(CH 3
  • R 88 has the meanings as disclosed herein.
  • R 12 represents —H, —F, —Cl, —Br, —I, —OH, —NH 2 , —CH 2 F, —CF 3 , —CH 2 —CH 2 F, —CH 2 —CF 3 , cyclo-C 3 H 5 , —CH 2 -cyclo-C 3 H 5 , —CH 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —CH 2 —CH(CH 3 ) 2 , —CH(CH 3 )—C 2 H 5 , —C(CH 3 ) 3 , —C 5 H 11 , —C 6 H 13 , —OCH 3 , —OCF 3 , —OC 2 F 5 , —OC 2 H 5 , —OC 3 H 7 , —O-cyclo-C 3 H 5 , —OCH 2 -cyclo-
  • R 94 represents preferably —CH 2 R 58 , —CH 2 —CH 2 R 58 , —CH 2 —CH 2 —CH 2 R 58 , —CH 2 —CH 2 —CH 2 R 58 , —CH 2 —CH 2 —CH 2 —CH 2 R 58 , —CH 2 —CH 2 —CH 2 —CH 2 R 58 ,
  • R 58 represents preferably —CH 3 , —CF 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , -Ph, —CH 2 -Ph, —OCH 3 , —OCF 3 , —OC 2 H 5 , —OC 3 H 7 , —OCH(CH 3 ) 2 , —OC 4 H 9 , —OCH 2 —CH(CH 3 ) 2 , —OCH(CH 3 )—C 2 H 5 , —OC(CH 3 ) 3 , —OC 5 H 11 , —OC 6 H 13 , —OPh, —OCH 2 -Ph, —NHCH 3 , —NHC 2 H 5 , —NHC 3 H 7 , —NHCH(CH 3 ) 2 , —NHC(CH 3 ) 3 , —N(CH 3 ) 2 , —N
  • R 86 represents preferably —H, —CH 3 , —CF 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , -Ph, —CH 2 -Ph.
  • R 12 represents —H, —F, —Cl, —Br, —CF 3 , cyclo-C 3 H 5 , —CH 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —C 4 H 9 , —OH, —NH 2 , —OCH 3 , —OCF 3 , —OC 2 H 5 , —OC 3 H 7 , —O-cyclo-C 3 H 5 , —OCH 2 -cyclo-C 3 H 5 , —OCH(CH 3 ) 2 , —OC(CH 3 ) 3 , —OC 4 H 9 , —NO 2 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —N(C 3 H 7 ) 2 , —OCH 2 R 58 , —OCH 2 —CH 2 R 58 , —OCH 2 —CH 2
  • R 68 represents preferably —CH 3 , —CF 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , -Ph, —OCH 3 , —OCF 3 , —OC 2 H 5 , —OC 3 H 7 , —OCH(CH 3 ) 2 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 , —N(C 3 H 7 ) 2 ,
  • R 86 represents preferably —H, —CH 3 , —CF 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 .
  • R 12 represents —H, —F, —Cl, —Br, —CF 3 , cyclo-C 3 H 5 , —CH 3 , —C 2 H 5 , —C 3 H 7 , —CH(CH 3 ) 2 , —OH, —NH 2 , —OCH 3 , —OCF 3 , —OC 2 H 5 , —OC 3 H 7 , —O-cyclo-C 3 H 5 , —OCH 2 -cyclo-C 3 H 5 , —OCH(CH 3 ) 2 , —OC(CH 3 ) 3 , —OC 4 H 9 , —NO 2 , —OCH 2 R 68 , —OCH 2 —CH 2 R 68 , —OCH 2 —CH 2 —CH 2 R 68 , —OCH 2 —CH 2 —CH 2 R 68 , —OCH 2 —CH 2 —CH 2 R 68 ,
  • R 58 represents preferably -Ph, —OCH 3 , —OCF 3 , —OC 2 H 5 , —N(CH 3 ) 2 , —N(C 2 H 5 ) 2 ,
  • R 86 represents preferably —H, —CH 3 , —CF 3 , —C 2 H 5 .
  • Residues for R 12 proved by examples and thus preferred resudes are:
  • R 12 is attached to a nitrogen atom
  • R 12 does preferably not represent an alkoxy group and not a halogen and represents preferably the groups and the preferred groups mentioned herein which are linked through a carbon atom to the ring nitrogen atom.
  • N-oxides of the compounds of formula (I) above include within its scope N-oxides of the compounds of formula (I) above.
  • N-oxides may be formed by conventional means, such as reacting the compound of formula I with oxone in the presence of wet alumina.
  • tautomer is defined as an organic compound that is interconvertible by a chemical reaction called tautomerization. Tautomerization can be catalyzed preferably by bases or acids or other suitable compounds.
  • the compounds of the present invention may form salts with organic or inorganic acids or bases.
  • suitable acids for such acid addition salt formation are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, p-toluenesul
  • the inventive compounds may exist in a number of different polymorphic forms.
  • salts could also be formed with inorganic or organic bases.
  • suitable inorganic or organic bases are, for example, NaOH, KOH, NH 4 OH, tetraalkylammonium hydroxide, lysine or arginine and the like.
  • Salts may be prepared in a conventional manner using methods well known in the art, for example by treatment of a solution of the compound of the general formula (I) with a solution of an acid, selected out of the group mentioned above.
  • a method to prepare compounds of formula (I) is shown in Scheme 1.
  • the reaction of acid chloride 1 and aniline 2 is carried out in the presence of a base like pyridine and optionally in an inert solvent like DCM (dichloromethane).
  • a base like pyridine
  • an inert solvent like DCM (dichloromethane).
  • Many of the acid chlorides 1 are commercially available.
  • the acid chlorides 1 can also be prepared from commercially available carboxylic acids via standard procedures, using thionyl chloride or oxalyl chloride as reagents.
  • carboxylic acids can be directly coupled with anilines 2 under standard procedures, such as using HBTU (N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate) or HATU (0-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate) to give compounds of formula (I).
  • HBTU N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate
  • HATU hexafluorophosphate
  • Diazonium derivatives 5 are obtained by the reaction of ethyl 4-chloro-3-oxo-butanoate 3 with different anilines 4. Subsequent cyclization of 5 to the corresponding pyrazoles 6 can be achieved using a base such as KOAc (potassium acetate), as described in literature (Chattaway, F. D.; Ashworth, D. R.; Grimwalde, M. Journal of the Chemical Society 1935, 117-120).
  • KOAc potassium acetate
  • the hydroxyl-group of 6 can be modified by alkylation, for instance using ethyl iodide and K 2 CO 3 in DMF (dimethylformamide) to give pyrazole 7.
  • a modification of the substituents of the pyrazole 11 is shown below in Scheme 3.
  • the bromide derivative 11 can be used in metal-catalyzed cross-couplings, for instance under Sonogashira conditions using an alkyne, copper iodide and dichloro-bis(triphenylphosphine)palladium in the presence of a base like NEt 3 (triethylamine). Subsequent modifications yield the pyrazole derivative 12.
  • anilines 2 The synthesis of anilines 2 is shown in Scheme 4. Here the quinoline derivative 13 is subjected to nucleophilic aromatic substitution of the appropriate fluoro(hetero) aromatic derivative 14. Subsequent reduction of the nitro derivative 15 yields the anilines 2.
  • compositions according to the present invention comprise at least one compound according to the present invention as an active ingredient together with at least one pharmaceutically acceptable (i.e. non-toxic) carrier, excipient and/or diluent.
  • pharmaceutically acceptable (i.e. non-toxic) carrier, excipient and/or diluent i.e. non-toxic carrier, excipient and/or diluent.
  • the pharmaceutical compositions of the present invention can be prepared in a conventional solid or liquid carrier or diluent and a conventional pharmaceutically made adjuvant at suitable dosage level in a known way.
  • the preferred preparations are adapted for oral application.
  • These administration forms include, for example, pills, tablets, film tablets, coated tablets, capsules, powders and deposits.
  • the present invention also includes pharmaceutical preparations for parenteral application, including dermal, intradermal, intragastral, intracutaneous, intravasal, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutan, rectal, subcutaneous, sublingual, topical, or transdermal application, which preparations in addition to typical vehicles and/or diluents contain at least one compound according to the present invention and/or a pharmaceutical acceptable salt thereof as active ingredient.
  • compositions according to the present invention containing at least one compound according to the present invention and/or a pharmaceutical acceptable salt thereof as active ingredient will typically be administered together with suitable carrier materials selected with respect to the intended form of administration, i.e. for oral administration in the form of tablets, capsules (either solid filled, semi-solid filled or liquid filled), powders for constitution, gels, elixirs, dispersable granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices.
  • suitable carrier materials selected with respect to the intended form of administration, i.e. for oral administration in the form of tablets, capsules (either solid filled, semi-solid filled or liquid filled), powders for constitution, gels, elixirs, dispersable granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices.
  • the active drug component may be combined with any oral non-toxic pharmaceutically acceptable carrier, preferably with an inert carrier like lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid filled capsules) and the like.
  • suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated into the tablet or capsule.
  • Powders and tablets may contain about 5 to about 95-weight % of the derivatives according to the general formula (I) or analogues compound thereof or the respective pharmaceutically active salt as active ingredient.
  • Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes.
  • suitable lubricants there may be mentioned boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like.
  • Suitable disintegrants include starch, methylcellulose, guar gum, and the like. Sweetening and flavoring agents as well as preservatives may also be included, where appropriate. The disintegrants, diluents, lubricants, binders etc. are discussed in more detail below.
  • compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimise the therapeutic effect(s), e.g. anti-cancer activity or activity against cancer metastases and the like.
  • Suitable dosage forms for sustained release include tablets having layers of varying disintegration rates or controlled release, polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
  • Liquid form preparations include solutions, suspensions, and emulsions. As an example, there may be mentioned water or water/propylene glycol solutions for parenteral injections or addition of sweeteners and opacifiers for oral solutions, suspensions, and emulsions. Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be present in combination with a pharmaceutically acceptable carrier such as an inert, compressed gas, e.g. nitrogen.
  • a pharmaceutically acceptable carrier such as an inert, compressed gas, e.g. nitrogen.
  • a low melting wax such as a mixture of fatty acid glycerides like cocoa butter is melted first, and the active ingredient is then dispersed homogeneously therein e.g. by stirring. The molten, homogeneous mixture is then poured into conveniently sized moulds, allowed to cool, and thereby solidified.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • the compounds according to the present invention may also be delivered transdermally.
  • the transdermal compositions may have the form of a cream, a lotion, an aerosol and/or an emulsion and may be included in a transdermal patch of the matrix or reservoir type as is known in the art for this purpose.
  • capsule refers to a specific container or enclosure made e.g. of methylcellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredient(s).
  • Capsules with hard shells are typically made of blended of relatively high gel strength gelatins from bones or pork skin.
  • the capsule itself may contain small amounts of dyes, opaquing agents, plasticisers and/or preservatives.
  • a compressed or moulded solid dosage form which comprises the active ingredients with suitable diluents.
  • the tablet may be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation, or by compaction well known to a person of ordinary skill in the art.
  • Oral gels refer to the active ingredients dispersed or solubilised in a hydrophilic semi-solid matrix.
  • Powders for constitution refers to powder blends containing the active ingredients and suitable diluents which can be suspended e.g. in water or in juice.
  • Suitable diluents are substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol, and sorbitol, starches derived from wheat, corn, rice, and potato, and celluloses such as microcrystalline cellulose.
  • the amount of diluent in the composition can range from about 5 to about 95% by weight of the total composition, preferably from about 25 to about 75 weight %, and more preferably from about 30 to about 60 weight %.
  • disintegrants refers to materials added to the composition to support break apart (disintegrate) and release the pharmaceutically active ingredients of a medicament.
  • Suitable disintegrants include starches, “cold water soluble” modified starches such as sodium carboxymethyl starch, natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar, cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose, microcrystalline celluloses, and cross-linked microcrystalline celluloses such as sodium croscaramellose, alginates such as alginic acid and sodium alginate, clays such as bentonites, and effervescent mixtures.
  • the amount of disintegrant in the composition may range from about 2 to about 20 weight % of the composition, more preferably from about 5 to about 10 weight %.
  • Binders are substances which bind or “glue” together powder particles and make them cohesive by forming granules, thus serving as the “adhesive” in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose, starches derived from wheat, corn, rice and potato, natural gums such as acacia, gelatin and tragacanth, derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate, cellulose materials such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose, polyvinylpyrrolidone, and inorganic compounds such as magnesium aluminum silicate. The amount of binder in the composition may range from about 2 to about 20 weight % of the composition, preferably from about 3 to about 10 weight %, and more preferably from about 3 to about 6 weight %.
  • Lubricants refer to a class of substances which are added to the dosage form to enable the tablet granules etc. after being compressed to release from the mould by reducing friction or wear.
  • Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate, or potassium stearate, stearic acid, high melting point waxes, and other water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and D,L-leucine. Lubricants are usually added at the very last step before compression, since they must be present at the surface of the granules.
  • the amount of lubricant in the composition may range from about 0.2 to about 5 weight % of the composition, preferably from about 0.5 to about 2 weight %, and more preferably from about 0.3 to about 1.5 weight % of the composition.
  • Glidents are materials that prevent caking of the components of the pharmaceutical composition and improve the flow characteristics of granulate so that flow is smooth and uniform.
  • Suitable glidents include silicon dioxide and talc.
  • the amount of glident in the composition may range from about 0.1 to about 5 weight % of the final composition, preferably from about 0.5 to about 2 weight %.
  • Coloring agents are excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide.
  • the amount of the coloring agent may vary from about 0.1 to about 5 weight % of the composition, preferably from about 0.1 to about 1 weight %.
  • the compounds of the present invention are suitable for use in medicine, particulary in human medicine, but also in veterinary medicine.
  • the dosage of the compounds may be determined by a skilled practitioner according to the type and severity of the disorder to be treated.
  • the compounds of the present invention may be admistered as a monotherapy or together with further active agents, particulary chemotherapeutic agents or antitumor antibodies. Furthermore they may be used in combination with surgery and/or irradiation.
  • Especially preferred compounds according to the present invention include compounds presented by Table 1.
  • ACN acetonitrile
  • br broad
  • CDCl 3 deuterated chloroform
  • cHex cyclohexane
  • DCM diichloromethane
  • DIPEA di-iso-propylethylamine
  • DMF dimethylformamide
  • DMSO dimethyl sulfoxide
  • Step 3 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1,5-dimethyl-pyrazole-3-carboxamide trifluoroacetate salt (A3)
  • C1 was prepared from A2 and 1-propylpyrazole-3-carboxylic acid following the general procedure reported in Preparative Example 11. The residue was purified by reverse phase RP-HPLC (column: C18), using H 2 O and ACN as eluents. The desired fractions were lyophilized to yield the title compound C1 (46 mg, 0.10 mmol, 17%) as a white powder.
  • Step 2 ethyl 4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxylate (D2)
  • Step 5 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (D5)
  • Acid chloride D4 (0.17 mmol, 1.0 eq.) was dissolved in dry pyridine (1.5 mL) at 0° C. and A2 (34 mg, 0.11 mmol, 0.65 eq.) was added. The reaction was allowed to reach RT overnight. The mixture was diluted with EtOAc and washed twice with aq. KOH-solution (0.5N), twice with aq. sat. NH 4 Cl-solution, and finally once with brine. The organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure.
  • E1 was prepared from D1 following the general procedure reported in Preparative Example 16 Step 2 using methyl iodide for the alkylation.
  • MS (ES) C 13 H 13 FN 2 O 3 requires: 264. Found: 265 (M+H) + and 287 (M+Na) + .
  • Step 4 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxamide trifluoroacetic acid salt (E4)
  • Acid chloride E3 (0.42 mmol, 1.0 eq.) was dissolved in dry pyridine (2 mL) at RT and A2 (133 mg, 0.42 mmol, 1.0 eq.) was added. The reaction was stirred at RT overnight. After adding methanol (0.1 mL) the reaction mixture was concentrated under reduced pressure. The residue was purified by reverse phase RP-HPLC (column: C18), using H 2 O (0.1% TFA) and MeOH (0.1% TFA) as eluents. The desired fractions were lyophilized to yield the title compound E4 (36 mg, 0.13 mmol, 13%) as a white powder.
  • Step 1 ethyl 4-(cyclopropylmethoxy)-1-(4-fluorophenyl)pyrazole-3-carboxylate (F1)
  • Step 2 4-(cyclopropylmethoxy)-1-(4-fluorophenyl)pyrazole-3-carboxylic acid (F2)
  • F2 was prepared from F1 following the general procedure reported in Preparative Example 16 Step 3.
  • MS (ES) C 14 H 13 FN 2 O 3 requires: 276. Found: 277 (M+H) + and 299 (M+Na) + .
  • Step 3 4-(cyclopropylmethoxy)-1-(4-fluorophenyl)pyrazole-3-carbonyl chloride (F3)
  • F3 was prepared from F2 following the general procedure reported in Preparative Example 16 Step 4.
  • Step 4 4-(cyclopropylmethoxy)-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide (F4)
  • F4 was prepared from F3 following the general procedure reported in Preparative Example 16 Step 5.
  • 1 H NMR 400 MHz, CD 3 OD, 300K
  • MS (ES) C 31 H 26 F 2 N 4 O 5 requires: 572. Found: 573 (M+H) + .
  • Step 1 4-(2-dimethylaminoethoxy)-1-(4-fluorophenyl)pyrazole-3-carbonyl chloride (G1)
  • G1 was prepared from D1 following the general procedure reported in Preparative Example 16 Step 2-4.
  • Step 2 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-(2-dimethylaminoethoxy)-1-(4-fluorophenyl)pyrazole-3-carboxamide (G2)
  • G2 was prepared from G1 following the general procedure reported in Preparative Example 16 Step 5.
  • MS (ES) C 31 H 29 F 2 N 5 O 5 requires: 589. Found: 590 (M+H) + .
  • H1 was prepared from D1 following the general procedure reported in Preparative Example 16 Step 2-4.
  • Step 2 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-(3-dimethylaminopropoxy)-1-(4-fluorophenyl)pyrazole-3-carboxamide (H2)
  • H2 was prepared from H1 following the general procedure reported in Preparative Example 16 Step 5. MS (ES) C 32 H 31 F 2 N 6 O 6 requires: 603. Found: 604 (M+H) + .
  • I2 was prepared from I1 following the general procedure reported in Preparative Example 16 Step 4.
  • Step 3 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carboxamide (I3)
  • I3 was prepared from I2 following the general procedure reported in Preparative Example 16 Step 5.
  • MS (ES) C 30 H 26 F 2 N 4 O 6 requires: 560. Found: 561 (M+H) + .
  • Step 1 ethyl 1-(4-fluoro-2-methyl-phenyl)-4-hydroxy-pyrazole-3-carboxylate (J1)
  • Step 2 ethyl 4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxylate (J2)
  • J2 was prepared from J1 following the general procedure reported in Preparative Example 16 Step 2 using iodoethane for the alkylation.
  • MS (ES) C 16 H 17 FN 2 O 3 requires: 292. Found: 293 (M+H) + and 315 (M+Na).
  • J4 was prepared from J3 following the general procedure reported in Preparative Example 16 Step 4.
  • Step 5 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide (J5)
  • K2 was prepared from K1 following the general procedure reported in Preparative Example 16 Step 4.
  • Step 3 1-(2-chloro-4-fluoro-phenyl)-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-pyrazole-3-carboxamide (K3)
  • Step 2 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (L2)
  • L2 was prepared from L1 and D4 following the general procedure reported in Preparative Example 16 Step 5.
  • MS (ES) C 29 H 25 FN 4 O 5 requires: 528. Found: 529 (M+H) + .
  • Step 2 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-methyl-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (M2)
  • M2 was prepared from M1 and D4 following the general procedure reported in Preparative Example 16 Step 5.
  • MS (ES) C 30 H 27 FN 4 O 5 requires: 542. Found: 543 (M+H) + .
  • N1 was prepared from 6,7-dimethoxyquinolin-4-ol and 2-chloro-1-fluoro-4-nitrobenzene following the general procedure reported in Preparative Example 1 Step 1-2.
  • MS (ES) C 17 H 16 ClN 2 O 3 requires: 330. Found: 331 (M+H) + .
  • Step 2 N-[3-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (N2)
  • N2 was prepared from N1 and D4 following the general procedure reported in Preparative Example 16 Step 5.
  • MS (ES) C 29 H 24 ClFN 4 O 6 requires: 562. Found: 563 (M+H) + .
  • Step 3 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxamide (O3)
  • Step 1 ethyl 1-(2-bromo-4-fluoro-phenyl)-4-hydroxy-pyrazole-3-carboxylate (P1)
  • Step 2 ethyl 1-(2-bromo-4-fluoro-phenyl)-4-ethoxy-pyrazole-3-carboxylate (P2)
  • Step 3 ethyl 4-ethoxy-1-[2-[(Z)-2-ethoxyvinyl]-4-fluoro-phenyl]pyrazole-3-carboxylate (P3)
  • Step 4 ethyl 4-ethoxy-1-[4-fluoro-2-(2-oxoethyl)phenyl]pyrazole-3-carboxylate (P4)
  • Step 5 ethyl 1-[2-(2-dimethylaminoethyl)-4-fluoro-phenyl]-4-ethoxy-pyrazole-3-carboxylate (P5)
  • Step 6 1-[2-(2-dimethylaminoethyl)-4-fluoro-phenyl]-4-ethoxy-pyrazole-3-carboxylic acid (P6)
  • Step 7 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-1-(2-(2-(dimethylamino)ethyl)-4-fluorophenyl)-4-ethoxy-1H-pyrazole-3-carboxamide hydrochloride (P7)
  • Carboxylic acid P6 (117 mg, 0.36 mmol, 1.0 eq.) was heated in thionyl chloride (3 mL) for 4 h under reflux. Solvent was removed in vacuo and the crude material was resolved in dry toluene and evaporated under reduced pressure again.
  • the crude material was solved in dry pyridine (3 mL) and A2 (115 mg, 0.36 mmol, 1.0 eq.) was added. The mixture was stirred at RT for 12 h. Water was added and the mixture was evaporated in vacuo. The residue was purified by reverse phase RP-HPLC (column: C18), using H 2 O and ACN as eluents. The desired fractions were lyophilized. The white solid (70 mg) was solved in water and ACN and than 1N HCl (0.13 mL) was added. The mixture was lyophilized to yield the title compound P7 (74 mg, 0.113 mmol, 32%) as a white powder.
  • Step 1 tert-butyl N-[3-[[4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-7-quinolyl]oxy]propyl]carbamate (R 1 )
  • Step 2 tert-butyl N-[3-[[4-(4-amino-2-fluoro-phenoxy)-6-methoxy-7-quinolyl]oxy]propyl]carbamate (R 2 )
  • Step 3 N-[4-[[7-(3-aminopropoxy)-6-methoxy-4-quinolyl]oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (R3)
  • Step 1 3-fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-quinolyl]oxy]aniline (S1)
  • S1 was prepared from 4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-ol and 1-(3-chloropropyl)-4-methylpiperazine following the general procedure reported in Preparative Example 54 Step 1-2.
  • Step 2 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide (S2)
  • S2 was prepared from S1 and J4 following the general procedure reported in Preparative Example 1 Step 3.
  • Step 1 tert-butyl 4-[3-[[4-(4-amino-2-fluoro-phenoxy)-6-methoxy-7-quinolyl]oxy]propyl]piperazine-1-carboxylate (T1)
  • T1 was prepared from 4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-ol and tert-butyl 4-(3-chloropropyl)piperazine-1-carboxylate following the general procedure reported in Preparative Example 54 Step 1-2.
  • Step 2 4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide trifluoroacetic acid salt (T2)
  • reaction mixture was concentrated under reduced pressure and the residue was purified by reverse phase RP-HPLC (column: C18), using H 2 O (0.1% TFA) and MeOH (0.1% TFA) as eluents.
  • the desired fractions were lyophilized to yield the title compound T2 as a white powder.
  • Step 2 N-[3-fluoro-4-[[6-methoxy-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxamide (U2)
  • Example 74 (39 mg, 0.06 mmol, 1.0 eq.) and acetaldehyde (5 mg, 0.12 mmol, 2.0 eq.) in dry MeOH (5 mL) was stirred for 2 h at RT. After adding sodium cyanoborohydride (6 mg, 0.09 mmol, 1.5 eq.) the mixture was stirred for 12 h. The mixture was diluted with EtOAc and the organic phase was washed twice with aq.NaHO 3 -solution. The organic phase was dried and solvents were removed in vacuo. The residue was purified by reverse phase RP-HPLC (column: C18), using H 2 O and MeOH as eluents. The desired fractions were lyophilized to yield the title compound V01 as a white powder. MS (ES) C 37 H 39 F 2 N 5 O 5 requires: 671. Found: 672 (M+H) + .
  • Example in the following table was prepared according to the procedure described in the previous Example 82.
  • Step 3 N-[5-[(6,7-dimethoxy-4-quinolyl)oxy]-2-pyridyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide trifluoroacetic acid salt (W3)
  • W3 was prepared from W2 and D4 following the general procedure reported in Preparative Example 1 Step 3.
  • MS (ES) C 28 H 24 FN 5 O 5 requires: 529. Found: 530 (M+H) + .
  • X1 was prepared from tert-butyl 4-(((4-((6-aminopyridin-3-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)piperidine-1-carboxylate and J4 following the general procedure reported in Preparative Example 16 Step 5.
  • Step 5 ⁇ 4 was prepared from A2 and 4-ethoxy-1-(4-methoxy-2-methylphenyl)-1H-pyrazole-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4.
  • Step 5 X7 was prepared from J4 and 4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methoxyaniline, which was prepared similar to Preparative Example 1 step 1-2.
  • Step 5 X9 was prepared from A2 and 4-ethoxy-1-(4-fluoro-3-methoxyphenyl)-1H-pyrazole-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4.
  • Step 5 X13 was prepared from tert-butyl 4-(((4-((6-aminopyridin-3-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)piperidine-1-carboxylate and 4-(2-methoxyphenyl)thiazole-2-carbonyl chloride, which was prepared similar to Preparative Example 16 step 4 from commercially available 4-(2-methoxyphenyl)thiazole-2-carboxylic acid.
  • Step 5 X15 was prepared from tert-butyl 4-(((4-((6-aminopyridin-3-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)piperidine-1-carboxylate and 4-bromothiazole-2-carbonyl chloride, which was prepared similar to Preparative Example 16 step 4 from commercially available 4-bromothiazole-2-carboxylic acid.
  • Step 5 X16 was prepared from J4 and 4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methoxyaniline, which was prepared similar to Preparative Example 1 step 1-2.
  • Step 5 X19 was prepared from A2 and 4-ethoxy-1-(pyridin-3-yl)-1H-pyrazole-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4.
  • Step 5 X20 was prepared from A2 and 4-ethoxy-1′-methyl-1′H-[1,3′-bipyrazole]-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4.
  • the exemplified compounds described herein were tested for activity and were found to have an IC 50 value less than 10 uM, particularly less than 500 nM, in one of the following assays:
  • the IMAP FP Sreening Express Kit (Molecular Devices) was employed for the detection of Axl activity in vitro.
  • a mix of FITC-labeled substrate peptide 400 nM final concentration; 5FITC-KKKKEEIYFFFG-NH 2 , Seq ID No. 01
  • recombinant Axl kinase (30 nM final concentration; Proqinase) was preincubated with a compound according to formula (I) at the suitable concentrations. Reaction was started by addition of ATP (Adenosine-5′-triphosphate, Sigma Aldrich) to a final concentration of 22 ⁇ M.
  • ATP Addenosine-5′-triphosphate
  • reaction buffer conditions were 20 mM HEPES (2-(4-(2-Hydroxyethyl)-1-piperazine)-ethanesulfonic acid) pH 8.0, 1 mM DTT (Dithiothreitol), 10 mM MgCl 2 and 0.01% Brij35 (all Sigma Aldrich).
  • IMAP binding buffer containing the large M(III)-based nanoparticles, who bind to the phosphorylated fluorescent substrat. This reduces the rotational speed of the bound substrate increasing its polarization signal.
  • the fluorescence polarization was determined using an EnVision Multilabelreader 2104 (Perkin Elmer).
  • the principle behind this assay is based upon the binding and displacement of an Alexa Fluor 647-labeled tracer to the kinase of interest. Binding of the tracer to the kinase is detected using an EU-labeled anti-tag antibody. Simultaneous binding of both the tracer and antibody to the kinase gives rise to a FRET-signal. Binding of an inhibitor to the kinase competes for binding with the tracer, resulting in a loss of FRET-signal.
  • a compound according to formula (I) was diluted in 20 mM Hepes pH 8.0, 1 mM DTT, 10 mM MgCl 2 and 0.01% Brij35.
  • HEK293 embryonal kidney fibroblasts were transfected in 96 wells with a plasmid containing Axl cDNA.
  • transfection reagent Superfect Qiagen
  • Transfection of the sole vector backbone served as negative control of Axl expression.
  • the cellular supernatant was replaced with fresh medium.
  • the Axl-expressing cells were incubated for 1 hour with a compound according to formula (I) at the suitable concentrations.
  • Cells were lysed with buffer and lysates were investigated for Axl expression and phosphorylation employing antibodies H-124 (Santa Cruz) and AF2228 (R&D), respectively.
  • the mesoscale technology was used for quantification.
  • Example 80 (Axl binding assay 0.184 uM) of the present invention it can be followed that the oxazole group as substituent D should be linked to the amide group through 2-yl-carbon atom or the 4-yl-carbon atom but not through the 5-yl-carbon atom.
  • Example 17 wherein the pyrazole residue is linked to the amide group through the 3-yl-carbon atom shows in the Axl binding assay a value of 0.172 ⁇ M
  • compound 20 of WO2008035209A2 wherein the pyrazole residue is linked to the amide group through the 4-yl-carbon atom shows with >10 ⁇ M a much more worse binding/inhibition in the Axl binding assay.
  • WO2007146824A2 was cited as D03 in the European Search Report (ESR). D03 does not cite any novelty destroying compounds for the present invention and does even not cite any similar compound. In WO2007146824A2 not a single compound is disclosed which has a 5-membered nitrogen heterocycle as substituent D so that the compounds of WO2007146824A2 are regarded as less relevant. Even compounds such as compounds 134, 172, 175, 176, 177, 178, 195 or 196 are only insignificantly similar to the compounds of the present invention.
  • Example 22 of the present invention was tested in an oncology in vivo model (orthotopic breast cancer model for metastasis):
  • mice Female BALB/c mice which developed tumours from 4T1 mouse breast tumour cells, (orthotopically inoculated into the third mammary fat pad) were selected for the study.
  • the mice were randomised, based on tumour volume into four groups on Day 0 of the study.
  • the mice in each group received treatment with either Vehicle Control (PEG400:H 2 O (70:30, v/v)), Example 22 (32 or 106.5 mg/kg) or Cisplatin (4 mg/kg).
  • the Vehicle Control and Example 22 were administered orally, twice daily (12 hours apart) for 15 days (Day 0-14) in a dosing volume of 5 mL/kg.
  • Cisplatin was administered intravenously on Day 0, 7 and 14 in a dosing volume of 10 mL/kg.
  • liver metastasis Remaining liver tissue from untreated and treated mice, and the liver from mice treated with Cisplatin was preserved in 10% neutral buffered formalin and embedded in paraffin. Liver sections were stained with haematoxylin and eosin, and micro-metastases were quantified. The number of liver metastasis was reduced significantly to roughly 50% by Example 22 (dosing 106.5 mg/kg) without any side effects.

Abstract

The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.

Description

The present invention relates to novel compounds which are inhibitors of Axl receptor tyrosine kinase subfamily which comprises Axl, Mer and Tyro3. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the Axl family. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.
Receptor tyrosine kinases (RTKs) are cell surface receptors that transmit signals from the extracellular environment to control growth, differentiation and survival of cells. Deregulated expression of protein kinases by gene deletion, -mutation or amplification has been found to be important for tumor initiation and progression, involving cancer cell proliferation, -survival, -motility and -invasivity as well tumor angiogenesis and chemotherapy resistance. Because of the advanced understanding of their critical role, protein kinases are important targets for novel therapies, especially for cancer (Hananhan et al., 2000; Blume-Jensen et al., 2001).
Axl is a member of the TAM (Tyro-Axl-Mer) receptor tyrosine kinases. This family is characterised by an extracellular domain, consisting of two immunoglobulin-like domains followed by two fibronectin type 3-like domains. The activation of the Axl RTK subfamily occurs by its cognate protein ligand, growth arrest specific 6 (Gas6). The affinity of Gas6 is highest for Axl, followed by Tyro3, and finally Mer, and thereby activates the three proteins to varying degrees. Gas6 is a member of the vitamin K-dependent family and shows a 43% sequence identity to and the same domain organisation as the protein S, a serum protein (Hafizi et al., 2006).
Axl is ubiquitously expressed at low levels and is detectable in a variety of organs. Expression patterns of the other two family members differ from that of Axl. Expression of Tyro3 is predominantly in the brain and CNS (central nervous system), while expression of Mer is almost exclusively in the monocyte cell lineage (Rescigno et al. 1991, Mark et al., 1994, Graham et al., 1994).
TAM family RTKs regulate a diverse range of cellular responses, including cell survival, proliferation, migration and adhesion (Hafizi et al., 2006). TAM receptor signalling has been shown to regulate vascular smooth muscle homeostasis (Korshunov et al., 2007), platelet function, thrombus stabilization (Angelillo-Scherrer et al., 2001; Gould et al., 2005), and erythropoiesis (Angelillo-Scherrer et al., 2008). Furthermore TAM receptors are implicated in the control of oligodendrocyte cell survival (Shankar et al., 2006) and the regulation of osteoclast function (Katagiri et al., 2001). The TAM receptors play pivotal roles in innate immunity (Lemke et al., 2008) and in inflammation (Sharif et al., 2006; Rothlin et al., 2007). The TAM family promotes the phagocytosis of apoptotic cells (Prasas et al., 2006) and stimulates the differentiation of natural killer cells (Park et al., 2009; Caraux et al., 2006). Axl activation is linked to several signal transduction pathways, including Akt, MAP kinases, NF-κB, STAT signal transduction pathways and others (Hafizi et al., 2006).
High Axl expression is observed in many human tumors (Berclaz et al., 2001; Craven et al., 1995; Shieh et al., 2005; Sun et al., 2004; Green et al., 2006; Ito et al., 1999) and it is associated with tumor stage and -progression in cancer patients (Gjerdrum et al., 2010; Sawabu et al., 2007; Green et al., 2006; Shieh et al., 2005; Sun et al., 2003).
It is object of the present invention to provide compounds and/or pharmaceutically acceptable salts thereof which can be used as pharmaceutically active agents, especially for treatment of cell proliferative diseases like cancer, as well as compositions comprising at least one of those compounds and/or pharmaceutically acceptable salts thereof as pharmaceutically active ingredients.
The compounds of the present invention are efficient inhibitors of TAM family RTKs and thus, are suitable for the treatment of disorders associated with, accompanied by and/or caused by TAM family RTKs hyperfunction, and thereby having an effect on cell survival, proliferation, autophagy, vascular smooth muscle homeostasis, migration, adhesion, angiogenesis, platelet aggregation, thrombus stabilization, erythropoiesis, oligodendrocyte cell survival, osteoclast function, innate immunity, inflammation, phagocytosis of apoptotic cells and/or natural killer cell differentiation.
The invention provides efficient inhibitors of Axl receptor tyrosine kinase which are suitable for the treatment of hyperproliferative disorders associated with, accompanied by and/or caused by Axl hyperfunction, particularly Axl receptor tyrosine kinase induced hyperproliferative disorders. The compounds of the invention are capable of inhibiting cell proliferation and thus, are suitable for the treatment and/or prevention of Axl receptor tyrosine kinase induced hyperproliferative disorders, particularly selected from the group comprising cancer and primary tumor metastases. In a preferred embodiment of the invention, the Axl receptor tyrosine kinase induced disorders are associated with Axl receptor tyrosine kinase receptor overexpression and/or hyperactivity, e.g. an increased degree of autophosphorylation compared to normal tissue. The disorders may be selected from breast cancer, colon cancer, prostate cancer, lung cancer, gastric cancer, ovarian cancer, endometrial cancer, renal cancer, hepatocellular cancer, thyroid cancer, uterine cancer, esophagus cancer, squamous cell cancer, leukemia, osteosarcoma, melanoma, glioblastoma and neuroblastoma. In an especially preferred embodiment, the disorders are selected from breast cancer, glioblastoma, renal cancer, non-small cell lung cancer (NSCLC), and melanoma. The compounds are also suitable for the prevention and/or treatment of other hyperproliferative disorders, particulary benign hyperproliferative disorders such as benign prostate hyperplasia.
Examples for disorders associated with, accompanied by and/or caused by Axl hyperfunction are acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, aids-related cancers, aids-related lymphoma, anal cancer, appendix cancer, astrocytomas, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, osteosarcoma and malignant fibrous histiocytoma, brain stem glioma, brain tumor, central nervous system atypical teratoid/rhabdoid tumor, astrocytomas, craniopharyngioma, ependymoblastoma, ependymoma, medulloblastoma, medulloepithelioma, pineal parenchymal tumors of intermediate differentiation, supratentorial primitive neuroectodermal tumors and pineoblastoma, brain and spinal cord tumors, breast cancer, bronchial tumors, burkitt lymphoma, carcinoid tumor, gastrointestinal cancer, central nervous system (CNS) lymphoma, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, colorectal cancer, craniopharyngioma, cutaneous t-cell lymphoma, mycosis fungoides, sézary syndrome, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, esthesioneuroblastoma, ewing sarcoma family of tumors, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (gist), gastrointestinal stromal cell tumor, extracranial germ cell tumor, extragonadal germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor, glioma, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular (liver) cancer, histiocytosis, hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), kaposi sarcoma, renal cell cancer, kidney cancer, langerhans cell histiocytosis, laryngeal cancer, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, leukemia, lip and oral cavity cancer, liver cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, aids-related lymphoma, burkitt lymphoma, (cutaneous t-cell lymphoma, hodgkin lymphoma, non-hodgkin lymphoma, primary central nervous system lymphoma, macroglobulinemia, malignant fibrous histiocytoma of bone and osteosarcoma, medulloblastoma, medulloepithelioma, melanoma, melanoma intraocular (eye), merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer with occult primary, mouth cancer, multiple endocrine neoplasia syndromes, multiple myeloma/plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, myelogenous leukemia, myeloid leukemia, myeloma (multiple), myeloproliferative disorders, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-hodgkin lymphoma, non-small cell lung cancer, oral cancer, oral cavity cancer, oropharyngeal cancer, osteosarcoma and malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, pregnancy and breast cancer, prostate cancer, rectal cancer, renal cell (kidney) cancer, transitional cell cancer, respiratory tract cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, ewing sarcoma, kaposi sarcoma, uterine sarcoma, nonmelanoma skin cancer, melanoma skin cancer, skin carcinoma, small cell lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, squamous neck cancer, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, t-cell lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, trophoblastic tumor, gestational cancer, ureter and renal pelvis cancer, transitional cell cancer, urethral cancer, uterine cancer, endometrial cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenström macroglobulinemia and Wilms tumor.
The preferred Axl receptor tyrosine kinase induced disorders are selected from adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, desmoid tumor, bladder cancer, bronchial carcinoma, breast cancer, Burkitt's lymphoma, corpus cancer, CUP-syndrome (carcinoma of unknown primary origin), colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors, gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, cervix, glioblastomas, gynecologic tumors, ear tumors, nose tumors and throat tumors, hematologic neoplasias, hairy cell leukemia, urethral cancer, skin cancer, skin testis cancer, brain tumors (gliomas), brain metastases, testicle cancer, hypophysis tumor, carcinoids, Kaposi's sarcoma, laryngeal cancer, germ cell tumor, bone cancer, colorectal carcinoma, head and neck tumors (tumors of the ear, nose and throat area), colon carcinoma, craniopharyngiomas, oral cancer (cancer in the mouth area and on lips), cancer of the central nervous system, liver cancer, liver metastases, leukemia, eyelid tumor, lung cancer, lymph node cancer (Hodgkin's/Non-Hodgkin's), lymphomas, stomach cancer, malignant melanoma, malignant neoplasia, malignant tumors of the gastrointestinal tract, breast carcinoma, rectal cancer, medulloblastomas, melanoma, meningiomas, Hodgkin's disease, mycosis fungoides, nasal cancer, neurinoma, neuroblastoma, kidney cancer, renal cell carcinomas, non-Hodgkin's lymphomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcomas, ovarial carcinoma, pancreatic carcinoma, penile cancer, plasmocytoma, prostate cancer, pharyngeal cancer, rectal carcinoma, retinoblastoma, vaginal cancer, thyroid carcinoma, Schneeberger disease, esophageal cancer, spinalioms, T-cell lymphoma (mycosis fungoides), thymoma, tube carcinoma, eye tumors, urethral cancer, urologic tumors, urothelial carcinoma, vulva cancer, wart appearance, soft tissue tumors, soft tissue sarcoma, Wilm's tumor, cervical carcinoma and tongue cancer.
The compounds of the present invention are efficient inhibitors of TAM family RTKs. The inventive compounds are suitable for the use as a pharmaceutically active agent. The inventive compounds are suitable for the treatment of disorders associated with, accompanied by and/or caused by TAM family RTKs hyperfunction. The inventive compounds are suitable for the treatment and/or prevention of Axl receptor tyrosine induced disorders.
The inventive compounds are used in the manufacture of a medicament or of a pharmaceutical composition for the treatment of disorders associated with, accompanied by and/or caused by TAM family RTKs hyperfunction. The inventive compounds are further used in the manufacture of a medicament or of a pharmaceutical composition for the treatment and/or prevention of Axl receptor tyrosine induced disorders.
The Axl receptor tyrosine kinase induced disorders are disorders caused by, associated with and/or accomplied by Axl kinase hyperfunction. The Axl receptor tyrosine kinase induced disorders are selected from a group comprising hyperproliferative disorders. The Axl receptor tyrosine kinase induced disorders are selected from the group comprising cancer and primary tumor metastases.
Further advantageous features, aspects and details of the invention are evident from the dependent claims, the description, the examples and the drawings.
It has now surprisingly been discovered that 1-nitrogen-heterocyclic-2-carboxamides of the present invention exhibit particularly high levels of inhibition of the activity of the Axl kinase. The novel compounds according to the present invention are defined by the general formula (I):
Figure US08999982-20150407-C00001
wherein
    • A represents C—R10, N;
    • B represents C—R11, N;
    • D represents one of the following heterocycles:
Figure US08999982-20150407-C00002
    • R1, R4, R88, R92, R100 are selected independently of each other from —H, —F, —Cl, —Br, —I, —OH, —NH2, —NHR19, —NR19R20, —OCH3, —OC2H5, —OC3H7, —OCH(CH3)2, —OC(CH3)3, —OC4H9, —NO2, —CHO, —COCH3, —COC2H5, —COC3H7, —O-cyclo-C3H5, —OCH2-cyclo-C3H5, —O—C2H4-cyclo-C3H5, —OPh, —COCH(CH3)2, —COC(CH3)3, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —OOC—CH3, —OOC—C2H5, —OOC3H7, —OOC—CH(CH3)2, —OOC—C(CH3)3, —NHCH3, —NHC2H5, —NHC3H7, —NHCH(CH3)2, —NHC(CH3)3, —N(CH3)2, —N(C2H5)2, —N(C3H7)2, —N[CH(CH3)2]2, —N[C(CH3)3]2, —OCF3, —OC2F5, —CH2F, —CHF2, —CF3, —CH2Cl, —CH2Br, —CH2I, —CH2—CH2F, —CH2—CHF2, —CH2—CF3, —CH2—CH2Cl, —CH2—CH2Br, —CH2—CH2I, cyclo-C3H5, —CH2-cyclo-C3H5, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CH═CH2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —CH═CH—C2H5, —CH2—C(CH3)═CH2, —CH(CH3)—CH═CH, —CH═C(CH3)2, —C(CH3)═CH—CH3, —CH═CH—CH═CH2, —C3H6—CH═CH2, —C2H4—CH═CH—CH3, —CH2—CH═CH—C2H5, —CH═CH—C3H7, —CH2—CH═CH—CH═CH2, —CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C2H4—C(CH3)═CH2, —CH2—CH(CH3)—CH═CH2, —CH(CH3)—CH2—CH═CH2, —CH2—CH═C(CH3)2, —CH2—C(CH3)═CH—CH3, —CH(CH3)—CH═CH—CH3, —CH═CH—CH(CH3)2, —CH═C(CH3)—C2H5, —C(CH3)═CH—C2H5, —C(CH3)═C(CH3)2, —C(CH3)2—CH═CH2, —CH(CH3)—C(CH3)═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C4H8—CH═CH2, —C3H6—CH═CH—CH3, —C2H4—CH═CH—C2H5, —CH2—CH═CH—C3H7, —CH═CH—C4H9, —C3H6—C(CH3)═CH2, —C2H4—CH(CH3)—CH═CH2, —CH2—CH(CH3)—CH2—CH═CH2, —CH(CH3)—C2H4—CH═CH2, —C2H4—CH═C(CH3)2, —C2H4—C(CH3)═CH—CH3, —CH2—CH(CH3)—CH═CH—CH3, —CH(CH3)—CH2—CH═CH—CH3, —CH2—CH═CH—CH(CH3)2, —CH2—CH═C(CH3)—C2H5, —CH2—C(CH3)═CH—C2H5, —CH(CH3)—CH═CH—C2H5, —CH═CH—CH2—CH(CH3)2, —CH═CH—CH(CH3)—C2H5, —CH═C(CH3)—C3H7, —C(CH3)═CH—C3H7, —CH2—CH(CH3)—C(CH3)═CH2, —CH(CH3)—CH2—C(CH3)═CH2, —CH(CH3)—CH(CH3)—CH═CH2, —CH2—C(CH3)2—CH═CH2, —C(CH3)2—CH2—CH═CH2, —CH2—C(CH3)═C(CH3)2, —CH(CH3)—CH═C(CH3)2, —C(CH3)2—CH═CH—CH3, —CH(CH3)—C(CH3)═CH—CH3, —CH═C(CH3)—CH(CH3)2, —C(CH3)═CH—CH(CH3)2, —C(CH3)═C(CH3)—C2H5, —CH═CH—C(CH3)3, —C(CH3)2—C(CH3)═CH2, —CH(C2H5)—C(CH3)═CH2, —C(CH3)(C2H5)—CH═CH2, —CH(CH3)—C(C2H5)═CH2, —CH2—C(C3H7)═CH2, —CH2—C(C2H5)═CH—CH3, —CH(C2H5)—CH═CH—CH3, —C(C4H9)═CH2, —C(C3H7)═CH—CH3, —C(C2H5)═CH—C2H5, —C(C2H5)═C(CH3)2, —C[C(CH3)3]═CH2, —C[CH(CH3)(C2H5)]═CH2, —C[CH2—CH(CH3)2]═CH2, —C2H4—CH═CH—CH═CH2, —CH2—CH═CH—CH2—CH═CH2, —CH═CH—C2H4—CH═CH2, —CH2CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH—CH3, —CH═CH—CH═CH—C2H5, —CH2—CH═CH—C(CH3)═CH2, —CH2—CH═C(CH3)—CH═CH2, —CH2—C(CH3)═CH—CH═CH2, —CH(CH3)—CH═CH—CH═CH2, —CH═CH—CH2—C(CH3)═CH2, —CH═CH—CH(CH3)—CH═CH2, —CH═C(CH3)—CH2—CH═CH2, —C(CH3)═CH—CH2—CH═CH2, —CH═CH—CH═C(CH3)2, —CH═CH—C(CH3)═CH—CH3, —CH═C(CH3)—CH═CH—CH3, —C(CH3)═CH—CH═CH—CH3, —CH═C(CH3)—C(CH3)═CH2, —C(CH3)═CH—C(CH3)═CH2, —C(CH3)═C(CH3)—CH═CH2, —CH═CH—CH═CH—CH═CH2, C≡CH, —C≡C—CH3, —CH2—C≡CH, —C2H4—C≡CH, —CH2—C≡C—CH3, —C≡C—C2H5, —C3H6—C≡CH, —C2H4—C≡C—CH3, —CH2—C≡C—C2H5, —C≡C—C3H7, —CH(CH3)—C≡CH, —CH2—CH(CH3)—C≡CH, —CH(CH3)—CH2—C≡CH, —CH(CH3)—C≡C—CH3, —C4H8—C≡CH, —C3H6—C≡C—CH3, —C2H4—C≡C—C2H5, —CH2—C═C—C3H7, —C≡C—C4H9, —C2H4—CH(CH3)—C≡CH, —CH2—CH(CH3)—CH2—C≡CH, —CH(CH3)—C2H4—C≡CH, —CH2—CH(CH3)—C≡C—CH3, —CH(CH3)—CH2—C≡C—CH3, —CH(CH3)—C≡C—C2H5, —CH2—C≡C—CH(CH3)2, —C≡C—CH(CH3)—C2H5, —C≡C—CH2—CH(CH3)2, —C═C—C(CH3)3, —CH(C2H5)—C≡C—CH3, —C(CH3)2—C≡C—CH3, —CH(C2H5)—CH2—C≡CH, —CH2—CH(C2H5)—C≡CH, —C(CH3)2—CH2—C≡CH, —CH2—C(CH3)2—C≡CH, —CH(CH3)—CH(CH3)—C≡CH, —CH(C3H7)—C≡CH, —C(CH3)(C2H5)—C≡CH, —C≡C—C≡CH, —CH2—C≡C—C≡CH, —C≡C—C═C—CH3, —CH(C≡CH)2, —C2H4—C═C—C≡CH, —CH2—C≡C—CH2—C≡CH, —C≡C—C2H4—C≡CH, —CH2—C≡C—C≡C—CH3, —C≡C—CH2—C≡C—CH3, —C≡C—C≡C—C2H5, —C≡C—CH(CH3)—C≡CH, —CH(CH3)—C≡C—C≡CH, —CH(C≡CH)—CH2—C≡CH, —C(C≡CH)2—CH3, —CH2—CH(C≡CH)2, —CH(C≡CH)—C≡C—CH3, —R21, —R35, —R38;
    • R2 and R3 are selected independently of each other from —R88, —R37, —R38, —R54, —O—R54, —R55, —O—R55, R56, —O—R56, —R57, —O—R57, wherein the C1-6alkyl, C2-6alkenyl, C2-8alkynyl or C1-6alkoxy groups represented by R88 are optionally mono- or polysubstituted by —OH, —F, —Cl, —Br, —I, —O—R71, —R72, —R138, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16R17, —SO2—NR16R17, —SOm—R16R17, —CR16R17H, —NR16R17;
    • or R2 and/or R3 are selected independently of each other from —O—R18, —O—CR73R74—R18, —O—CR73R74—CR75R76—R18, —O—CR73R74—CR75R76—CR77R78—R18, —O—CR73R74—CR75R76—CR77R78—CR79R80—R18, —O—CR73R74—CR75R76—CR77R78—CR79R80—CR81R82—R18, —O—CR73R74—CR75R76—CR77R78—CR79R80—CR81R82—CR83R84—R18,
R73-R84 independently of each other represent —H, —OH, —F, —Cl, —Br, —I, —R85;
    • R18 represents —H, —OH, —F, —Cl, —Br, —I, —O—R86, —R87, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16R17, —SO2—NR16R17, —SOmR16R17, —NR16R17; m=0, 1, 2;
    • R5 and R6, which may be the same or different, represent —H, —OH, —F, —Cl, —Br, —I, —CN, —NO2, —CH3, —C2H5, —C3H7, —CH(CH3)2, cyclo-C3H5, —CH2-cyclo-C3H5, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CH═CH2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —CH═CH—C2H5, —CH2—C(CH3)═CH2, —CH(CH3)—CH═CH, —CH═C(CH3)2, —C(CH3)═CH—CH3, —CH═CH—CH═CH2, —C3H6—CH═CH2, —C2H4—CH═CH—CH3, —CH2—CH═CH—C2H5, —CH═CH—C3H7, —CH2—CH═CH—CH═CH2, —CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C2H4—C(CH3)═CH2, —CH2—CH(CH3)—CH═CH2, —CH(CH3)—CH2—CH═CH2, —CH2—CH═C(CH3)2, —CH2—C(CH3)═CH—CH3, —CH(CH3)—CH═CH—CH3, —CH═CH—CH(CH3)2, —CH═C(CH3)—C2H5, —C(CH3)═CH—C2H5, —C(CH3)═C(CH3)2, —C(CH3)2—CH═CH2, —CH(CH3)—C(CH3)═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C4H8—CH═CH2, —C3H6—CH═CH—CH3, —C2H4—CH═CH—C2H5, —CH2—CH═CH—C3H7, —CH═CH—C4H9, —C3H6—C(CH3)═CH2, —C2H4—CH(CH3)—CH═CH2, —CH2—CH(CH3)—CH2—CH═CH2, —CH(CH3)—C2H4—CH═CH2, —C2H4—CH═C(CH3)2, —C2H4—C(CH3)═CH—CH3, —CH2—CH(CH3)—CH═CH—CH3, —CH(CH3)—CH2—CH═CH—CH3, —CH2—CH═CH—CH(CH3)2, —CH2—CH═C(CH3)—C2H5, —CH2—C(CH3)═CH—C2H5, —CH(CH3)—CH═CH—C2H5, —CH═CH—CH2—CH(CH3)2, —CH═CH—CH(CH3)—C2H5, —CH═C(CH3)—C3H7, —C(CH3)═CH—C3H7, —CH2—CH(CH3)—C(CH3)═CH2, —CH(CH3)—CH2—C(CH3)═CH2, —CH(CH3)—CH(CH3)—CH═CH2, —CH2—C(CH3)2—CH═CH2, —C(CH3)2—CH2—CH═CH2, —CH2—C(CH3)═C(CH3)2, —CH(CH3)—CH═C(CH3)2, —C(CH3)2—CH═CH—CH3, —CH(CH3)—C(CH3)═CH—CH3, —CH═C(CH3)—CH(CH3)2, —C(CH3)═CH—CH(CH3)2, —C(CH3)═C(CH3)—C2H5, —CH═CH—C(CH3)3, —C(CH3)2—C(CH3)═CH2, —CH(C2H5)—C(CH3)═CH2, —C(CH3)(C2H5)—CH═CH2, —CH(CH3)—C(C2H5)═CH2, —CH2—C(C3H7)═CH2, —CH2—C(C2H5)═CH—CH3, —CH(C2H5)—CH═CH—CH3, —C(C4H9)═CH2, —C(C3H7)═CH—CH3, —C(C2H5)═CH—C2H5, —C(C2H5)═C(CH3)2, —C[C(CH3)3]═CH2, —C[CH(CH3)(C2H5)]═CH2, —C[CH2—CH(CH3)2]═CH2, —C2H4—CH═CH—CH═CH2, —CH2—CH═CH—CH2—CH═CH2, —CH═CH—C2H4—CH═CH2, CH2—CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH—CH3, —CH═CH—CH═CH—C2H5, —CH2—CH═CH—C(CH3)═CH2, —CH2—CH═C(CH3)—CH═CH2, —CH2—C(CH3)═CH—CH═CH2, —CH(CH3)—CH═CH—CH═CH2, —CH═CH—CH2—C(CH3)═CH2, —CH═CH—CH(CH3)—CH═CH2, —CH═C(CH3)—CH2—CH═CH2, —C(CH3)═CH—CH2—CH═CH2, —CH═CH—CH═C(CH3)2, —CH═CH—C(CH3)═CH—CH3, —CH═C(CH3)—CH═CH—CH3, —C(CH3)═CH—CH═CH—CH3, —CH═C(CH3)—C(CH3)═CH2, —C(CH3)═CH—C(CH3)═CH2, —C(CH3)═C(CH3)—CH═CH2, —CH═CH—CH═CH—CH═CH2, —C≡CH, —C≡C—CH3, —CH2—C—CH, —C2H4—C≡CH, —CH2—C≡C—CH3, —C≡C—C2H5, —C3H6—C≡CH, —C2H4—C≡C—CH3, —CH2—C≡C—C2H5, —C≡C—C3H7, —CH(CH3)—C≡CH, —CH2—CH(CH3)—C≡CH, —CH(CH3)—CH2—C≡CH, —CH(CH3)—C≡C—CH3, —C4H6—C≡CH, —C3H6—C≡C—CH3, —C2H4—C≡C—C2H5, —CH2—C≡C—C3H7, —C≡C—C4H9, —C2H4—CH(CH3)—C≡CH, —CH2—CH(CH3)—CH2—C≡CH, —CH(CH3)—C2H4—C≡CH, —CH2—CH(CH3)—C≡C—CH3, —CH(CH3)—CH2—C≡C—CH3, —CH(CH3)—C≡C—C2H5, —CH2—C≡C—CH(CH3)2, —C≡C—CH(CH3)—C2H5, —C≡C—CH2—CH(CH3)2, —C≡C—C(CH3)3, —CH(C2H5)—C═C—CH3, —C(CH3)2—C═C—CH3, —CH(C2H5)—CH2—C≡CH, —CH2—CH(C2H5)—C≡CH, —C(CH3)2—CH2—C≡CH, —CH2—C(CH3)2—C≡CH, —CH(CH3)—CH(CH3)—C≡CH, —CH(C3H7)—C≡CH, —C(CH3)(C2H5)—C≡CH, —C≡C—C≡CH, —CH2—C≡C—C≡CH, CH3, —CH(C—CH)2, —C2H4—C≡C—C≡CH, —CH2—C≡C—CH2—C≡CH, —C≡C—C2H4—CH2—C≡C—C≡C—CH3, —C≡C—CH2—C≡C—CH3, —C≡C—C═C—C2H5, —C≡C—CH(CH3)—C≡CH, —CH(CH3)—C≡C—C≡CH, —CH(C≡CH)—CH2—C≡CH, —C(C≡CH)2—CH3, —CH2—CH(C≡CH)2, —CH(C≡CH)—C≡C—CH3, —O—R89;
    • R7, R8, R10 and R11, which may be the same or different, represent —H, —F, —Cl, —Br, —I, —CN, —NO2, —CH3, —C2H5, —C3H7, —CH(CH3)2, cyclo-C3H5, —CH2-cyclo-C3H5, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CH═CH2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —CH═CH—C2H5, —CH2—C(CH3)═CH2, —CH(CH3)—CH═CH, —CH═C(CH3)2, —C(CH3)═CH—CH3, —CH═CH—CH═CH2, —C3H6—CH═CH2, —C2H4—CH═CH—CH3, —CH2—CH═CH—C2H5, —CH═CH—C3H7, —CH2—CH═CH—CH═CH2, CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C2H4—C(CH3)═CH2, —CH2—CH(CH3)—CH═CH2, —CH(CH3)—CH2—CH═CH2, —CH2—CH═C(CH3)2, —CH2—C(CH3)═CH—CH3, —CH(CH3)—CH═CH—CH3, —CH═CH—CH(CH3)2, —CH═C(CH3)—C2H5, —C(CH3)═CH—C2H5, —C(CH3)═C(CH3)2, —C(CH3)2—CH═CH2, —CH(CH3)—C(CH3)═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C4H8—CH═CH2, —C3H6—CH═CH—CH3, —C2H4—CH═CH—C2H5, —CH2—CH═CH—C3H7, —CH═CH—C4H9, —C3H6—C(CH3)═CH2, —C2H4—CH(CH3)—CH═CH2, —CH2—CH(CH3)—CH2—CH═CH2, —CH(CH3)—C2H4—CH═CH2, —C2H4—CH═C(CH3)2, —C2H4—C(CH3)═CH—CH3, —CH2—CH(CH3)—CH═CH—CH3, —CH(CH3)—CH2—CH═CH—CH3, —CH2—CH═CH—CH(CH3)2, —CH2—CH═C(CH3)—C2H5, —CH2—C(CH3)═CH—C2H5, —CH(CH3)—CH═CH—C2H5, —CH═CH—CH2—CH(CH3)2, —CH═CH—CH(CH3)—C2H5, —CH═C(CH3)—C3H7, —C(CH3)═CH—C3H7, —CH2—CH(CH3)—C(CH3)═CH2, —CH(CH3)—CH2—C(CH3)═CH2, —CH(CH3)—CH(CH3)—CH═CH2, —CH2—C(CH3)2—CH═CH2, —C(CH3)2—CH2—CH═CH2, —CH2—C(CH3)═C(CH3)2, —CH(CH3)—CH═C(CH3)2, —C(CH3)2—CH═CH—CH3, —CH(CH3)—C(CH3)═CH—CH3, —CH═C(CH3)—CH(CH3)2, —C(CH3)═CH—CH(CH3)2, —C(CH3)═C(CH3)—C2H5, —CH═CH—C(CH3)3, —C(CH3)2—C(CH3)═CH2, —CH(C2H5)—C(CH3)═CH2, —C(CH3)(C2H5)—CH═CH2, —CH(CH3)—C(C2H5)═CH2, —CH2—C(C3H7)═CH2, —CH2—C(C2H5)═CH—CH3, —CH(C2H5)—CH═CH—CH3, —C(C4H9)═CH2, —C(C3H7)═CH—CH3, —C(C2H5)═CH—C2H5, —C(C2H5)═C(CH3)2, —C[C(CH3)3]═CH2, —C[CH(CH3)(C2H5)]═CH2, —C[CH2—CH(CH3)2]═CH2, —C2H4—CH═CH—CH═CH2, —CH2—CH═CH—CH2—CH═CH2, —CH═CH—C2H4—CH═CH2, —CH2—CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH—CH3, —CH═CH—CH═CH—C2H5, CH2CH═CH—C(CH3)═CH2, —CH2—CH═C(CH3)—CH═CH2, —CH2—C(CH3)═CH—CH═CH2, —CH(CH3)—CH═CH—CH═CH2, —CH═CH—CH2—C(CH3)═CH2, —CH═CH—CH(CH3)—CH═CH2, —CH═C(CH3)—CH2—CH═CH2, —C(CH3)═CH—CH2—CH═CH2, —CH═CH—CH═C(CH3)2, —CH═CH—C(CH3)═CH—CH3, —CH═C(CH3)—CH═CH—CH3, —C(CH3)═CH—CH═CH—CH3, —CH═C(CH3)—C(CH3)═CH2, —C(CH3)═CH—C(CH3)═CH2, —C(CH3)═C(CH3)—CH═CH2, —CH═CH—CH═CH—CH═CH2, —C≡CH, —C═C—CH3, —CH2—C—CH, —C2H4—C≡CH, —CH2—C═C—CH3, —C≡C—C2H5, —C3H6—C≡CH, —C2H4—C≡C—CH3, —CH2—C≡C—C2H5, —C≡C—C3H7, —CH(CH3)—C≡CH, —CH2—CH(CH3)—C≡CH, —CH(CH3)—CH2—C≡CH, —CH(CH3)—C≡C—CH3, —C4H8—C≡CH, —C3H6—C≡C—CH3, —C2H4—C≡C—C2H5, —CH2—C≡C—C3H7, —C≡C—C4H9, —C2H4—CH(CH3)—C≡CH, —CH2—CH(CH3)—CH2—C≡CH, —CH(CH3)—C2H4—C≡CH, —CH2—CH(CH3)—C≡C—CH3, —CH(CH3)—CH2—C≡C—CH3, —CH(CH3)—C≡C—C2H5, —CH2—C≡C—CH(CH3)2, —C≡C—CH(CH3)—C2H5, —C≡C—CH2—CH(CH3)2, —C═C—C(CH3)3, —CH(C2H5)—C≡C—CH3, —C(CH3)2—C≡C—CH3, —CH(C2H5)—CH2—C≡CH, —CH2—CH(C2H5)—C≡CH, —C(CH3)2—CH2—C≡CH, —CH2—C(CH3)2—C≡CH, —CH(CH3)—CH(CH3)—C≡CH, —CH(C3H7)—C≡CH, —C(CH3)(C2H5)—C≡CH, —C≡C—C≡CH, —CH2—C≡C—C≡CH, —C≡C—C≡C—CH3, —CH(C≡CH)2, —C2H4—C≡C—C≡CH, —CH2—C≡C—CH2—C≡CH, —C≡C—C2H4—C≡C—C≡C—CH3, —C≡C—CH2—C≡C—CH3, —C≡C—C≡C—C2H5, —C≡C—CH(CH3)—C≡CH, —CH(CH3)—C≡C—C≡CH, —CH(C≡CH)—CH2—C≡CH, —C(C≡CH)2—CH3, —CH2—CH(C≡CH)2, —CH(C≡CH)—C≡C—CH3, —O—R90, —O—R110, —O—R111, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl and C1-6alkoxy groups are optionally mono- or polysubstituted by —OH, —F, —Cl, —Br, —I;
    • R9 represents —H, —R91;
    • R12 represent —R92, —CN, —R93, —R94, —OR94, phenyl, naphtalinyl, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl or C1-6alkoxy groups represented by R92 are optionally mono- or polysubstituted by —OH, —F, —Cl, —Br, —I, —O—R95, —R96, —R137, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16R17, —SO2—NR16R17, —SOm—R16R17, —CR16R17H, —NR16R17; and wherein the saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring systems represented by R137 are optionally mono- or polysubstituted by —OH, —F, —Cl, —Br, —I, —R96;
    • R13 is selected from —H, —OH, —F, —Cl, —Br, —I, —NO2, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH3)—CH(CH3)2, (CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CH═CH2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —CH═CH—C2H5, —CH2—C(CH3)═CH2, —CH(CH3)—CH═CH, —CH═C(CH3)2, —C(CH3)═CH—CH3, —CH═CH—CH═CH2, —C3H6—CH═CH2, —C2H4—CH═CH—CH3, —CH2—CH═CH—C2H5, —CH═CH—C3H7, —CH2—CH═CH—CH═CH2, —CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C2H4—C(CH3)═CH2, —CH2—CH(CH3)—CH═CH2, —CH(CH3)—CH2—CH═CH2, —CH2—CH═C(CH3)2, —CH2—C(CH3)═CH—CH3, —CH(CH3)—CH═CH—CH3, —CH═CH—CH(CH3)2, —CH═C(CH3)—C2H5, —C(CH3)═CH—C2H5, —C(CH3)═C(CH3)2, —C(CH3)2—CH═CH2, —CH(CH3)—C(CH3)═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C4H8—CH═CH2, —C3H6—CH═CH—CH3, —C2H4—CH═CH—C2H5, —CH2—CH═CH—C3H7, —CH═CH—C4H9, —C3H6—C(CH3)═CH2, —C2H4—CH(CH3)—CH═CH2, —CH2—CH(CH3)—CH2—CH═CH2, —CH(CH3)—C2H4—CH═CH2, —C2H4—CH═C(CH3)2, —C2H4—C(CH3)═CH—CH3, —CH2—CH(CH3)—CH═CH—CH3, —CH(CH3)—CH2—CH═CH—CH3, —CH2—CH═CH—CH(CH3)2, —CH2—CH═C(CH3)—C2H5, —CH2—C(CH3)═CH—C2H5, —CH(CH3)—CH═CH—C2H5, —CH═CH—CH2—CH(CH3)2, —CH═CH—CH(CH3)—C2H5, —CH═C(CH3)—C3H7, —C(CH3)═CH—C3H7, —CH2—CH(CH3)—C(CH3)═CH2, —CH(CH3)—CH2—C(CH3)═CH2, —CH(CH3)—CH(CH3)—CH═CH2, —CH2—C(CH3)2—CH═CH2, —C(CH3)2—CH2—CH═CH2, —CH2—C(CH3)═C(CH3)2, —CH(CH3)—CH═C(CH3)2, —C(CH3)2—CH═CH—CH3, —CH(CH3)—C(CH3)═CH—CH3, —CH═C(CH3)—CH(CH3)2, —C(CH3)═CH—CH(CH3)2, —C(CH3)═C(CH3)—C2H5, —CH═CH—C(CH3)3, —C(CH3)2—C(CH3)═CH2, —CH(C2H5)—C(CH3)═CH2, —C(CH3)(C2H5)—CH═CH2, —CH(CH3)—C(C2H5)═CH2, —CH2—C(C3H7)═CH2, —CH2—C(C2H5)═CH—CH3, —CH(C2H5)—CH═CH—CH3, —C(C4H9)═CH2, —C(C3H7)═CH—CH3, —C(C2H5)═CH—C2H5, —C(C2H5)═C(CH3)2, —C[C(CH3)3]═CH2, —C[CH(CH3)(C2H5)]═CH2, —C[CH2—CH(CH3)2]═CH2, —C2H4—CH═CH—CH═CH2, —CH2—CH═CH—CH2—CH═CH2, —CH═CH—C2H4—CH═CH2, CH2—CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH—CH3, —CH═CH—CH═CH—C2H5, CH2CH═CH—C(CH3)═CH2, —CH2—CH═C(CH3)—CH═CH2, —CH2—C(CH3)═CH—CH═CH2, —CH(CH3)—CH═CH—CH═CH2, —CH═CH—CH2—C(CH3)═CH2, —CH═CH—CH(CH3)—CH═CH2, —CH═C(CH3)—CH2—CH═CH2, —C(CH3)═CH—CH2—CH═CH2, —CH═CH—CH═C(CH3)2, —CH═CH—C(CH3)═CH—CH3, —CH═C(CH3)—CH═CH—CH3, —C(CH3)═CH—CH═CH—CH3, —CH═C(CH3)—C(CH3)═CH2, —C(CH3)═CH—C(CH3)═CH2, —C(CH3)═C(CH3)—CH═CH2, —CH═CH—CH═CH—CH═CH2, —C≡CH, —C≡C—CH3, —CH2—C≡CH, —C2H4—C≡CH, —CH2—C≡C—CH3, —C≡C—C2H5, —C3H6—C≡CH, —C2H4—C≡C—CH3, —CH2—C≡C—C2H5, —C≡C—C3H7, —CH(CH3)—C≡CH, —CH2—CH(CH3)—C≡CH, —CH(CH3)—CH2—C≡CH, —CH(CH3)—C≡C—CH3, —C4H8—C≡CH, —C3H6—C≡C—CH3, —C2H4—C≡C—C2H5, —CH2—C═C—C3H7, —C≡C—C4H9, —C2H4—CH(CH3)—C≡CH, —CH2—CH(CH3)—CH2—C≡CH, —CH(CH3)—C2H4—C≡CH, —CH2—CH(CH3)—C≡C—CH3, —CH(CH3)—CH2—C≡C—CH3, —CH(CH3)—C≡C—C2H5, —CH2—C≡C—CH(CH3)2, —C≡C—CH(CH3)—C2H5, —C≡C—CH2—CH(CH3)2, —C≡C—C(CH3)3, —CH(C2H5)—C≡C—CH3, —C(CH3)2—C≡C—CH3, —CH(C2H5)—CH2—C≡CH, —CH2—CH(C2H5)—C≡CH, —C(CH3)2—CH2—C≡CH, —CH2—C(CH3)2—C≡CH, —CH(CH3)—CH(CH3)—C≡CH, —CH(C3H7)—C≡CH, —C(CH3)(C2H5)—C≡CH, —C≡C—C≡CH, —CH2—C═C—C≡CH, —C≡C—C═C—CH3, —CH(C—CH)2, —C2H4—C≡C—C≡CH, —CH2—C≡C—CH2—C≡CH, —C≡C—C2H4—C≡CH, —CH2—C≡C—C≡C—CH3, —C≡C—CH2—C═C—CH3, —C≡C—C═C—C2H5, —C≡C—CH(CH3)—C≡CH, —CH(CH3)—C≡C—C≡CH, —CH(C≡CH)—CH2—C≡CH, —C(C≡CH)2—CH3, —CH2—CH(C—CH)2, —CH(C≡CH)—C≡C—CH3, cyclo-C3H5, -Ph, —O—R97, —R98, —R99,
Figure US08999982-20150407-C00003
when R12 and R13 represent alkenylene groups, R12 and R13 may combine to form a condensed aromatic ring together with the atoms of residue D to which R12 and R13 are attached in order to form a bicyclic group with residue D;
    • R14 represents
      (i) —H, —OH, —F, —Cl, —Br, —I, —NO2, —CN, NH2;
      (ii) —R100, —R101, —R102, —O—R102, —R103, —O—R103, —R136, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl and C1-6alkoxy groups represented by R10° and the ether groups represented by —R136 are optionally mono- or polysubstituted by —OH, —F, —Cl, —Br, —I, —O—R104, —R105, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16-17, —SO2—NR16R17, —SOm—R16R17, —CR16R17H, —NR16R17;
      (iii) —R113, wherein the saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system represented by —R113 is optionally mono- or polysubstituted by —F, —Cl, —Br, —I, —OH, —NO2, —NH2, —C2H4—N(CH3)2, —CN, —CF3, ═O, —R16, —R17, —R106, —O—R107, —R108, —R109, a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, wherein the C1-6alkyl groups represented by R106, the C1-6alkenyl groups represented by R108, the C2-6alkynyl groups represented by R109, the C1-6alkoxy groups represented by —O—R107 are optionally mono- or polysubstituted by —OH, —F, —Cl, —Br, —I, —O—R104, —R105, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16R17, —SO2—NR16R17, —SOm—R16R17, —CR16R17H, —NR16R17;
    • R16 and R17, which may be the same or different, represent —H, —R112, optionally substituted by —OH, —F, —Cl, —Br, —I, —NH2, —CN;
    • or alternatively R16 and R17 may combine with the nitrogen atom attached thereto to form a saturated or unsaturated five to eight-membered heterocyclic group selected from —R114; which is optionally mono- or poysubstituted by —OH, ═O, —R116, —R117, —R118, —O—R119, —R120, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system selected from —R115; wherein the C1-6alkyl group represented by R116, C2-6alkenyl group represented by R117, C2-6alkynyl group represented by R118 are optionally substituted by —OH, —R122, or a saturated or unsaturated three- to twelve-membered carbocylic or heterocyclicring system selected from —R121;
    • amino group in which one or two hydrogen atoms on the amino group are optionally substituted by —R123, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system selected from —R124, and the C1-6alkyl group represented by R123 is optionally substituted by —OH, —R125, or a saturated or unsaturated three- to twelve-membered carbocylic or heterocyclic ring system selected from —R126;
    • or a saturated or unsaturated three- to twelve-membered carbocyclic ring system selected from —R127; optionally substituted by —OH, ═O, —R128, —R129, —R130, —O—R131, —R132, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system selected from —R133, wherein the C1-6alkyl group represented by R128, C2-6alkenyl group represented by R129 and C2-6alkynyl group represented by R130 are optionally substituted by —OH, —R134, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system selected from —R135;
    • when the carbocyclic or heterocyclic group is substituted by C1-6alkyl groups, two alkyl groups may combine together to form an alkylene chain; and the carbocyclic or heterocyclic group may be condensed with another saturated or unsaturated five to seven-membered carbocyclic or heterocyclic group to form a bicyclic group;
R19, R20, R71, R85, R86, R89, R90, R91, R95, R97, R104, R106, R107, R110, R111, R112, R116, R119, R122, R123, R125, R128, R131 and R134 independently of each other represent —CH3, —H, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CF3, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H6, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, -Ph, —CH2-Ph;
R21 and R98 represent independently of each other —CR22R23R24, —CR23R24—CR25R26R22, —CR23R23R24—CR25R26—CR27R28R22, —CR23R24—CR25R26—CR27R28—CR29R30R22, —CR23R24—CR25R26—CR27R28—CR29R30—CR31R32R22, —CR23R24—CR25R26—CR27R28—CR29R30—CR31R32—CR33R34R22;
R22-R34 independently of each other represent —H, —F, —Cl, —Br, —I, —CH3, —CF3, —OCH3, —OCF3, —C3H7;
R35 and R99 represent independently of each other —O—CR22R23R24, —O—CR23R24—CR25R26R22, —O—CR23R24—CR25R26—CR27R28R22, —O—R23R24—CR25R26—CR27R28—CR29R30R22, —O—CR23R24—CR25R26—CR27R28—CR29R30—CR31R32R22, —O—CR23R24—CR25R26—CR27R28—CR29R30—CR31R32—CR33R34R22;
R36, R72, R87, R96, R105, R120, R132 and R136 represent independently of each other —CR23R24—XH, —X—CR22R23R24—X—CR23R24—CR25R26R22, —CR23R24—X—CR25R26R22, —CR23R24—CR25R26—XH, —X—CR23R24—CR25R26—CR27R28R22, —CR23R24—X—CR25R26—R27R28R22, —CR23R24—CR25R26—X—CR27R28R22, —CR23R24—CR25R26—CR27R28—XH, —X—CR23R24—CR25R26—CR27R28—CR29R30R22, —CR23R24—X—CR25R26—CR27R28—CR29R30R22, —CR23R24—CR25R26—X—CR27R28—CR29R30R22, —CR23R24—CR25R26—CR27R28—X—CR29R30R22, —CR23R24—CR25R26—CR27R28—CR29R30—XH, —X—CR23R24—CR25R26—CR27R28—CR29R30—CR31R32R22, —CR23R24—X—CR25R26—CR27R28—CR29R30—CR31R32R22, —CR23R24—CR25R26—X—CR27R28—CR29R30—CR31R32R22, —CR23R24—CR25R26—CR27R28—X—CR29R30—CR31R32R22, —CR23R24—CR25R26—CR27R28—CR29R30—X—CR31R32R22, —CR23R24—CR25R26—CR27R28—COR29R30—CR31R32—XH, —X—CR23R24—CR25R26—CR27R28—CR29R30—CR31R32—CR33R34R22, —CR23R24—X—CR25R26—CR27R28—CR29R30—CR31R32—CR33R34R22, —CR23R24—CR25R26—X—CR27R28—CR29R30—CR31R32—CR33R34R22, —CR23R24—CR25R26—CR27R28—X—CR29R30—CR31R32—CR33R34R22, —CR23R24—CR25R26—CR27R28—CR29R30—X—CR31R32—CR33R34R22, —CR23R24—CR25R26—CR27R28—CR29R30—CR31R32—X—CR33R34R22, —CR23R24—CR25R26—CR27R28—CR29R30—OR31R32—CR33R34—XH;
X represents —O—, —CO—, —O—CO—
R37, R38, R93 and R101 represent independently of each other —CR40R41—YH, —Y—CR39R40R41, —Y—CR40R41—CR42R43R39, —CR40R41—Y—CR42R43R39, —CR40R41—CR42R43—YH, —Y—CR40R41—CR42R43—CR44R45R39, —CR40R41—Y—CR42R43—CR44R45R39, —CR40R41—CR42R43—Y—CR44R45R39, —CR40R41—CR42R43—CR44R45—YH, —Y—CR40R41—CR42R43—CR44R45—CR46R47R39, —CR40R41—Y—CR42R43—CR44R45—CR46R47R39, —CR40R41—CR42R43—Y—CR44R45—CR46R47R39, —CR40R41—CR42R43—CR44R45—Y—CR46R46R39, —CR40R42—CR42R43—CR44R45—CR46R47—YH, —Y—CR40R41CR42R43—CR44R45—CR46R47—CR48R49R39, —CR40R41—Y—CR42R43—CR44R45—CR46R47—CR48R49R39, —CR40R41—CR42R43—Y—CR44R45—CR46R47—CR48R49R39, —CR40R41—CR42R43—CR44R45—Y—CR46R47—COR48R49R39, —CR40R41—CR42R43—CR44R45—CR46R47—Y—CR48R49R39, —CR40R41—CR42R43—CR44R45—CR46R47—CR48R49—YH, —Y—CR40R41—CR42R43—CR44R45—CR46R47—CR48R49—CR50R51R39, —CR40R41—Y—CR42R43—CR44R45—CR46R47—CR48R49—CR50R51R39, —CR40R41—CR42R43—Y—CR44R45—CR46R47—CR48R49—CR50R51R39, —CR40R41—CR42R43—CR44R45—Y—CR46R47—CR48R49—CR50R51R39, —CR40R41—CR42R43—CR44R45—CR46R47—Y—CR48R49—CR50R51R39, —CR40R41—CR42R43—CR44R45—CR46R47—CR48R49—Y—CR50R51R39, —CR40R41—CR42R43—CR44R45—CR46R47—CR48R49—CR50R51—YH;
R39—R53 represent independently of each other —H, —CH3, —C2H5, —C3H7;
Y represents —NR52—CO—, —CO—NR13—;
R54, R55 and R102 represent independently of each other
Figure US08999982-20150407-C00004
Figure US08999982-20150407-C00005
Figure US08999982-20150407-C00006
R56, R57, R94 and R103 represent independently of each other —CR58R16R17, —CR58R59R60—CR16R17—CR61R62R58, —CR59R60—CR61R62R58, —CR59R60—CR16R17R58, —CR16R17—CR61R62—CR63R64R58, —CR59R60—CR61R62—CR63R64R58, —CR59R60—CR16R17—CR63R64R58, —CR59R60—CR61R62—CR16R17R58, —CR16R17—CR61R62—CR63R64—CR65R66R58, —CR59R60—CR61R62—CR63R64—CR65R66R58, —CR59R60—CR16R17—CR63R64—CR66R67R58, —CR59R60—CR61R62—CR16R17—CR65R66R58, —CR59R60—CR61R62—CR63R64—CR16R17R58, —CR16R17—CR61R62—CR63R64—CR65R66—CR67R68R58, —CR59R60—CR61R62—CR63R64—CR65R66—CR67R68R58, —CR59R60—CR16R17—CR63R64—CR65R66—CR67R68R58, —CR59R60—CR61R62—CR16R17—CR65R66—CR67R68R69, —CR59R60—CR61R62—CR63R64—CR16R17—CR67R68R58, —CR59R60—CR61R62—CR63R64—CR65R66—CR16R17R58, —CR16R17—CR61R62—CR63R64—CR65R66—CR67R68—CR69R70R58, —CR59R60—CR16R17—CR63R64—CR65R66—CR67R68—CR69R70R58, —CR59R60—CR61R62—CR16R17—CR65R66—CR67R68—CR69R70R58, —CR59R60—CR61R62—CR63R64—CR16R17—CR67R68—CR69R70R58, —CR59R60—CR61R62—CR63R64—CR65R66—CR16R17—CR69R70R58, —CR59R60—CR61R62—CR63R64—CR65R66—CR67R68—CR16R17R58;
R58-R70 represent independently of each other —H, —NH2, —OH, —F, —Cl, —Br, —I, —R71, —O—R71, —R72, —O—R95, —R96, —O—R104, —R105, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16R17, —SO2—NR16R17, —SOm—R16R17, —CR16R17H, —NR16R17;
R108, R117 and R129 represent independently of each other —CH═CH2, —CH2—CH═CH2, —H, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —CH═CH—C2H5, —CH2—C(CH3)═CH2, —CH(CH3)—CH═CH, —CH═C(CH3)2, —C(CH3)═CH—CH3, —CH═CH—CH═CH2, —C3H6—CH═CH2, —C2H4—CH═CH—CH3, —CH2—CH═CH—C2H5, —CH═CH—C3H7, —CH2—CH═CH—CH═CH2, —CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C2H4—C(CH3)═CH2, —CH2—CH(CH3)—CH═CH2, —CH(CH3)—CH2—CH═CH2, —CH2—CH═C(CH3)2, —CH2—C(CH3)═CH—CH3, —CH(CH3)—CH═CH—CH3, —CH═CH—CH(CH3)2, —CH═C(CH3)—C2H5, —C(CH3)═CH—C2H5, —C(CH3)═C(CH3)2, —C(CH3)2—CH═CH2, —CH(CH3)—C(CH3)═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C4H8—CH═CH2, —C3H6—CH═CH—CH3, —C2H4—CH═CH—C2H5, —CH2—CH═CH—C3H7, —CH═CH—C4H9, —C3H6—C(CH3)═CH2, —C2H4—CH(CH3)—CH═CH2, —CH2—CH(CH3)—CH2—CH═CH2, —CH(CH3)—C2H4—CH═CH2, —C2H4—CH═C(CH3)2, —C2H4—C(CH3)═CH—CH3, —CH2—CH(CH3)—CH═CH—CH3, —CH(CH3)—CH2—CH═CH—CH3, —CH2—CH═CH—CH(CH3)2, —CH2—CH═C(CH3)—C2H5, —CH2—C(CH3)═CH—C2H5, —CH(CH3)—CH═CH—C2H5, —CH═CH—CH2—CH(CH3)2, —CH═CH—CH(CH3)—C2H5, —CH═C(CH3)—C3H7, —C(CH3)═CH—C3H7, —CH2—CH(CH3)—C(CH3)═CH2, —CH(CH3)—CH2—C(CH3)═CH2, —CH(CH3)—CH(CH3)—CH═CH2, —CH2—C(CH3)2—CH═CH2, —C(CH3)2—CH2—CH═CH2, —CH2—C(CH3)═C(CH3)2, —CH(CH3)—CH═C(CH3)2, —C(CH3)2—CH═CH—CH3, —CH(CH3)—C(CH3)═CH—CH3, —CH═C(CH3)—CH(CH3)2, —C(CH3)═CH—CH(CH3)2, —C(CH3)═C(CH3)—C2H5, —CH═CH—C(CH3)3, —C(CH3)2—C(CH3)═CH2, —CH(C2H5)—C(CH3)═CH2, —C(CH3)(C2H5)—CH═CH2, —CH(CH3)—C(C2H5)═CH2, —CH2—C(C3H7)═CH2, —CH2—C(C2H5)═CH—CH3, —CH(C2H5)—CH═CH—CH3, —C(C4H9)═CH2, —C(C3H7)═CH—CH3, —C(C2H5)═CH—C2H5, —C(C2H5)═C(CH3)2, —C[C(CH3)3]═CH2, —C[CH(CH3)(C2H5)]═CH2, —C[CH2—CH(CH3)2]═CH2, —C2H4—CH═CH—CH═CH2, —CH2—CH═CH—CH2—CH═CH2, —CH═CH—C2H4—CH═CH2, CH2—CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH—CH3, —CH═CH—CH═CH—C2H5, —CH2—CH═CH—C(CH3)═CH2, —CH2—CH═C(CH3)—CH═CH2, —CH2—C(CH3)═CH—CH═CH2, —CH(CH3)—CH═CH—CH═CH2, —CH═CH—CH2—C(CH3)═CH2, —CH═CH—CH(CH3)—CH═CH2, —CH═C(CH3)—CH2—CH═CH2, —C(CH3)═CH—CH2—CH═CH2, —CH═CH—CH═C(CH3)2, —CH═CH—C(CH3)═CH—CH3, —CH═C(CH3)—CH═CH—CH3, —C(CH3)═CH—CH═CH—CH3, —CH═C(CH3)—C(CH3)═CH2, —C(CH3)═CH—C(CH3)═CH2, —C(CH3)═C(CH3)—CH═CH2, —CH═CH—CH═CH—CH═CH2;
R109, R118 and R130 represent independently of each other —H, —C≡CH, —C≡C—CH3, —CH2—C≡CH, —C2H4—C≡CH, —CH2—C≡C—CH3, —C═C—C2H5, —C3H6—C≡CH, —C2H4—C═C—CH3, —CH2—C≡C—C2H5, —C≡C—C3H7, —CH(CH3)—C≡CH, CH(CH3)—C≡CH, —CH(CH3)—CH2—C≡CH, —CH(CH3)—C≡C—CH3, —C4H8—C≡CH, —C3H6—C≡C—CH3, —C2H4—C≡C—C2H5, —CH2—C≡C—C3H7, —C≡C—C4H9, —C2H4—CH(CH3)—C≡CH, —CH2—CH(CH3)—CH2—C≡CH, —CH(CH3)—C2H4—C≡CH, —CH2—CH(CH3)—C≡C—CH3, —CH(CH3)—CH2—C≡C—CH3, —CH(CH3)—C≡C—C2H5, —CH2—C≡C—CH(CH3)2, —C≡C—CH(CH3)—C2H5, —C≡C—CH2—CH(CH3)2, —C≡C—C(CH3)3, —CH(C2H5)—C≡C—CH3, —C(CH3)2—C≡C—CH3, —CH(C2H5)—CH2—C≡CH, —CH2—CH(C2H5)—C≡CH, —C(CH3)2—CH2—C≡CH, —CH2—C(CH3)2—C≡CH, —CH(CH3)—CH(CH3)—C≡CH, —CH(C3H7)—C≡CH, —C(CH3)(C2H5)—C≡CH, —C≡C—C≡CH, —CH2—C≡C—C≡CH, —C≡C—C≡C—CH3, —CH(C—CH)2, —C2H4—C≡C—C≡CH, —CH2—C≡C—CH2—C≡CH, —C≡C—C2H4—C≡CH, —CH2—C≡C—C≡C—CH3, —C≡C—CH2—C≡C—CH3, —C≡C—C≡C—C2H5, —C≡C—CH(CH3)—C≡CH, —CH(CH3)—C≡C—C≡CH, —CH(C≡CH)—CH2—C≡CH, —C(C≡CH)2—CH3, —CH2—CH(C≡CH)2, —CH(C≡CH)—C≡C—CH3;
R113, R115, R121, R124, R126, R127, R133, R135, R137 and R138 independently of each other represent
Figure US08999982-20150407-C00007
Figure US08999982-20150407-C00008
Figure US08999982-20150407-C00009
Figure US08999982-20150407-C00010
Figure US08999982-20150407-C00011
Figure US08999982-20150407-C00012
Figure US08999982-20150407-C00013
Figure US08999982-20150407-C00014
R114 represents
Figure US08999982-20150407-C00015
and enantiomers, stereoisomeric forms, mixtures of enantiomers, diastereomers, mixtures of diastereomers, prodrugs, hydrates, solvates, acid salt forms, tautomers, and racemates of the above mentioned compounds and pharmaceutically acceptable salts thereof.
The expression prodrug is defined as a substance, which is applied in an inactive or significantly less active form. Once applied and incorporated, the prodrug is metabolized in the body in vivo into the active compound. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example in “Design of Prodrugs”, ed. H. B. Bundgaard, Elsevier, 1985.
The residue D contains at least one nitrogen atom. Said residue may contain one oxygen atom or one sulfur atom in addition to said one nitrogen atom. If no oxygen and no sulfur atom is present, said residue may contain one, two or three additional nitrogen atoms so that said residue contains in total one, two, three or four nitrogen atoms. The position of the nitrogen atom in residue D is essential to the activity of the compound. It is important that this nitrogen atom is in β position to the carbonyl group and that the ring D which is most preferably aromatic forms a conjugated system with the attached carbonyl group or that at least the ring nitrogen in β position together with the alpha carbon atom and the attached carbonyl group form a conjugated system.
Thus, as residues D pyrazoles, imidazoles, oxazoles, isoxazoles, thiazoles, isothiazoles, triazoles, and tetrazoles are preferred. In order to obtain a high anti-cancer activity is seems to be important that the heterocyclic ring D contains a nitrogen atom next to the carbon atom through which the ring D is connected to the amid bond. Moreover pyrazoles, imidazoles, triazoles, and tetrazoles are more preferred than oxazoles, isoxazoles, thiazoles, and isothiazoles and pyrazoles are more preferred than triazoles, and tetrazoles which are again more preferred than imidazoles. Furthermore isoxazoles and isothiazoles are more preferred than oxazoles and thiazoles.
Concerning isoxazole residues as substituent D it is important that the isoxazole residue is linked through the 3-yl-carbon atom to the amide group and not through the 4-yl-carbon atom or the 5-yl-carbon atom. In case of an oxazole group as substituent D it is important that the oxazole group is linked to the amide group through 2-yl-carbon atom or the 4-yl-carbon atom but not through the 5-yl-carbon atom. A pyrazole residue should be linked to the amide group through the 3-yl-carbon atom and not through the 4-yl-carbon atom or the through the 5-yl-carbon atom.
Thiazole residues as substituent D are linked to the amide group through the 2-yl-carbon atom or the 4-yl-carbon atom, but not through the 5-yl-carbon atom. Similiar, isothiazoles are linked through the 3-yl carbon atom, but not through the 4-yl-carbon atom or 5-yl-carbon atom. Imidazoles are linked through the 2-yl-carbon or 4-yl-carbon atom, but not through the 5-yl-carbon position.
Moreover it is important that the residue D is directly connected to the amide group and not through a linker such as a methylene or ethylene linker so that the carbonyl function of the amide group can be in conjugation with the preferably aromatic ring D.
SAR
The structure activity relationship (SAR) of the compounds of the present invention as represented by the Formula (SAR)
Figure US08999982-20150407-C00016
shows that ring D need to be an aromatic 5-membered heterocyclic ring with at least one nitrogen atom attached to the carbon atom of the aromatic ring which is attached to the amide group. Moreover it seems advantageous that the ring D is linked through a carbon atom to the amide group. The nitrogen atom of the amide group may be substituted by alkyl and substituted alkyl residues. Moreover the aromatic 5-membered ring D has to have a specific substitution pattern in order to provide active compounds for the uses disclosed herein. Said specific substitution pattern requires that substituent R13 is only a small group such as hydrogen, methyl, trifluoromethyl, fluoro, ethyl, otherwise the activity drops. Furthermore it seems to be advantageous that a larger group such as a substituted phenyl group is attached as R14 to the atom next to the ring nitrogen atom as shown in Formula (SAR). In addition a substituent R12 in position next to the ring carbon atom of ring D which is attached to the amide group seems to increase the activity. As substituent R12 short carbon chains as well as longer carbon chains, short or long alkoxy groups, ether or polyether residues or amines seem to be suitable. Thus compounds with an aromatic nitrogen containing 5-membered ring as substituent D with a small substituent R13 and a cyclic substituent R14 and a smaller or longer carbon chain as substituent R12 containing optionally oxygen (ethers) and/or nitrogen (amines) and/or cyclic structures such as saturated or unsaturated carbocyclic or heterocyclic rings seem to perfectly fit into the active side of the enzyme. In addition it is not important for the activity if A and B are carbon or nitrogen atoms. It seems also not important if substituents R7, R8, R5, R6, R2, and R1 are smaller groups such as nitro, halogen, lower alkyl, lower alkoxy, hydroxy etc. and substituents R2 and R3 can be modified in a broard range. The sort of residue R2 and R3 is not important for the activity so that R2 and R3 can be hydrogen, smaller groups such as methyl or methoxy as well as longer residues with a carbon chain containing optionally oxygen, nitrogen or saturated, unsaturated carbocyclic or heterocyclic rings.
Preferred is the formula (I), wherein the residue D represents one of the following heterocycles:
Figure US08999982-20150407-C00017
The substituents R12-R14 have the meanings as defined in formula (I) above.
Still more preferred are the following D residues:
Figure US08999982-20150407-C00018
Particularly preferred are compounds of the general formula (Ia),
Figure US08999982-20150407-C00019
wherein residue D is a substituted or unsubstituted pyrazole ring.
Especially preferred are compounds of the general formula (Ib) or the general formula (Ic),
Figure US08999982-20150407-C00020
wherein both, group A and group B are carbon atoms or wherein group A is a carbon atom and group B is a nitrogen atom, respectively.
Further preferred are compounds of the general formulas (I), (Ia), (Ib), or (Ic), wherein R1, R4, R5 and R6 are selected from hydrogen or C1-6alkyl, particularly from hydrogen.
Furthermore preferred are compounds of the general formulas (I), (Ia), (Ib), or (Ic), wherein R9 is a hydrogen atom.
In regard to A and B it is preferred that non of both or only one of both represents N.
Substituents R1, R4, R5, and R6 are preferably hydrogen.
Substituents R2 and R3 are preferably selected independently of each other from:
—O—R18, —O—CR73R74—R18, —O—CR73R74—CR75R76—R18, —O—CR73R74—CR75R76—CR77R78—R18, —C—CR73R74—CR75R76—CR77R78—CR79R80—R18, —O—CR73R74—CR75R76—CR77R78—CR79R80—CR81R82—R18, —O—CR73R74—CR75R76—CR77R78—CR79R80—CR81R82—CR83R84—R18,
wherein R73— R84 independently of each other represent —H, —OH, —F, —Cl, —Br, —I, —CH3, —CF3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3;
and R18 represents —H, —OH, —F, —Cl, —Br, —I, —O—R86, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16R17, —CR16R17H, NR16R17, —NR16R17;
R86 represents —CH3, —CF3, —H, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—O2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3;
R16 and R17 represent independently of each other —CH3, —CF3, —H, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —OH, —F, —Cl, —Br, —I, —NH2, —CN,
the residue —NR16R17 may represent a nitrogen heterocyclic group selected from
Figure US08999982-20150407-C00021
and more preferably selected from
Figure US08999982-20150407-C00022
the residue —CR16R17H may represent a carbocyclic or heterocyclic group selected from
Figure US08999982-20150407-C00023
Substituents R7 and R8 are preferably selected independently of each other from:
—H, —F, —Cl, —Br, —I, —CN, —NO2, —CH3, —C2H5, —C3H7, —CH(CH3)2, cyclo-C3H5, —CH2-cyclo-C3H5, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH═CH2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —C≡CH, —C≡C—CH3, —CH2—C≡CH, —C2H4—C≡CH, —CH2—C≡C—CH3; and are more preferably selected from —H, —F, —Cl, —Br, —CN, —CH3, —C2H5, —C3H7, —CH(CH3)2, cyclo-C3H5, —CH═CH2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C≡CH, —C≡C—CH3, —CH2—C≡CH; and are still more preferably selected from —H, —F, —Cl, —Br, —CH3, —C2H5, —C3H7, —CH(CH3)2, cyclo-C3H5, —CH═CH2, —CH2—CH═CH2, —C≡CH, —CH2—C≡CH; and R7 and R8 are most preferably selected independently of each other from —H, —F, —Cl, —CH3.
Moreover it is preferred that one of R7 and R8 represents hydrogen.
A and B represent preferably independently of each other C—H, C—F, C—Cl, C—Br, C—CN, C—CH3, C—C2H5, C—C3H7, C—CH(CH3)2, C-cyclo-C3H5, C—CH═CH2, C—CH2—CH═CH2, C—CH═CH—CH3, C—C≡CH, C—C≡C—CH3, C—CH2—C≡CH, C—OCH3, C—OH, C—OC2H5, C—OC3H7, C—OCH(CH3)2, C—OC4H9, C—OCH2—CH(CH3)2, C—OCH(CH3)—C2H5, C—OC(CH3)3, C—OC5H11, N. Moreover it is preferred that one of A and B represents C—H. In addition it is preferred that only one of A and B represents N. More preferably A and B represent independently of each other C—H, C—F, C—Cl, C—Br, C—CH3, C—C2H5, C—C3H7, C—CH(CH3)2, C-cyclo-C3H5, C—CH═CH2, C—CH2—CH═CH2, C—C≡CH, C—OCH3, C—OH, C—OC2H5, C—OC3H7, C—OCH(CH3)2, N; still more preferably C—H, C—F, C—Cl, C—CH3, C—C2H5, C—C3H7, C—CH2—CH═CH2, C—OCH3, C—OH, C—OC2H5, C—OC3H7, N; and most preferably A and B represent independently of each other C—H, C—F, C—CH3, C—OCH3, and N.
R9 represents preferably hydrogen.
R14 represents preferably —H, —OH, —F, —Cl, —Br, —I, —NO2, —CN, —NH2, —R100, —R101, —R102, —O—R102, —R103, —O—R103, —R136, or —R113, wherein the saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system represented by —R113 is optionally mono- or polysubstituted by —F, —Cl, —Br, —I, —OH, —NO2, —NH2, —C2H4—N(CH3)2, —CN, —CF3, ═O, —R16, —R17, —R106, —O—R107, —R108, —R109, wherein the substituents R16, R17, R100, R101, R102, R103, R106, R107, R100, R109, R113, and R136 have the meanings as disclosed herein.
More preferably R14 represents —Cl, —Br, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —R103, —R136, and —R113, wherein the saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system represented by —R113 is optionally mono- or polysubstituted by —F, —Cl, —Br, —OH, —NO2, —NH2, —C2H4—N(CH3)2, —R16, —R106, —O—R107, —R108, —R109;
Preferably R103 represents preferably —CR58R16R17, —CR59R60—CR16R17R58, —CR59R60—CR61R62—CR16R17R58, —CR59R60—CR61R62—CR63R64—CR16R17R58, —CR59R60—CR61R62—CR63R64—CR65R66—CR16R17R58, —CR59R60—CR61R62—CR63R64—CR65R66—CR67R68—CR16R17R58, —CR58R59R60, CR59R60—CR61R62R58, CR59R60—CR61R62—CR63R64R58, —CR59R60—CR61R62—CR63R64—CR65R66R58, —CR59R60—CR61R62—CR63R64—CR65R66—CR67R68R58, and
R58-R68 represent independently of each other —H, —NH2, —OH, —F, —Cl, —Br, —I, —OCH3, —OCF3, —OC2H5, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CF3, —C(CH3)3, —CR16R17H, —NR16R17; wherein R16 and R17 have the meanings as disclosed herein.
More preferably R103 represents —CR68R69R60, —CR59R60—CR61R62R58, —CR59R60—CR61R62—CR63R64R58, —CR59R60—CR61R62—CR63R64—CR65R66R58, —CR59R60—CR61R62—CR63R64—CR65R66—CR67R68R58, and R58 represents —CR16R17H or —NR18R17; and
R59-R68 represent independently of each other —H, —NH2, —OH, —F, —Cl, —Br, —I, —OCH3, —OC2H5, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CF3, —C(CH3)3; and R16 and R17 represent independently of each other —H, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C5H11, —CF3, -Ph, —CH2-Ph, or represent together with the atom to which they are attached a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system selected from —R133, wherein R133 has the meanings as disclosed herein.
Still more preferably R103 represents —CR58R59R60, —CR59R60—CR61R62R58, —CR59R60—CR61R62—CR63R64R58, —CR59R60—CR61R62—CR63R64—CR65R66R58, —CR59R60—CR61R62—CR63R64—CR65R66—CR67R68R58, and R58 represents
Figure US08999982-20150407-C00024
and R59-R68 represent independently of each other —H, —CH3, —C2H5, —CF3.
Still even more preferably R103 represents —CH2R58, —CH2—CH2R58, —CH2—CH2—CH2R58, —CH2—CH2—CH2—CH2R58, CH2—CH2—CH2—CH2—CH2R58, and R58 represents
Figure US08999982-20150407-C00025
Most preferably R103 represents —CH2R58, —CH2—CH2R58, —CH2—CH2—CH2R58, —CH2—CH2—CH2—CH2R58, and R58 represents
Figure US08999982-20150407-C00026
Preferably R136 represents —CR23R24—X—CR25R26R22, —CR23R24—X—CR25R26—CR27R28R22, —CR23R24—CR25R26—X—CR27R28R22, —CR23R24—X—CR25R26—CR27R28—CR29R30R22, —CR23R24—CR25R26—X—CR27R28—CR29R30R22, —CR23R24—CR25R26—CR27R28—X—CR29R30R22, —CR23R24—X—CR25R26—CR27R28—CR29R30—CR31R32R22, —CR23R24—CR25R26—X—CR27R28—CR29R30—CR31R32R22, —CR23R24—CR25R26—CR27R28—X—CR29R30—CR31R32R22, —CR23R24—CR25R26—CR27R28—CR29R30—X—CR31R32R22, —CR23R24—X—CR25R26—CR27R28—CR29R30—CR31R32—CR33R34R22, —CR23R24—CR25R26—X—CR27R28—CR29R30—CR31R32—CR33R34R22, —CR23R24—CR25R26—CR27R28—X—CR29R30—CR31R32—CR33R34R22, —CR23R24—CR25R26—CR27R28—CR29R30—X—CR31R32—CR33R34R22, —CR23R24—CR25R26—CR27R28—CR29R30—CR31R32—X—CR33R34R22; and X represents —O—, —CO—, —O—CO— and R22— R34 represent independently of each other —H, —F, —Cl, —CH3, —CF3, —C2H5, —C3H7.
More preferably R136 represents —CR23R24—X—CR25R26R22, —CR23R24—X—CR25R26—CR27R28R22, —CR23R24—CR25R26—X—CR27R28R22, —CR23R24—X—CR25R26—CR27R28—CR29R30R22, —CR23R24—CR25R26—X—CR27R28—CR29R30R22, —CR23R24—CR25R26—CR27R28—X—CR29R30R22, —CR23R24—X—CR25R26—CR27R28—CR29R30—CR31R32R22, —CR23R24—CR25R26—X—CR27R28—CR29R30—CR31R32R22, —CR23R24—CR25R26—CR27R28—X—CR29R30—CR31R32R22, —CR23R24—CR25R26—CR27R28—CR29R30—X—CR31R32R22; and X represents —O—, and R22— R32 represent independently of each other —H, —CH3, —CF3, —C2H5, —C3H7.
Still more preferably R136 represents —CH2—O—CH2R22, —CH2—O—CH2—CH2R22, —CH2—CH2—O—CH2R22, —CH2—O—CH2—CH2—CH2R22, —CH2—C2—CH—O—CH2—CH2R22, —CH2—CH2—CH2—O—CH2R22, —CH2—O—CH2—H2—CH2—CH2—CH2R22, —CH2—CH2—O—CH2—CH2—CH2R22, —CH2—CH2—CH2—O—CH2—CH2R22, —CH2—CH2—CH2—CH2—O—CH2R22; and R22 represents —H, —CH3, —CF3, —C2H5, —C3H7.
Still even more preferably R136 represents —CH2—O—CH2R22, —CH2—O—CH2—CH2R22, —CH2—CH2—O—CH2R22, —CH2—O—CH2—CH2—CH2R22, —CH2—CH2—O—CH2—CH2R22, —CH2—CH2—CH2—O—CH2R22; and R22 represents —H, —CH3, —CF3, —C2H5.
Most preferably R136 represents —CH2—O—CH2CF3, —CH2—O—CH2—CH2CF3, —CH2—CH2—O—CH2CF3.
R113 represents preferably
Figure US08999982-20150407-C00027
Figure US08999982-20150407-C00028
Figure US08999982-20150407-C00029
Figure US08999982-20150407-C00030
Figure US08999982-20150407-C00031
wherein the afore-mentioned residues R113 can be substituted by one or more substituents selected from —F, —Cl, —Br, —I, —OH, —NO2, —NH2, —C2H4—N(CH3)2, —CN, —CF3, ═O, —R16, —R17, —R106, —O—R107, —R108, —R109, and wherein R16, R17, R100, R101, R102, R103, R106, R107, R108, R109, R113, and R136 have the meanings as disclosed herein.
Still more preferably R113 represents
Figure US08999982-20150407-C00032
Figure US08999982-20150407-C00033
wherein the afore-mentioned residues R113 can be substituted by one or more substituents selected from —F, —Cl, —Br, —I, —OH, —NO2, —NH2, —C2H4—N(CH3)2, —CN, —CF3, ═O, —R16, —R17, —R106, —O—R107, —R108, —R109, and wherein R16, R17, R100, R101, R102, R103, R106, R107, R108, R109, R113, and R136 have the meanings as disclosed herein.
Still more preferably R113 represents
Figure US08999982-20150407-C00034
Figure US08999982-20150407-C00035
wherein R15, R15*, R16, R106, R107, R108, and R109 have the meanings as disclosed herein and more preferably R109 represent —H, —C≡CH, or —CH2—C≡CH; and R108 represent —H, —CH═CH2, or —CH2—CH═CH2; and
R16, R106 and R107 represent independently of each other —H, —CH3, —CF3, -Ph, —CH2-Ph, —O2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3;
and R15 and R15* represent independently of each other —H, —F, —Cl, —Br, —I, —OH, —NO2, —NH2, —C2H4—N(CH3)2, —CN, —CF3, ═O;
Still more preferably R15 and R15* represent independently of each other —H, —F, —Cl, —Br, —OH, —NO2, —NH2, —C2H4—N(CH3)2, and still more preferably R16 represents —H, —CH3, —CF3, —C2H5; R106 represents more preferably —H, —CH3, —CF3, —C2H5; and R107 represents more preferably —H, —CH3, —CF3, -Ph, —CH2-Ph, —C2H5, —C3H7, —CH(CH3)2, —C4H9;
Most preferably R113 represents
Figure US08999982-20150407-C00036
Residues for R14 proved by examples and thus preferred resudes are: —H, —Br, —CH3, —C3H7, —C(CH3)3, -Ph, —CH2—O—CH2—CF3
Figure US08999982-20150407-C00037
In case R14 is attached to a nitrogen atom, R14 does not represent —Br.
Preferably R13 represents —H, —OH, —F, —Cl, —Br, —NO2, —CH3, —CF3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH═CH2, —CH2—CH═CH2, —CH═CH—CH3, —C≡CH, —C═C—CH3, —CH2—C≡CH, cyclo-C3H5, —OCH3, —OCF3, —OC2H5, —OC3H7, —OCH(CH3)2, or —OC4H9;
More preferably R13 represents —H, —OH, —F, —Cl, —NO2, —CH3, —CF3, —C2H5, —C3H7, —CH═CH2, —CH2—CH═CH2, —C≡CH, —CH2—C≡CH, cyclo-C3H5, —OCH3, —OCF3, —OC2H5, or —OC3H7.
Still more preferably R13 represents —H, —OH, —F, —CH3, —CF3, —C2H5, —CH═CH2, —C≡CH, —OCH3, —OCF3, or —OC2H5.
Most preferably R13 represents —H, —F, —CH3, —CF3, or —C2H5.
Preferably R12 represents —H, —F, —Cl, —Br, —I, —OH, —NH2, —NHR19, —NR19R20, —OCH3, —OCF3, —OC2F5, —OC2H5, —OC3H7, —O-cyclo-C3H5, —OCH2-cyclo-C3H5, —O—C2H4-cyclo-C3H5, —O—C3H5-cyclo-C3H5, —OCH(CH3)2, —OC(CH3)3, —OC4H9, —OPh, —NO2, —R94, —OR94, —NHCH3, —NHC2H5, —NHC3H7, —NHCH(CH3)2, —NHC(CH3)3, —N(CH3)2, —N(C2H5)2, —N(C3H7)2, —N[CH(CH3)2]2, —N[C(CH3)3]2, —CH2F, —CHF2, —CF3, —CH2Cl, —CH2Br, —CH2I, —CH2—CH2F, —CH2—CHF2, —CH2—CF3, —CH2—CH2Cl, —CH2—CH2Br, —CH2—CH2I, cyclo-C3H5, —CH2-cyclo-C3H5, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CH═CH2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —CH═CH—C2H5, —C≡CH, —C≡C—CH3, —CH2—C≡CH, —C2H4—C≡CH, —CH2—C≡C—CH3, —C≡C—C2H5, —C3H6—C≡CH, —C2H4—C≡C—CH3, —CH2—C≡C—C2H5, —C≡C—C3H7;
and R94 represents preferably —CR58R16R17, —CR59R69—CR16R17R58, —CR59R69—CR61R62—CR16R17R68, —CR59R66—CR61R62—CR63R64—CR16R17R68, —CR59R69—CR61R62—CR63R64—CR66R66—CR16R17R68, —CR59R60—CR61R62—CR63R64—CR65R66—CR67R68—CR16R17R58, —CR58R59R69, —CR59R69—CR61R62R58, —CR59R60—CR61R62—CR63R64R58, —CR59R69—CR61R62—CR63R64—CR65R66R58, —CR59R60—CR61R62—CR63R64—CR66R66—CR67R68R58,
and R58— R68 preferably represent preferably independently of each other —H, —NH2, —OH, —F, —Cl, —Br, —I, —R71, —O—R71, —R72, —O—R95, —R96, —O—R104, R—R105, —CR16R17H, —NR16R17;
wherein R16, R17, R19, R20, R71, R72, R95, R96, R104, and R105 have the meanings as disclosed herein.
More preferably R12 represents —H, —F, —Cl, —Br, —I, —OH, —NH2, —CH2F, —CF3, —CH2—CH2F, —CH2—CF3, cyclo-C3H5, —CH2-cyclo-C3H5, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C6H11, —C6H13, —CH═CH2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —CH═CH—C2H5, —C≡CH, —C≡C—CH3, —CH2—C≡CH, —C2H4—C≡CH, —CH2—C≡C—CH3, —C≡C—C2H5, —C3H6—C≡CH, —C2H4—C≡C—CH3, —CH2—C≡C—C2H5, —OCH3, —OCF3, —OC2F5, —OC2H5, —OC3H7, —O-cyclo-C3H5, —OCH2-cyclo-C3H5, —O—C2H4-cyclo-C3H5, —O—C3H8-cyclo-C3H5, —OCH(CH3)2, —OC(CH3)3, —OC4H9, —OPh, —NO2, —R94, —OR94, —NHCH3, —NHC2H5, —NHC3H7, —NHCH(CH3)2, —NHC(CH3)3, —N(CH3)2, —N(C2H5)2, —N(C3H7)2, —N[CH(CH3)2]2, —N[C(CH3)3]2;
and R94 represents preferably —CR58R59R69, —CR59R69—CR61R62R58—CR59R69—CR61R62—CR63R64R68, —CR59R69—CR61R62—CR63R64—CR65R66R58, —CR59R69—CR61R62—CR63R64—CR65R66—CR67R68R58,
and R59-R68 represent independently of each other —H, —NH2, —OH, —F, —Cl, —Br, —I, —OCH3, —OCF3, —OC2H5, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CF3, —C(CH3)3;
and R58 represents preferably —CH3, —CF3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, -Ph, —CH2-Ph, —OCH3, —OCF3, —OC2H5, —OC3H7, —OCH(CH3)2, —OC4H9, —OCH2—CH(CH3)2, —OCH(CH3)—C2H5, —OC(CH3)3, —OCH2—C(CH3)3, —OCH(C2H5)2, —OC2H4—CH(CH3)2, —OC6H13, —OPh, —OCH2-Ph, —NHCH3, —NHC2H5, —NHC3H7, —NHCH(CH3)2, —NHC(CH3)3, —N(CH3)2, —N(C2H5)2, —N(C3H7)2, —N[CH(CH3)2]2, —N[C(CH3)3]2,
Figure US08999982-20150407-C00038
wherein R88 has the meanings as disclosed herein.
Still more preferably R12 represents —H, —F, —Cl, —Br, —I, —OH, —NH2, —CH2F, —CF3, —CH2—CH2F, —CH2—CF3, cyclo-C3H5, —CH2-cyclo-C3H5, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —C6H13, —OCH3, —OCF3, —OC2F5, —OC2H5, —OC3H7, —O-cyclo-C3H5, —OCH2-cyclo-C3H5, —O—C2H4-cyclo-C3H5, —O—C3H6-cyclo-C3H5, —OCH(CH3)2, —OC(CH3)3, —OC4H9, —OPh, —NO2, —R94, —NHCH3, —NHC2H5, —NHC3H7, —NHCH(CH3)2, —NHC(CH3)3, —N(CH3)2, —N(C2H5)2, —N(C3H7)2, —N[CH(CH3)2]2, —N[C(CH3)3]2;
and R94 represents preferably —CH2R58, —CH2—CH2R58, —CH2—CH2—CH2R58, —CH2—CH2—CH2—CH2R58, —CH2—CH2—CH2—CH2—CH2R58,
and R58 represents preferably —CH3, —CF3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, -Ph, —CH2-Ph, —OCH3, —OCF3, —OC2H5, —OC3H7, —OCH(CH3)2, —OC4H9, —OCH2—CH(CH3)2, —OCH(CH3)—C2H5, —OC(CH3)3, —OC5H11, —OC6H13, —OPh, —OCH2-Ph, —NHCH3, —NHC2H5, —NHC3H7, —NHCH(CH3)2, —NHC(CH3)3, —N(CH3)2, —N(C2H5)2, —N(C3H7)2,
Figure US08999982-20150407-C00039
and R86 represents preferably —H, —CH3, —CF3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, -Ph, —CH2-Ph.
Even still more preferably R12 represents —H, —F, —Cl, —Br, —CF3, cyclo-C3H5, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —OH, —NH2, —OCH3, —OCF3, —OC2H5, —OC3H7, —O-cyclo-C3H5, —OCH2-cyclo-C3H5, —OCH(CH3)2, —OC(CH3)3, —OC4H9, —NO2, —N(CH3)2, —N(C2H5)2, —N(C3H7)2, —OCH2R58, —OCH2—CH2R58, —OCH2—CH2—CH2R58, —OCH2—CH2—CH2—CH2R68, —CH2R68, —CH2—CH2R68, —CH2—CH2—CH2R68, —CH2—CH2—CH2—CH2R58,
and R68 represents preferably —CH3, —CF3, —C2H5, —C3H7, —CH(CH3)2, -Ph, —OCH3, —OCF3, —OC2H5, —OC3H7, —OCH(CH3)2, —N(CH3)2, —N(C2H5)2, —N(C3H7)2,
Figure US08999982-20150407-C00040
and R86 represents preferably —H, —CH3, —CF3, —C2H5, —C3H7, —CH(CH3)2.
Most preferably R12 represents —H, —F, —Cl, —Br, —CF3, cyclo-C3H5, —CH3, —C2H5, —C3H7, —CH(CH3)2, —OH, —NH2, —OCH3, —OCF3, —OC2H5, —OC3H7, —O-cyclo-C3H5, —OCH2-cyclo-C3H5, —OCH(CH3)2, —OC(CH3)3, —OC4H9, —NO2, —OCH2R68, —OCH2—CH2R68, —OCH2—CH2—CH2R68, —OCH2—CH2—CH2—CH2R68, —CH2R68, —CH2—CH2R58, —CH2—CH2—CH2R58,
and R58 represents preferably -Ph, —OCH3, —OCF3, —OC2H5, —N(CH3)2, —N(C2H5)2,
Figure US08999982-20150407-C00041
and R86 represents preferably —H, —CH3, —CF3, —C2H5.
Residues for R12 proved by examples and thus preferred resudes are:
—H, —Br, —CH3, —NH2, —OCH3, —OC2H5, —OCH2-cyclo-C3H5, —OCH(CH3)2, —NO2, —OCH2R68, —OCH2—CH2R68, —OCH2—CH2—CH2R68, —CH2—CH2R68, and R58 represents preferably -Ph, —OCH3, —N(CH3)2,
Figure US08999982-20150407-C00042
In case R12 is attached to a nitrogen atom, R12 does preferably not represent an alkoxy group and not a halogen and represents preferably the groups and the preferred groups mentioned herein which are linked through a carbon atom to the ring nitrogen atom.
The present invention also includes within its scope N-oxides of the compounds of formula (I) above. In general, such N-oxides may be formed by conventional means, such as reacting the compound of formula I with oxone in the presence of wet alumina.
The expression tautomer is defined as an organic compound that is interconvertible by a chemical reaction called tautomerization. Tautomerization can be catalyzed preferably by bases or acids or other suitable compounds.
The compounds of the present invention may form salts with organic or inorganic acids or bases. Examples of suitable acids for such acid addition salt formation are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, p-toluenesulfonic acid, naphthylsulfonic acid, sulfanilic acid, camphorsulfonic acid, china acid, mandelic acid, o-methylmandelic acid, hydrogen-benzenesulfonic acid, picric acid, adipic acid, D-o-tolyltartaric acid, tartronic acid, (o, m, p)-toluic acid, naphthylamine sulfonic acid, trifluoroacetic acid, and other mineral or carboxylic acids well known to those skilled in the art. The salts are prepared by contacting the free base form of the compounds of formula (I) with a sufficient amount of the desired acid to produce a salt in the conventional manner well known to those skilled in the art.
The inventive compounds may exist in a number of different polymorphic forms.
In the case the inventive compounds bear acidic groups, salts could also be formed with inorganic or organic bases. Examples for suitable inorganic or organic bases are, for example, NaOH, KOH, NH4OH, tetraalkylammonium hydroxide, lysine or arginine and the like. Salts may be prepared in a conventional manner using methods well known in the art, for example by treatment of a solution of the compound of the general formula (I) with a solution of an acid, selected out of the group mentioned above.
Syntheses of Compounds
A method to prepare compounds of formula (I) is shown in Scheme 1. The reaction of acid chloride 1 and aniline 2 is carried out in the presence of a base like pyridine and optionally in an inert solvent like DCM (dichloromethane). Many of the acid chlorides 1 are commercially available. The acid chlorides 1 can also be prepared from commercially available carboxylic acids via standard procedures, using thionyl chloride or oxalyl chloride as reagents. Alternatively, carboxylic acids can be directly coupled with anilines 2 under standard procedures, such as using HBTU (N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate) or HATU (0-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate) to give compounds of formula (I).
Figure US08999982-20150407-C00043
The synthesis of substituted pyrazoles 8/10 is shown in Scheme 2. Diazonium derivatives 5 are obtained by the reaction of ethyl 4-chloro-3-oxo-butanoate 3 with different anilines 4. Subsequent cyclization of 5 to the corresponding pyrazoles 6 can be achieved using a base such as KOAc (potassium acetate), as described in literature (Chattaway, F. D.; Ashworth, D. R.; Grimwalde, M. Journal of the Chemical Society 1935, 117-120). The hydroxyl-group of 6 can be modified by alkylation, for instance using ethyl iodide and K2CO3 in DMF (dimethylformamide) to give pyrazole 7. Alternatively, the hydroxyl-moiety of 6 can be converted into the corresponding triflate which than can be used for metal-catalyzed cross-couplings to obtain derivatives 9. Finally, hydrolysis of 7/9 and subsequent acid chloride formation yields 8/10.
Figure US08999982-20150407-C00044
A modification of the substituents of the pyrazole 11 is shown below in Scheme 3. The bromide derivative 11 can be used in metal-catalyzed cross-couplings, for instance under Sonogashira conditions using an alkyne, copper iodide and dichloro-bis(triphenylphosphine)palladium in the presence of a base like NEt3 (triethylamine). Subsequent modifications yield the pyrazole derivative 12.
Figure US08999982-20150407-C00045
The synthesis of anilines 2 is shown in Scheme 4. Here the quinoline derivative 13 is subjected to nucleophilic aromatic substitution of the appropriate fluoro(hetero) aromatic derivative 14. Subsequent reduction of the nitro derivative 15 yields the anilines 2.
Figure US08999982-20150407-C00046
The pharmaceutical compositions according to the present invention comprise at least one compound according to the present invention as an active ingredient together with at least one pharmaceutically acceptable (i.e. non-toxic) carrier, excipient and/or diluent. The pharmaceutical compositions of the present invention can be prepared in a conventional solid or liquid carrier or diluent and a conventional pharmaceutically made adjuvant at suitable dosage level in a known way. The preferred preparations are adapted for oral application. These administration forms include, for example, pills, tablets, film tablets, coated tablets, capsules, powders and deposits.
Furthermore, the present invention also includes pharmaceutical preparations for parenteral application, including dermal, intradermal, intragastral, intracutaneous, intravasal, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutan, rectal, subcutaneous, sublingual, topical, or transdermal application, which preparations in addition to typical vehicles and/or diluents contain at least one compound according to the present invention and/or a pharmaceutical acceptable salt thereof as active ingredient.
The pharmaceutical compositions according to the present invention containing at least one compound according to the present invention and/or a pharmaceutical acceptable salt thereof as active ingredient will typically be administered together with suitable carrier materials selected with respect to the intended form of administration, i.e. for oral administration in the form of tablets, capsules (either solid filled, semi-solid filled or liquid filled), powders for constitution, gels, elixirs, dispersable granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices. For example, for oral administration in the form of tablets or capsules, the active drug component may be combined with any oral non-toxic pharmaceutically acceptable carrier, preferably with an inert carrier like lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid filled capsules) and the like. Moreover, suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated into the tablet or capsule. Powders and tablets may contain about 5 to about 95-weight % of the derivatives according to the general formula (I) or analogues compound thereof or the respective pharmaceutically active salt as active ingredient.
Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. Among suitable lubricants there may be mentioned boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Suitable disintegrants include starch, methylcellulose, guar gum, and the like. Sweetening and flavoring agents as well as preservatives may also be included, where appropriate. The disintegrants, diluents, lubricants, binders etc. are discussed in more detail below.
Moreover, the pharmaceutical compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimise the therapeutic effect(s), e.g. anti-cancer activity or activity against cancer metastases and the like. Suitable dosage forms for sustained release include tablets having layers of varying disintegration rates or controlled release, polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
Liquid form preparations include solutions, suspensions, and emulsions. As an example, there may be mentioned water or water/propylene glycol solutions for parenteral injections or addition of sweeteners and opacifiers for oral solutions, suspensions, and emulsions. Liquid form preparations may also include solutions for intranasal administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be present in combination with a pharmaceutically acceptable carrier such as an inert, compressed gas, e.g. nitrogen.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides like cocoa butter is melted first, and the active ingredient is then dispersed homogeneously therein e.g. by stirring. The molten, homogeneous mixture is then poured into conveniently sized moulds, allowed to cool, and thereby solidified.
Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions, and emulsions.
The compounds according to the present invention may also be delivered transdermally. The transdermal compositions may have the form of a cream, a lotion, an aerosol and/or an emulsion and may be included in a transdermal patch of the matrix or reservoir type as is known in the art for this purpose.
The term capsule as recited herein refers to a specific container or enclosure made e.g. of methylcellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredient(s). Capsules with hard shells are typically made of blended of relatively high gel strength gelatins from bones or pork skin. The capsule itself may contain small amounts of dyes, opaquing agents, plasticisers and/or preservatives.
Under tablet a compressed or moulded solid dosage form is understood which comprises the active ingredients with suitable diluents. The tablet may be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation, or by compaction well known to a person of ordinary skill in the art.
Oral gels refer to the active ingredients dispersed or solubilised in a hydrophilic semi-solid matrix.
Powders for constitution refers to powder blends containing the active ingredients and suitable diluents which can be suspended e.g. in water or in juice.
Suitable diluents are substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol, and sorbitol, starches derived from wheat, corn, rice, and potato, and celluloses such as microcrystalline cellulose. The amount of diluent in the composition can range from about 5 to about 95% by weight of the total composition, preferably from about 25 to about 75 weight %, and more preferably from about 30 to about 60 weight %.
The term disintegrants refers to materials added to the composition to support break apart (disintegrate) and release the pharmaceutically active ingredients of a medicament. Suitable disintegrants include starches, “cold water soluble” modified starches such as sodium carboxymethyl starch, natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar, cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose, microcrystalline celluloses, and cross-linked microcrystalline celluloses such as sodium croscaramellose, alginates such as alginic acid and sodium alginate, clays such as bentonites, and effervescent mixtures. The amount of disintegrant in the composition may range from about 2 to about 20 weight % of the composition, more preferably from about 5 to about 10 weight %.
Binders are substances which bind or “glue” together powder particles and make them cohesive by forming granules, thus serving as the “adhesive” in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose, starches derived from wheat, corn, rice and potato, natural gums such as acacia, gelatin and tragacanth, derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate, cellulose materials such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose, polyvinylpyrrolidone, and inorganic compounds such as magnesium aluminum silicate. The amount of binder in the composition may range from about 2 to about 20 weight % of the composition, preferably from about 3 to about 10 weight %, and more preferably from about 3 to about 6 weight %.
Lubricants refer to a class of substances which are added to the dosage form to enable the tablet granules etc. after being compressed to release from the mould by reducing friction or wear. Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate, or potassium stearate, stearic acid, high melting point waxes, and other water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and D,L-leucine. Lubricants are usually added at the very last step before compression, since they must be present at the surface of the granules. The amount of lubricant in the composition may range from about 0.2 to about 5 weight % of the composition, preferably from about 0.5 to about 2 weight %, and more preferably from about 0.3 to about 1.5 weight % of the composition.
Glidents are materials that prevent caking of the components of the pharmaceutical composition and improve the flow characteristics of granulate so that flow is smooth and uniform. Suitable glidents include silicon dioxide and talc. The amount of glident in the composition may range from about 0.1 to about 5 weight % of the final composition, preferably from about 0.5 to about 2 weight %.
Coloring agents are excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide. The amount of the coloring agent may vary from about 0.1 to about 5 weight % of the composition, preferably from about 0.1 to about 1 weight %.
The compounds of the present invention are suitable for use in medicine, particulary in human medicine, but also in veterinary medicine. The dosage of the compounds may be determined by a skilled practitioner according to the type and severity of the disorder to be treated.
The compounds of the present invention may be admistered as a monotherapy or together with further active agents, particulary chemotherapeutic agents or antitumor antibodies. Furthermore they may be used in combination with surgery and/or irradiation.
Especially preferred compounds according to the present invention include compounds presented by Table 1.
TABLE 1
Ex-
am-
ple Structure Nomenclature
1
Figure US08999982-20150407-C00047
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]- 1,5- dimethyl-pyrazole-3-carboxamide
2
Figure US08999982-20150407-C00048
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-2- [4- (trifluoromethyl)phenyl]thiazole-4- carboxamide
3
Figure US08999982-20150407-C00049
 		4-bromo-N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-1- methyl-pyrazole-3-carboxamide
4
Figure US08999982-20150407-C00050
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-1- methyl-pyrazole-3-carboxamide
5
Figure US08999982-20150407-C00051
 		1-tert-butyl-N-[4-[(6,7-dimethoxy- 4-quinolyl)oxy]-3-fluoro-phenyl]- 5-methyl-pyrazole-3-carboxamide
6
Figure US08999982-20150407-C00052
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro- phenyl]thiazole-2-carboxamide
7
Figure US08999982-20150407-C00053
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-2- methyl-thiazole-4-carboxamide
8
Figure US08999982-20150407-C00054
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-1- methyl-indazole-3-carboxamide
9
Figure US08999982-20150407-C00055
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-5- methyl-isoxazole-3-carboxamide
10
Figure US08999982-20150407-C00056
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-2- phenyl-thiazole-4-carboxamide
11
Figure US08999982-20150407-C00057
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-1- methyl-imidazole-2-carboxamide
12
Figure US08999982-20150407-C00058
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-1- methyl-imidazole-4-carboxamide
13
Figure US08999982-20150407-C00059
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-1- propyl-pyrazole-3-carboxamide
14
Figure US08999982-20150407-C00060
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fIuoro-phenyl]-1- [3-(1-piperidyl)propyl]pyrazole-3- carboxamide
15
Figure US08999982-20150407-C00061
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-1- (2,2,2- trifluoroethoxymethyl)pyrazole-3- carboxamide
16
Figure US08999982-20150407-C00062
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-4- ethoxy-1-(4- fluorophenyl)pyrazole-3- carboxamide
17
Figure US08999982-20150407-C00063
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-1- (4-fluorophenyl)-4-methoxy- pyrazole-3-carboxamide
18
Figure US08999982-20150407-C00064
 		4-(cyclopropylmethoxy)-N-[4- [(6,7-dimethoxy-4-quinolyl)oxy]- 3-fluoro-phenyl]-1-(4- fluorophenyl)pyrazole-3- carboxamide
19
Figure US08999982-20150407-C00065
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-4- (2-dimethylaminoethoxy)-1-(4- fluorophenyl)pyrazole-3- carboxamide
20
Figure US08999982-20150407-C00066
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-4- (2-dimethylaminoethoxy)-1-(4- fluorophenyl)pyrazole-3- carboxamide
21
Figure US08999982-20150407-C00067
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-1- (4-fluorophenyl)-4-isopropoxy- pyrazole-3-carboxamide
22
Figure US08999982-20150407-C00068
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-4- ethoxy-1-(4-fluoro-2-methyl- phenyl)pyrazole-3-carboxamide
23
Figure US08999982-20150407-C00069
 		1-(2-chloro-4-fluoro-phenyl)-N- [4-[(6,7-dimethoxy-4- quinolyl)oxy]-3- fluoro-phenyl]-4-ethoxy-pyrazole- 3-carboxamide
24
Figure US08999982-20150407-C00070
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]phenyl]-4-ethoxy-1- (4-fluorophenyl)pyrazole-3- carboxamide
25
Figure US08999982-20150407-C00071
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]phenyl]-1-(4- fluorophenyl)-4-isopropoxy- pyrazole-3-carboxamide
26
Figure US08999982-20150407-C00072
 		4-(cyclopropylmethoxy)-N-[4- [(6,7-dimethoxy-4- quinolyl)oxy]phenyl]-1-(4- fluorophenyl)pyrazole-3- carboxamide
27
Figure US08999982-20150407-C00073
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]phenyl]-4-ethoxy-1- (4-fluoro-2-methyl- phenyl)pyrazole-3-carboxamide
28
Figure US08999982-20150407-C00074
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-methyl-phenyl]- 4-ethoxy-1-(4- fluorophenyl)pyrazole-3- carboxamide
29
Figure US08999982-20150407-C00075
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-methyl-phenyl]-1- (4-fluorophenyl)-4-isopropoxy- pyrazole-3-carboxamide
30
Figure US08999982-20150407-C00076
 		4-(cyclopropylmethoxy)-N-[4- [(6,7-dimethoxy-4-quinolyl)oxy]- 3-methyl-phenyl]-1-(4- fluorophenyl)pyrazole-3- carboxamide
31
Figure US08999982-20150407-C00077
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-methyl-phenyl]- 4-ethoxy-1-(4-fluoro-2-methyl- phenyl)pyrazole-3-carboxamide
32
Figure US08999982-20150407-C00078
 		N-[3-chloro-4-[(6,7-dimethoxy-4- quinolyl)oxy]phenyl]-4-ethoxy-1- (4-fluorophenyl)pyrazole-3- carboxamide
33
Figure US08999982-20150407-C00079
 		N-[3-chloro-4-[(6,7-dimethoxy-4- quinolyl)oxy]phenyl]-1-(4- fluorophenyl)-4-isopropoxy- pyrazole-3-carboxamide
34
Figure US08999982-20150407-C00080
 		N-[3-chloro-4-[(6,7-dimethoxy-4- quinolyl)oxy]phenyl]-4- (cyclopropylmethoxy)-1-(4- fluorophenyl)pyrazole-3- carboxamide
35
Figure US08999982-20150407-C00081
 		N-[3-chloro-4-[(6,7-dimethoxy-4- quinolyl)oxy]phenyl]-4-ethoxy-1- (4-fluoro-2-methyl- phenyl)pyrazole-3-carboxamide
36
Figure US08999982-20150407-C00082
 		N-(4-((6,7-dimethoxyquinolin-4- yl)oxy)-3-fluorophenyl)-4-(2- (dimethylamino)ethyl)-1-(4- fluorophenyl)-1H-pyrazole-3- carboxamide
37
Figure US08999982-20150407-C00083
 		N-[4-[(6,7-dimethoxy-4- quinolyl)oxy]-3-fluoro-phenyl]-1- [2-(2-dimethylaminoethyl)-4- fluoro-phenyl]-4-ethoxy-pyrazole- 3-carboxamide
38
Figure US08999982-20150407-C00084
 		N-[3-fluoro-4-[[6-methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-2-phenyl- thiazole-4-carboxamide
39
Figure US08999982-20150407-C00085
 		4-bromo-N-[3-fluoro-4-[[6- methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-1-methyl- pyrazole-3-carboxamide
40
Figure US08999982-20150407-C00086
 		N-[3-fluoro-4-[[6-methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-1-methyl- pyrazole-3-carboxamide
41
Figure US08999982-20150407-C00087
 		1-tert-butyl-N-[3-fluoro-4-[[6- methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-5-methyl- pyrazole-3-carboxamide
42
Figure US08999982-20150407-C00088
 		N-[3-fluoro-4-[[6-methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-1,5- dimethyl- pyrazole-3-carboxamide
43
Figure US08999982-20150407-C00089
 		4-ethoxy-N-[3-fluoro-4-[[6- methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-1- (4-fluoro-2- methyl-phenyl)pyrazole-3- carboxamide
44
Figure US08999982-20150407-C00090
 		N-[3-fluoro-4-[[6-methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)-4-methoxy- pyrazole-3-carboxamide
45
Figure US08999982-20150407-C00091
 		N-[3-fluoro-4-[[6-methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)-4-isopropoxy- pyrazole-3-carboxamide
46
Figure US08999982-20150407-C00092
 		4-(cyclopropylmethoxy)-N-[3- fluoro-4-[[6-methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)pyrazole-3- carboxamide
47
Figure US08999982-20150407-C00093
 		1-(2-chloro-4-fluoro-phenyl)-4- ethoxy-N-[3-fluoro-4-[[6- methoxy- 7-(3-morpholinopropoxy)-4- quinolyl]oxy]phenyl]pyrazole-3- carboxamide
48
Figure US08999982-20150407-C00094
 		4-(2-dimethylaminoethoxy)-N-[3- fluoro-4-[[6-methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)pyrazole-3- carboxamide
49
Figure US08999982-20150407-C00095
 		1-(2-bromo-4-fluoro-phenyl)-4- ethoxy-N-[3-fluoro-4-[[6- methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]pyrazole-3- carboxamide
50
Figure US08999982-20150407-C00096
 		N-[3-fluoro-4-[[6-methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)-4-(2- methoxyethoxy)pyrazole-3- carboxamide
51
Figure US08999982-20150407-C00097
 		4-benzyloxy-N-[3-fluoro-4-[[6- methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)pyrazole-3- carboxamide
52
Figure US08999982-20150407-C00098
 		N-[3-fluoro-4-[[6-methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)-4-nitro-pyrazole-3- carboxamide
53
Figure US08999982-20150407-C00099
 		4-amino-N-[3-fluoro-4-[[6- methoxy-7-(3- morpholinopropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)pyrazole-3- carboxamide
54
Figure US08999982-20150407-C00100
 		N-[4-[[7-(3-aminopropoxy)-6- methoxy-4-quinolyl]oxy]-3-fluoro- phenyl]-4-ethoxy-1-(4- fluorophenyl)pyrazole-3- carboxamide
55
Figure US08999982-20150407-C00101
 		N-[4-[[7-(3-aminopropoxy)-6- methoxy-4-quinolyl]oxy]-3-fluoro- phenyl]-4-ethoxy-1-(4-fluoro-2- methyl-phenyl)pyrazole-3- carboxamide
56
Figure US08999982-20150407-C00102
 		N-[4-[[7-(3-aminopropoxy)-6- methoxy-4-quinolyl]oxy]-3-fluoro- phenyl]-5-ethoxy-2-(4- fluorophenyl)oxazole-4- carboxamide
57
Figure US08999982-20150407-C00103
 		4-ethoxy-N-[3-fluoro-4-[[6- methoxy-7-[3-(4-methylpiperazin- 1-yl)propoxy]-4- quinolyl]oxy]phenyl]-1-(4-fluoro-2- methyl-phenyl)pyrazole-3- carboxamide
58
Figure US08999982-20150407-C00104
 		4-ethoxy-N-[3-fluoro-4-[[6- methoxy-7-[3-(4-methylpiperazin- 1-yl)propoxy]-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)pyrazole-3- carboxamide
59
Figure US08999982-20150407-C00105
 		N-[3-fluoro-4-[[6-methoxy-7-[3-(4- methylpiperazin-1-yl)propoxy]-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)-4-methoxy- pyrazole-3-carboxamide
60
Figure US08999982-20150407-C00106
 		1-(2-chloro-4-fluoro-phenyl)-4- ethoxy-N-[3-fluoro-4-[[6-methoxy- 7-[3-(4-methylpiperazin-1- yl)propoxy]-4- quinolyl]oxy]phenyl]pyrazole-3- carboxamide
61
Figure US08999982-20150407-C00107
 		4-(cyclopropylmethoxy)-N-[3- fluoro-4-[[6-methoxy-7-[3-(4- methylpiperazin-1-yl)propoxy]-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)pyrazole-3- carboxamide
62
Figure US08999982-20150407-C00108
 		N-[3-fluoro-4-[[6-methoxy-7-[3-(4- methylpiperazin-1-yl)propoxy]-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)-4-isopropoxy- pyrazole-3-carboxamide
63
Figure US08999982-20150407-C00109
 		5-ethoxy-N-[3-fluoro-4-[[6- methoxy-7-[3-(4- methylpiperazin-1- yl)propoxy]-4- quinolyl]oxy]phenyl]-2-(4- fluorophenyl)oxazole-4- carboxamide
64
Figure US08999982-20150407-C00110
 		4-(cyclopropylmethoxy)-N-[3- fluoro-4-[[6-methoxy-7-(3- piperazin-1-ylpropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)pyrazole-3- carboxamide trifluoroacetic acid salt
65
Figure US08999982-20150407-C00111
 		4-ethoxy-N-[3-fluoro-4-[[6- methoxy-7-(3-piperazin-1- ylpropoxy)-4-quinolyl]oxy]phenyl]- 1-(4-fluorophenyl)pyrazole-3- carboxamide
66
Figure US08999982-20150407-C00112
 		N-[3-fluoro-4-[[6-methoxy-7-(3- piperazin-1-ylpropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)-4-methoxy- pyrazole-3-carboxamide
67
Figure US08999982-20150407-C00113
 		N-[3-fluoro-4-[[6-methoxy-7-(3- piperazin-1-ylpropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)-4-isopropoxy- pyrazole-3-carboxamide
68
Figure US08999982-20150407-C00114
 		1-(2-chloro-4-fluoro-phenyl)-4- ethoxy-N-[3-fluoro-4-[[6-methoxy- 7-(3-piperazin-1-ylpropoxy)-4- quinolyl]oxy]phenyl]pyrazole-3- carboxamide
69
Figure US08999982-20150407-C00115
 		4-ethoxy-N-[3-fluoro-4-[[6- methoxy-7-(3-piperazin-1- ylpropoxy)-4-quinolyl]oxy)phenyl]- 1-(4-fluoro-2-methyl- phenyl)pyrazole-3-carboxamide
70
Figure US08999982-20150407-C00116
 		N-[3-fluoro-4-[[6-methoxy-7-(3- piperazin-1-ylpropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)-4-(2- methoxyethoxy)pyrazole-3- carboxamide
71
Figure US08999982-20150407-C00117
 		N-[3-fluoro-4-[[6-methoxy-7-(3- piperazin-1-ylpropoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)-4-[(1- methylpyrrolidin-3- yl)methoxy]pyrazole-3- carboxamide
72
Figure US08999982-20150407-C00118
 		N-[3-fluoro-4-[[6-methoxy-7-(3- piperazin-1-ylpropoxy)-4- quinolyl]oxy]phenyl]-2-phenyl- thiazole-4-carboxamide
73
Figure US08999982-20150407-C00119
 		N-[3-fluoro-4-[[6-methoxy-7-(4- piperidylmethoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)-4-methoxy- pyrazole-3-carboxamide
74
Figure US08999982-20150407-C00120
 		4-ethoxy-N-[3-fluoro-4-[[6- methoxy-7-(4-piperidylmethoxy)- 4-quinolyl]oxy]phenyl]-1-(4-fluoro- 2-methyl-phenyl)pyrazole-3- carboxamide
75
Figure US08999982-20150407-C00121
 		4-(cyclopropylmethoxy)-N-[3- fluoro-4-[[6-methoxy-7-(4- piperidylmethoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)pyrazole-3- carboxamide
76
Figure US08999982-20150407-C00122
 		4-bromo-N-[3-fluoro-4-[[6- methoxy-7-(4-piperidylmethoxy)- 4-quinolyl]oxy]phenyl]-1-(4- fluorophenyl)pyrazole-3- carboxamide
77
Figure US08999982-20150407-C00123
 		N-[3-fluoro-4-[[6-methoxy-7-(4- piperidylmethoxy)-4- quinolyl]oxy]phenyl]-1-(4- fluorophenyl)-4-[(4- fluorophenyl)methoxy]pyrazole-3- carboxamide
78
Figure US08999982-20150407-C00124
 		1-tert-butyl-N-[3-fluoro-4-[[6- methoxy-7-(4-piperidylmethoxy)- 4-quinolyl]oxy]phenyl]-5-methyl- pyrazole-3-carboxamide
79
Figure US08999982-20150407-C00125
 		N-[3-fluoro-4-[[6-methoxy-7-(4- piperidylmethoxy)-4- quinolyl]oxy]phenyl]-4-nitro-1-[3- (1-piperidyl)propyl]pyrazole-3- carboxamide
80
Figure US08999982-20150407-C00126
 		N-[3-fluoro-4-[[6-methoxy-7-(4- piperidylmethoxy)-4- quinolyl]oxy]phenyl]-5-methyl-2- phenyl-oxazole-4-carboxamide
81
Figure US08999982-20150407-C00127
 		N-[3-fluoro-4-[[6-methoxy-7-(4- piperidylmethoxy)-4- quinolyl]oxy]phenyl]-2-phenyl- thiazole-4-carboxamide
82
Figure US08999982-20150407-C00128
 		4-ethoxy-N-[4-[[7-[(1-ethyl-4- piperidyl)methoxy]-6-methoxy-4- quinolyl]oxy]-3-fluoro-phenyl]-1- (4-fluoro-2-methyl- phenyl)pyrazole-3-carboxamide
83
Figure US08999982-20150407-C00129
 		4-ethoxy-N-[3-fluoro-4-[[7-[(1- isobutyl-4-piperidyl)methoxy]-6- methoxy-4-quinolyl]oxy]phenyl]-1- (4-fluoro-2-methyl- phenyl)pyrazole-3-carboxamide
84
Figure US08999982-20150407-C00130
 		N-[5-[(6,7-dimethoxy-4- quinolyl)oxy]-2-pyridyl]-4-ethoxy- 1-(4-fluorophenyl)pyrazole-3- carboxamide
85
Figure US08999982-20150407-C00131
 		N-[5-[(6,7-dimethoxy-4- quinolyl)oxy]-2-pyridyl]-4-ethoxy- 1-(4-fluoro-2-methyl- phenyl)pyrazole-3-carboxamide
86
Figure US08999982-20150407-C00132
 		1-(2-chloro-4-fluoro-phenyl)-N-[5- [(6,7-dimethoxy-4-quinolyl)oxy]-2- pyridyl]-4-ethoxy-pyrazole-3- carboxamide
87
Figure US08999982-20150407-C00133
 		N-[5-[(6,7-dimethoxy-4- quinolyl)oxy]-2-pyridyl]-4-(2- dimethylaminoethyl)-1-(4- fluorophenyl)pyrazole-3- carboxamide
88
Figure US08999982-20150407-C00134
 		tert-butyl 4-(((4-((6-(4-ethoxy-1- (4-fluoro-2-methylphenyl)-1H- pyrazole-3-carboxamido)pyridin- 3-yl)oxy)-6-methoxyquinolin-7- yl)oxy)methyl)piperidine-1- carboxylate
89
Figure US08999982-20150407-C00135
 		N-(5-((6,7-dimethoxyquinolin-4- yl)oxy)pyridin-2-yl)-4-ethoxy-1-(4- methoxy-2-methylphenyl)-1H- pyrazole-3-carboxamide
90
Figure US08999982-20150407-C00136
 		N-(4-((6,7-dimethoxyquinolin-4- yl)oxy)-3-fluorophenyl)-4-ethoxy- 1-(3-nitrophenyl)-1H-pyrazole-3- carboxamide
91
Figure US08999982-20150407-C00137
 		N-(4-((6,7-dimethoxyquinolin-4- yl)oxy)-3-fluorophenyl)-4-ethoxy- 1-(4-methoxy-2-methylphenyl)- 1H-pyrazole-3-carboxamide
92
Figure US08999982-20150407-C00138
 		N-(5-((6,7-dimethoxyquinolin-4- yl)oxy)pyridin-2-yl)-4-ethoxy-1-(3- nitrophenyl)-1H-pyrazole-3- carboxamide
93
Figure US08999982-20150407-C00139
 		1-(2-(benzyloxy)-4-fluorophenyl)- N-(5-((6,7-dimethoxyquinolin-4- yl)oxy)pyridin-2-yl)-4-ethoxy-1H- pyrazole-3-carboxamide
94
Figure US08999982-20150407-C00140
 		N-(4-((6,7-dimethoxyquinolin-4- yl)oxy)-2-methoxyphenyl)-4- ethoxy-1-(4-fluoro-2- methylphenyl)-1H-pyrazole-3- carboxamide
95
Figure US08999982-20150407-C00141
 		N-(4-((6,7-dimethoxyquinolin-4- yl)oxy)-2-methylphenyl)-4-ethoxy- 1-(4-fluoro-2-methylphenyl)-1H- pyrazole-3-carboxamide
96
Figure US08999982-20150407-C00142
 		N-(4-((6,7-dimethoxyquinolin-4- yl)oxy)-3-fluorophenyl)-4-ethoxy- 1-(4-fluoro-3-methoxyphenyl)-1H- pyrazole-3-carboxamide
97
Figure US08999982-20150407-C00143
 		N-(5-((6,7-dimethoxyquinolin-4- yl)oxy)pyridin-2-yl)-4-ethoxy-1-(4- fluoro-3-methoxyphenyl)-1H- pyrazole-3-carboxamide
98
Figure US08999982-20150407-C00144
 		N-(5-((6,7-dimethoxyquinolin-4- yl)oxy)pyridin-2-yl)-4-ethoxy-1-(4- nitrophenyl)-1H-pyrazole-3- carboxamide
99
Figure US08999982-20150407-C00145
 		1-(4-aminophenyl)-N-(5-((6,7- dimethoxyquinolin-4- yl)oxy)pyridin-2-yl)-4-ethoxy-1H- pyrazole-3-carboxamide
100
Figure US08999982-20150407-C00146
 		N-(5-((6-methoxy-7-(piperidin-4- ylmethoxy)quinolin-4- yl)oxy)pyridin-2-yl)-4-(2- methoxyphenyl)thiazole-2- carboxamide
101
Figure US08999982-20150407-C00147
 		N-(5-((6-methoxy-7-(piperidin-4- ylmethoxy)quinolin-4- yl)oxy)pyridin-2-yl)-4- phenylthiazole-2-carboxamide
102
Figure US08999982-20150407-C00148
 		4-bromo-N-(5-((6-methoxy-7- (piperidin-4-ylmethoxy)quinolin-4- yl)oxy)pyridin-2-yl)thiazole-2- carboxamide
103
Figure US08999982-20150407-C00149
 		N-(4-((6,7-dimethoxyquinolin-4- yl)oxy)-2-methoxyphenyl)-4- ethoxy-1-(4-fluoro-2- methylphenyl)-1H-pyrazole-3- carboxamide
104
Figure US08999982-20150407-C00150
 		N-(5-((6,7-dimethoxyquinolin-4- yl)oxy)pyridin-2-yl)-4-ethoxy-1-(4- fluoro-2-hydroxyphenyl)-1H- pyrazole-3-carboxamide
105
Figure US08999982-20150407-C00151
 		N-(4-((6,7-dimethoxyquinolin-4- yl)oxy)-3-fluorophenyl)-4-ethoxy- 1-(pyridin-3-yl)-1H-pyrazole-3- carboxamide
106
Figure US08999982-20150407-C00152
 		N-(4-((6,7-dimethoxyquinolin-4- yl)oxy)-3-fluorophenyl)-4-ethoxy- 1′-methyl-1′H-[1,3′-bipyrazole]-3- carboxamide
EXAMPLES Preparation of Compounds
Abbreviations used in the description of the chemistry and in the Examples that follow are:
ACN (acetonitrile); br (broad); CDCl3 (deuterated chloroform); cHex (cyclohexane); DCM (dichloromethane); DIPEA (di-iso-propylethylamine); DMF (dimethylformamide); DMSO (dimethyl sulfoxide); eq. (equivalent); ES (electrospray); EtOAc (ethyl acetate); EtOH (ethanol); HATU (0-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate); HCl (hydrochloric acid); HOAc (acetic acid); H2O (water); K2CO3 (potassium carbonate); KOH (potassium hydroxide); MeOH (methanol); MS (mass spectrometry); NaHCO3 (sodium hydrogencarbonate); NH3 (ammonia); NH4Cl (ammonium chloride); NMR (nuclear magnetic resonance); Pd(dppf)Cl2 ([1,1′-bis(diphenylphosphino)ferrocene]dichloro palladium(II) complex with dichloromethane); iPrOH (iso-propanol); RT (room temperature); sat. aq. (saturated aqueous); SiO2 (silica gel); TEA (trifluoroacetic acid); THF (tetrahydrofurane).
Preparative Examples Example 1 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1,6-dimethyl-pyrazole-3-carboxamide trifluoroacetic acid salt (A3) Step 1: 4-(2-fluoro-4-nitro-phenoxy)-6,7-dimethoxy-quinoline (A1)
A mixture of 6,7-dimethoxyquinolin-4-ol (1.4 g, 6.8 mmol, 1.0 eq.), 3,4-difluoro-nitrobenzene (1.44 g, 8.84 mmol, 1.3 eq.) and cesium carbonate (3.6 g, 10.9 mmol, 1.6 eq.) in dry DMF (10 mL) was heated for 1 h at 50° C. in a microwave oven. After cooling to RT the mixture was diluted with water and extracted with EtOAc. The combined organic phase was dried over Na2SO4 and evaporated in vacuo. The crude product was purified by flash chromatography on silica gel (DCM/MeOH=100:0 to 5:1) to yield the desired product A1 (909 mg, 2.64 mmol, 38.8%) as a yellow solid. 1H NMR (400 MHz, CDCl3, 300K) δ 4.04 (s, 3H), 4.06 (s, 3H), 6.55 (d, J=5.2 Hz, 1H), 7.34 (dd, J=7.8 Hz, J=8.8 Hz, 1H), 7.44 (s, 1H), 7.46 (s, 1H), 8.13 (m, 1H), 8.19 (dd, J=9.8 Hz, J=2.5 Hz, 1H), 8.58 (d, J=5.2 Hz, 1H). MS (ES) C17H13FN2O5 requires: 344, found: 345 (M+H)+. Furthermore an isomer (941 mg, 2.74 mmol, 40.2%) was isolated as a yellow solid. MS (ES) C17H13FN2O6 requires: 344. Found: 345 (M+H)+.
Step 2: 4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-aniline (A2)
To a suspension of A1 (230 mg, 0.67 mmol, 1.0 eq.) in MeOH (50 mL) Pd/C (10% w/w, 23 mg) and aq. HCl-solution (1N, 1.34 mL, 2.0 eq.) were added. The reaction mixture was stirred under hydrogen atmosphere (1 atm) at RT for 48 h. The suspension was filtered through a pad of Celite®. The solvent was removed in vacuo and the crude product was purified using an Isolute® SPE column SCX, loading the reaction mixture as a MeOH solution and then eluting the desired compound with 2N NH3 in MeOH. The title compound A2 was isolated after evaporation of the solvent under reduced pressure as a white solid (200 mg, 0.64 mmol, 95%). 1H NMR (400 MHz, d6-DMSO, 300K) δ 3.92 (s, 6H), 4.97 (br s, 2H), 6.38 (d, J=5.3 Hz, 1H), 6.45 (dd, J=2.4 Hz, J=8.5 Hz, 1H), 6.53 (dd, J=2.4 Hz, J=13.2 Hz, 1H), 7.05 (t, J=9.0 Hz, 1H), 7.36 (s, 1H), 7.49 (s, 1H), 8.44 (d, J=5.3 Hz, 1H). MS (ES) C17H16FN2O3 requires: 314. Found: 315 (M+H)+.
Step 3: N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1,5-dimethyl-pyrazole-3-carboxamide trifluoroacetate salt (A3)
To a solution of A2 (100 mg, 0.31 mmol, 1.0 eq.) in dry DCM (2.5 mL) and dry pyridine (2.5 mL) was added 1,5-dimethyl-1H-pyrazole-3-carbonyl chloride (56 mg, 0.38 mmol, 1.2 eq.) and the reaction mixture was stirred at RT overnight. The solvent was removed in vacuo. The residue was purified by reverse phase RP-HPLC (column: C18), using H2O (0.1% TFA) and MeOH (0.1% TFA) as eluents. The desired fractions were lyophilized to yield the title compound A3 (61.8 mg, 36%) as a white powder. 1H NMR (400 MHz, d6-DMSO, 300K) δ 2.30 (s, 3H), 3.83 (s, 3H), 4.00 (s, 6H), 6.57 (s, 1H), 6.87 (d, J=6.9 Hz, 1H), 7.51 (m, 2H), 7.69 (s, 1H), 7.84 (d, J=7.8 Hz, 1H), 8.11 (dd, J=2.3 Hz, J=13.5 Hz, 1H), 8.74 (d, J=6.3 Hz, 1H), 10.43 (s, 1H). MS (ES) C23H21FN4O4 requires: 436. Found: 437 (M+H)+.
The Examples in the following table were prepared according to the procedure described in the previous Example 1.
Ex-
am- [M +
ple Name Mwt H]+
2 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- 569 570
phenyl]-2-[4-(trifluoromethyl)phenyl]thiazole-4-
carboxamide trifluoroacetic acid salt
3 4-bromo-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3- 501 501/
fluoro-phenyl]-1-methyl-pyrazole-3-carboxamide 503
trifluoroacetic acid salt
4 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- 422 423
phenyl]-1-methyl-pyrazole-3-carboxamide
trifluoroacetic acid salt
5 1-tert-butyl-N-[4-[(6,7-dimethoxy-4-quinolyl)- 478 479
oxy]-3-fluoro-phenyl]-5-methyl-pyrazole-3-
carboxamide trifluoroacetic acid salt
6 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- 425 426
phenyl]thiazole-2-carboxamide trifluoroacetic acid
salt
7 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- 439 440
phenyl]-2-methyl-thiazole-4-carboxamide
trifluoroacetic acid salt
8 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- 472 473
phenyl]-1-methyl-indazole-3-carboxamide
trifluoroacetic acid salt
9 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- 423 424
phenyl]-5-methyl-isoxazole-3-carboxamide
trifluoroacetic acid salt
10  N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- 501 502
phenyl]-2-phenyl-thiazole-4-carboxamide
trifluoroacetic acid salt
Example 11 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-methyl-imidazole-2-carboxamide trifluoroacetic acid salt (B1)
1-Methyl-1H-imidazol-2-carboxylic acid (126 mg, 1 mmol, 1.0 eq.) in SOCl2 (10 mL) was heated for 6 h under reflux. Solvent was removed in vacuo and the crude product was resolved in dry toluene and evaporated under reduced pressure again. The solid was solved in dry DCM (2 mL) and dry pyridine (2 mL) and 4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-aniline (A2) (376 mg, 1.2 mmol, 1.2 eq.) was added. The reaction mixture was stirred at RT overnight. The solvent was removed in vacuo. The residue was purified by reverse phase RP-HPLC (column: C18), using H2O (0.1% TFA) and MeOH (0.1% TFA) as eluents. The desired fractions were lyophilized to yield the title compound B1 (33 mg, 0.06 mmol, 6%) as a white powder. 1H NMR (400 MHz, d6-DMSO, 300K) δ 3.99 (s, 3H), 4.02 (s, 3H), 4.03 (s, 3H), 6.94 (d, J=6.5 Hz, 1H), 7.12 (d, J=1.0 Hz, 1H), 7.48 (d, J=1.0 Hz, 1H), 7.55 (t, J=9.0 Hz, 1H), 7.56 (s, 1H), 7.73 (s, 1H), 7.87 (d, J=9.0 Hz, 1H), 8.13 (dd, J=2.4 Hz, J=13.3 Hz, 1H), 8.79 (d, J=6.5 Hz, 1H), 10.81 (s, 1H). MS (ES) C22H19FN4O4 requires: 422. Found: 423 (M+H)+.
The Example in the following table was prepared according to the procedure described in the previous Example 11.
Exam- [M +
ple Name Mwt H]+
12 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3- 422 423
fluoro-phenyl]-1-methyl-imidazole-4-
carboxamide
Example 13 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-propyl-pyrazole-3-carboxamide (C1)
C1 was prepared from A2 and 1-propylpyrazole-3-carboxylic acid following the general procedure reported in Preparative Example 11. The residue was purified by reverse phase RP-HPLC (column: C18), using H2O and ACN as eluents. The desired fractions were lyophilized to yield the title compound C1 (46 mg, 0.10 mmol, 17%) as a white powder. 1H NMR (400 MHz, d6-DMSO, 300K) δ 0.85 (t, J=7.3 Hz, 3H), 1.86 (sext., J=7.3 Hz, 2H), 3.94 (s, 6H), 4.18 (t, J=7.3 Hz, 2H), 6.45 (d, J=5.1 Hz, 1H), 6.79 (d, J=2.3 Hz, 1H), 7.39 (s, 1H), 7.42 (t, J=9.0 Hz, 1H), 7.52 (s, 1H), 7.78 (d, J=9.0 Hz, 1H), 7.90 (d, J=2.3 Hz, 1H), 8.05 (dd, J=13.4 Hz, J=2.3 Hz, 1H), 8.46 (d, J=5.2 Hz, 1H), 10.34 (s, 1H). MS (ES) C24H23FN4O4 requires: 450. Found: 451 (M+H)+.
The Examples in the following table were prepared according to the procedure described in the previous Example 13.
Exam- [M +
ple Name Mwt H]+
14 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3- 533 534
fluoro-phenyl]-1-[3-(1-
piperidyl)propyl]pyrazole-3-carboxamide
15 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3- 520 521
fluoro-phenyl]-1-(2,2,2-
trifluoroethoxymethyl)pyrazole-3-
carboxamide
Example 16 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (D5) Step 1: Ethyl 1-(4-fluorophenyl)-4-hydroxy-pyrazole-3-carboxylate (D1)
To a solution of 4-fluoroaniline (10 g, 90.0 mmol, 1.0 eq.) in DCM/HOAc (1/1, 180 mL, 0.5M) at 0° C. was added dropwise a precooled solution of sodium nitrite (9.02 g, 108 mmol, 1.2 eq.) in conc. sulfuric acid (40 mL). After stirring for 30 min at 0° C. a mixture of ethyl 4-chloroacetoacetate (14.6 mL, 17.8 g, 108 mmol, 1.2 eq.) in HOAc (60 mL) and H2O (120 mL) was added within 5 min. After further 15 min at 0° C. a solution of sodium acetate (100 g, 1.219 mol, 13.5 eq.) in H2O (210 mL) was added slowly. The mixture was stirred for 30 min at 0° C. and 1 h at RT. DCM (200 mL) was added and the organic phase was separated. The aq. phase was extracted with DCM (3×100 mL). The combined organic phase was washed with water, phosphate buffer and subsequent with brine. The organic layer was dried over Na2SO4 and concentrated under reduced pressure to give the product ethyl 4-chloro-2-(4-fluorophenyl)azo-3-oxo-butanoate as a orange solid. MS (ES) C12H12ClFN2O3 requires: 286. Found: 287 (M+H)+ and 309 (M+Na)+.
Without further purification the crude material was dissolved in dry ethanol (180 mL) and after adding potassium acetate (12.4 g, 126 mmol, 1.4 eq.) the mixture was refluxed for 1 h. The reaction mixture was diluted with EtOAc and washed three times with water. The combined aq. phase was extracted with EtOAc. The combined organic phase was then washed with phosphate buffer and brine. The organic layer was dried over Na2SO4 and concentrated under reduced pressure. The crude product was crystallized from ethanol to give the desired product D1 as a brown solid (18.21 g, 81%). 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.29 (t, J=7.0 Hz, 3H), 4.28 (q, J=7.0 Hz, 2H), 7.33 (t, J=8.8 Hz, 2H), 7.83 (m, 2H), 8.03 (s, 1H), 9.15 (s, 1H). MS (ES) C12H11FN2O3 requires: 250. Found: 251 (M+H)+ and 273 (M+Na)+.
Step 2: ethyl 4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxylate (D2)
To a mixture of D1 (9.6 g, 38 mmol, 1.0 eq.) and K2CO3 (6.8 g, 50 mmol, 1.3 eq.) in dry DMF (100 mL) was added at RT iodoethane (4.0 mL, 7.8 g, 50 mmol, 1.3 eq.). After stirring for 72 h at RT the mixture was cooled to 0° C. MeOH (5 mL) was added, the mixture was diluted with DCM (200 mL) and washed with water and phosphate buffer. The organic layer was dried over Na2SO4 and concentrated under reduced pressure to give the product D2 as a brown solid which was used without further purification in the subsequent step. MS (ES) C14H15FN2O3 requires: 278. Found: 279 (M+H)+.
Step 3: 4-Ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxylic acid (D3)
D2 (38 mmol, 1.0 eq.) and aq. KOH-solution (3M, 190 mmol, 5.0 eq.) in EtOH (152 mL) were heated for 45 min at 50° C. The mixture was cooled to RT and diluted with DCM and water. The aq. phase was washed a second time with DCM. The aq. phase was acidified with aq. HCl-solution (1N) to pH=1 and extracted with EtOAc. The combined organic phase was washed with brine and dried over Na2SO4. Removal of the solvent yielded the product D3 as a brown solid (8.88 g, 93% over 2 steps). 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.34 (t, J=7.0 Hz, 3H), 4.02 (q, J=7.0 Hz, 2H), 7.37 (dd, J=J=9.0 Hz, 2H), 7.87 (dd, J=9.0 Hz, J=4.6 Hz, 2H), 8.38 (s, 1H), 12.68 (br s, 1H). MS (ES) C12H11FN2O3 requires: 250. Found: 251 (M+H)+ and 273 (M+Na)+.
Step 4: 4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carbonyl chloride (D4)
D3 (43 mg, 0.17 mmol, 1.0 eq.) was heated in thionyl chloride (1 mL) for 4 h at 67° C. Solvent was removed in vacuo and the crude material was resolved in dry toluene and evaporated under reduced pressure again to yield D4. The crude material was used in the next step without further purification.
Step 5: N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (D5)
Acid chloride D4 (0.17 mmol, 1.0 eq.) was dissolved in dry pyridine (1.5 mL) at 0° C. and A2 (34 mg, 0.11 mmol, 0.65 eq.) was added. The reaction was allowed to reach RT overnight. The mixture was diluted with EtOAc and washed twice with aq. KOH-solution (0.5N), twice with aq. sat. NH4Cl-solution, and finally once with brine. The organic layer was dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel (DCM/MeOH=100:0 to 10:1) to yield the desired product D5 (31 mg, 52% over 2 steps) as a white solid. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.38 (t, J=7.0 Hz, 3H), 3.94 (s, 6H), 4.09 (q, J=7.0 Hz, 2H), 6.48 (d, J=5.3 Hz, 1H), 7.43 (m, 4H), 7.53 (s, 1H), 7.70 (d, J=9.4 Hz, 1H), 8.01 (m, 3H), 8.47 (m, 2H), 10.17 (s, 1H). MS (ES) C29H24F2N4O5 requires: 546. Found: 547 (M+H)+.
Example 17 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxamide trifluoroacetic acid salt (E4) Step 1: ethyl 1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxylate (E1)
E1 was prepared from D1 following the general procedure reported in Preparative Example 16 Step 2 using methyl iodide for the alkylation. MS (ES) C13H13FN2O3 requires: 264. Found: 265 (M+H)+ and 287 (M+Na)+.
Step 2: 1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxylic acid (E2)
E1 (2 mmol, 1.0 eq.) and KOH (6 mmol, 3.0 eq.) in THF/H2O (1/1, 30 mL) were heated for 2 h at 60° C. The mixture was cooled to RT and then acidified with aq. HCl-solution (1N) to pH=1. The aq. phase was extracted with EtOAc. The combined organic phase was dried over Na2SO4. Removal of the solvent yielded the product E2 as a yellow solid (450 mg, 95%). 1H NMR (400 MHz, d6-DMSO, 300K) δ 3.80 (s, 3H), 7.37 (dd, J=J=9.0 Hz, 2H), 7.87 (dd, J=9.0 Hz, J=4.7 Hz, 2H), 8.40 (s, 1H), 12.72 (br s, 1H). MS (ES) C11H9FN2O3 requires: 236. Found: 237 (M+H)+.
Step 3: 1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carbonyl chloride (E3)
E2 (100 mg, 0.42 mmol, 1.0 eq.) was heated in thionyl chloride (1 mL) for 4 h under reflux. Solvent was removed in vacuo and the crude material was resolved in dry toluene and evaporated under reduced pressure again to yield E3. The crude material was used in the next step without further purification.
Step 4: N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxamide trifluoroacetic acid salt (E4)
Acid chloride E3 (0.42 mmol, 1.0 eq.) was dissolved in dry pyridine (2 mL) at RT and A2 (133 mg, 0.42 mmol, 1.0 eq.) was added. The reaction was stirred at RT overnight. After adding methanol (0.1 mL) the reaction mixture was concentrated under reduced pressure. The residue was purified by reverse phase RP-HPLC (column: C18), using H2O (0.1% TFA) and MeOH (0.1% TFA) as eluents. The desired fractions were lyophilized to yield the title compound E4 (36 mg, 0.13 mmol, 13%) as a white powder. 1H NMR (400 MHz, d6-DMSO, 300K) δ 3.88 (s, 3H), 4.04 (s, 3H), 4.05 (s, 3H), 6.85 (s, 1H), 6.96 (d, J=6.4 Hz, 1H), 7.43 (dd, J=J=9.0 Hz, 2H), 7.57 (s, 1H), 7.59 (t, J=9.1 Hz, 1H), 7.75 (s, 1H), 7.81 (d, J=9.1 Hz, 1H), 8.02 (dd, J=9.0 Hz, J=4.8 Hz, 2H), 8.12 (dd, J=13.3 Hz, J=2.4 Hz, 1H), 8.52 (s, 1H), 8.81 (d, J=6.5 Hz, 1H), 10.30 (s, 1H). MS (ES) C29H22F2N4O5 requires: 532. Found: 533 (M+H)+.
Example 18 4-(cyclopropylmethoxy)-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide (F4) Step 1: ethyl 4-(cyclopropylmethoxy)-1-(4-fluorophenyl)pyrazole-3-carboxylate (F1)
F1 was prepared from D1 following the general procedure reported in Preparative Example 16 Step 2 using (bromomethyl)cyclopropane for the alkylation. MS (ES) C16H17FN2O3 requires: 304. Found: 305 (M+H)+ and 327 (M+Na).
Step 2: 4-(cyclopropylmethoxy)-1-(4-fluorophenyl)pyrazole-3-carboxylic acid (F2)
F2 was prepared from F1 following the general procedure reported in Preparative Example 16 Step 3. 1H NMR (400 MHz, d6-DMSO, 300K) δ 0.32 (dt, J=5.0 Hz, J=5.0 Hz, 2H), 0.57 (dt, J=8.0 Hz, J=5.0 Hz, 2H), 1.27 (m, 1H), 3.81 (d, J=7.0 Hz, 2H), 7.36 (t, J=8.9 Hz, 2H), 7.86 (dd, J=8.9 Hz, J=4.7 Hz, 2H), 8.37 (s, 1H), 12.69 (br s, 1H). MS (ES) C14H13FN2O3 requires: 276. Found: 277 (M+H)+ and 299 (M+Na)+.
Step 3: 4-(cyclopropylmethoxy)-1-(4-fluorophenyl)pyrazole-3-carbonyl chloride (F3)
F3 was prepared from F2 following the general procedure reported in Preparative Example 16 Step 4.
Step 4: 4-(cyclopropylmethoxy)-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide (F4)
F4 was prepared from F3 following the general procedure reported in Preparative Example 16 Step 5. 1H NMR (400 MHz, CD3OD, 300K) δ 0.46 (m, 2H), 0.70 (m, 2H), 1.43 (m, 1H), 4.00 (d, J=7.2 Hz, 1H), 4.05 (s, 3H), 4.06 (s, 3H), 6.75 (d, J=5.5 Hz, 1H), 7.25 (t, J=8.8 Hz, 2H), 7.40 (s, 1H), 7.44 (t, J=8.8 Hz, 2H), 7.59 (m, 1H), 7.73 (s, 1H), 7.89 (m, 3H), 8.04 (dd, J=12.6 Hz, J=2.3 Hz, 1H), 8.18 (s, 1H), 8.55 (m, 1H). MS (ES) C31H26F2N4O5 requires: 572. Found: 573 (M+H)+.
Example 19 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-(2-dimethylaminoethoxy)-1-(4-fluorophenyl)pyrazole-3-carboxamide (G2) Step 1: 4-(2-dimethylaminoethoxy)-1-(4-fluorophenyl)pyrazole-3-carbonyl chloride (G1)
G1 was prepared from D1 following the general procedure reported in Preparative Example 16 Step 2-4.
Step 2: N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-(2-dimethylaminoethoxy)-1-(4-fluorophenyl)pyrazole-3-carboxamide (G2)
G2 was prepared from G1 following the general procedure reported in Preparative Example 16 Step 5. 1H NMR (400 MHz, d6-DMSO, 300K) δ 2.45 (s, 6H), 2.95 (t, J=5.2 Hz, 2H), 3.96 (s, 6H), 4.25 (t, J=5.2 Hz, 2H), 6.49 (d, J=5.3 Hz, 1H), 7.43 (m, 3H), 7.48 (t, J=9.2 Hz, 1H), 7.54 (s, 1H), 7.71 (d, J=9.2 Hz, 1H), 8.00 (m, 3H), 8.49 (d, J=5.1 Hz, 1H), 8.59 (s, 1H), 10.27 (s, 1H). MS (ES) C31H29F2N5O5 requires: 589. Found: 590 (M+H)+.
Example 20 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-(3-dimethylaminopropoxy)-1-(4-fluorophenyl)pyrazole-3-carboxamide (H2) Step 1: 4-(3-dimethylaminopropoxy)-1-(4-fluorophenyl)pyrazole-3-carbonyl chloride (H1)
H1 was prepared from D1 following the general procedure reported in Preparative Example 16 Step 2-4.
Step 2: N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-(3-dimethylaminopropoxy)-1-(4-fluorophenyl)pyrazole-3-carboxamide (H2)
H2 was prepared from H1 following the general procedure reported in Preparative Example 16 Step 5. MS (ES) C32H31F2N6O6 requires: 603. Found: 604 (M+H)+.
Example 21 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carboxamide (I3) Step 1: 1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carboxylic acid (I1)
I1 was prepared from D1 following the general procedure reported in Preparative Example 16 Step 2 and 3. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.29 (d, J=6.0 Hz, 6H), 4.34 (sept, J=6.0 Hz, 1H), 7.37 (t, J=8.8 Hz, 2H), 7.88 (dd, J=8.8 Hz, J=4.7 Hz, 2H), 8.39 (s, 1H), 12.63 (br s, 1H). MS (ES) C13H13FN2O3 requires: 264. Found: 265 (M+H)+.
Step 2: 1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carbonyl chloride (12)
I2 was prepared from I1 following the general procedure reported in Preparative Example 16 Step 4.
Step 3: N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carboxamide (I3)
I3 was prepared from I2 following the general procedure reported in Preparative Example 16 Step 5. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.34 (d, J=6.1 Hz, 6H), 3.94 (s, 6H), 4.43 (sept., J=6.1 Hz, 1H), 6.47 (d, J=5.2 Hz, 1H), 7.42 (m, 4H), 7.53 (s, 1H), 7.68 (d, J=9.1 Hz, 1H), 8.02 (m, 3H), 8.48 (m, 2H), 10.15 (s, 1H). MS (ES) C30H26F2N4O6 requires: 560. Found: 561 (M+H)+.
Example 22 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide (J5) Step 1: ethyl 1-(4-fluoro-2-methyl-phenyl)-4-hydroxy-pyrazole-3-carboxylate (J1)
J1 was prepared following the general procedure reported in Preparative Example 16 Step 1. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.26 (t, J=7.1 Hz, 3H), 2.16 (s, 3H), 4.25 (q, J=7.1 Hz, 2H), 7.15 (ddd, J=8.5 Hz, J=J=3.0 Hz, 1H), 7.26 (dd, J=9.6 Hz, J=3.0 Hz, 1H), 7.39 (dd, J=8.5 Hz, J=5.5 Hz, 1H), 7.60 (s, 1H). MS (ES) C13H13FN2O3 requires: 264. Found: 265 (M+H)+ and 287 (M+Na)+.
Step 2: ethyl 4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxylate (J2)
J2 was prepared from J1 following the general procedure reported in Preparative Example 16 Step 2 using iodoethane for the alkylation. MS (ES) C16H17FN2O3 requires: 292. Found: 293 (M+H)+ and 315 (M+Na).
Step 3: 4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxylic acid (J3)
J3 was prepared from J2 following the general procedure reported in Preparative Example 16 Step 3. MS (ES) C13H13FN2O3 requires: 264. Found: 265 (M+H)+.
Step 4: 4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carbonyl chloride (J4)
J4 was prepared from J3 following the general procedure reported in Preparative Example 16 Step 4.
Step 5: N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide (J5)
J5 was prepared following the general procedure reported in Preparative Example 16 Step 5. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.38 (t, J=7.0 Hz, 3H), 2.26 (s, 3H), 4.02 (s, 3H), 4.03 (s, 3H), 4.07 (q, J=7.0 Hz, 2H), 6.89 (d, J=6.4 Hz, 1H), 7.23 (dt, J=8.5 Hz, J=3.0 Hz, 1H), 7.33 (dd, J=9.9 Hz, J=3.0 Hz, 1H), 7.53 (m, 3H), 7.72 (s, 1H), 7.78 (d, J=9.2 Hz, 1H), 8.05 (s, 1H), 8.11 (dd, J=13.3 Hz, J=2.6 Hz, 1H), 8.77 (d, J=6.4 Hz, 1H), 10.24 (s, 1H). MS (ES) C30H26F2N4O5 requires: 560. Found: 561 (M+H)+.
Example 23 1-(2-chloro-4-fluoro-phenyl)-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-pyrazole-3-carboxamide (K3) Step 1: 1-(2-chloro-4-fluoro-phenyl)-4-ethoxy-pyrazole-3-carboxylic acid (K1)
K1 was prepared following the general procedure reported in Preparative Example 16 Step 1-3. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.31 (t, J=7.0 Hz, 3H), 3.96 (q, J=7.0 Hz, 2H), 7.40 (m, 1H), 7.66 (dd, J=8.9 Hz, J=5.6 Hz, 1H), 7.72 (dd, J=8.5 Hz, J=2.8 Hz, 1H), 7.98 (s, 1H), 12.64 (br s, 1H). MS (ES) C12H10ClFN2O3 requires: 284. Found: 285 (M+H)+ and 307 (M+Na)+.
Step 2: 1-(2-chloro-4-fluoro-phenyl)-4-ethoxy-pyrazole-3-carbonyl chloride (K2)
K2 was prepared from K1 following the general procedure reported in Preparative Example 16 Step 4.
Step 3: 1-(2-chloro-4-fluoro-phenyl)-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-pyrazole-3-carboxamide (K3)
K3 was prepared following the general procedure reported in Preparative Example 16 Step 5. 1H NMR (400 MHz, CDCl3, 300K) δ 1.56 (t, J=6.9 Hz, 3H), 4.05 (s, 3H), 4.07 (s, 3H), 4.18 (q, J=6.9 Hz, 2H), 6.45 (d, J=5.3 Hz, 1H), 7.14 (ddd, J=10.0 Hz, J=7.4 Hz, J=2.7 Hz, 1H), 7.23 (t, J=8.8 Hz, 1H), 7.29 (dd, J=8.0 Hz, J=2.7 Hz, 1H), 7.38 (d, J=8.8 Hz, 1H), 7.45 (s, 1H), 7.55 (s, 1H), 7.59 (s, 1H), 7.62 (dd, J=8.8 Hz, J=5.3 Hz, 1H), 7.91 (dd, J=12.1 Hz, J=2.7 Hz, 1H), 8.50 (d, J=5.3 Hz, 1H), 8.90 (s, 1H). MS (ES) C26H23ClF2N4O6 requires: 580. Found: 581 (M+H)+.
Example 24 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (L2) Step 1: 4-((6,7-dimethoxyquinolin-4-yl)oxy)aniline (L1)
L1 was prepared from 6,7-dimethoxyquinolin-4-ol and 4-fluoro-nitrobenzene following the general procedure reported in Preparative Example 1 Step 1-2. 1H NMR (400 MHz, d6-DMSO, 300K) δ 3.91 (s, 3H), 3.92 (s, 3H), 5.16 (br s, 2H), 6.36 (d, J=5.3 Hz, 1H), 6.65 (d, J=8.8 Hz, 2H), 6.91 (d, J=8.8 Hz, 2H), 7.34 (s, 1H), 7.49 (s, 1H), 8.41 (d, J=5.3 Hz, 1H). MS (ES) C17H16N2O3 requires: 296. Found: 297 (M+H)+.
Step 2: N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (L2)
L2 was prepared from L1 and D4 following the general procedure reported in Preparative Example 16 Step 5. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.38 (t, J=7.0 Hz, 3H), 3.93 (s, 3H), 3.94 (s, 3H), 4.10 (q, J=7.0 Hz, 2H), 6.51 (d, J=5.4 Hz, 1H), 7.28 (d, J=9.1 Hz, 2H), 7.39 (m, 3H), 7.53 (s, 1H), 7.91 (d, J=9.1 Hz, 2H), 7.98 (m, 2H), 8.47 (s, 1H), 8.49 (d, J=5.4 Hz, 1H), 9.98 (s, 1H). MS (ES) C29H25FN4O5 requires: 528. Found: 529 (M+H)+.
The Examples in the following table were prepared according to the procedure described in the previous Example 24.
Exam- [M +
ple Name Mwt H]+
25 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]- 542 543
1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-
carboxamide
26 4-(cyclopropylmethoxy)-N-[4-[(6,7- 554 555
dimethoxy-4-quinolyl)oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
27 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]- 542 543
4-ethoxy-1-(4-fluoro-2-methyl-
phenyl)pyrazole-3-carboxamide
Example 28 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-methyl-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (M2) Step 1: 4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-methyl-aniline (M1)
M1 was prepared from 6,7-dimethoxyquinolin-4-ol and 1-fluoro-2-methyl-4-nitrobenzene following the general procedure reported in Preparative Example 1 Step 1-2. 1H NMR (400 MHz, d5-DMSO, 300K) δ 1.93 (s, 3H), 3.92 (s, 6H), 5.06 (br s, 2H), 6.24 (d, J=5.2 Hz, 1H), 6.48 (dd, J=8.4 Hz, J=2.5 Hz, 1H), 6.53 (d, J=2.5 Hz, 1H), 6.83 (d, J=8.4 Hz, 1H), 7.35 (s, 1H), 7.53 (s, 1H), 8.40 (d, J=5.2 Hz, 1H). MS (ES) C19H19N2O3 requires: 310. Found: 311 (M+H)+.
Step 2: N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-methyl-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (M2)
M2 was prepared from M1 and D4 following the general procedure reported in Preparative Example 16 Step 5. 1H NMR (400 MHz, d5-DMSO, 300K) δ 1.38 (t, J=7.0 Hz, 3H), 2.11 (s, 3H), 3.94 (s, 3H), 3.95 (s, 3H), 4.10 (q, J=7.0 Hz, 2H), 6.30 (d, J=5.2 Hz, 1H), 7.18 (d, J=8.7 Hz, 1H), 7.39 (m, 3H), 7.57 (s, 1H), 7.74 (dd, J=8.7 Hz, J 2.4 Hz, 1H), 7.83 (d, J=2.4 Hz, 1H), 7.99 (m, 2H), 8.44 (d, J=5.2 Hz, 1H), 8.47 (s, 1H), 9.90 (s, 1H). MS (ES) C30H27FN4O5 requires: 542. Found: 543 (M+H)+.
The Examples in the following table were prepared according to the procedure described in the previous Example 28.
Exam- [M +
ple Name Mwt H]+
29 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3- 556 557
methyl-phenyl]-1-(4-fluorophenyl)-4-
isopropoxy-pyrazole-3-carboxamide
30 4-(cyclopropylmethoxy)-N-[4-[(6,7- 568 569
dimethoxy-4-quinolyl)oxy]-3-methyl-phenyl]-
1-(4-fluorophenyl)pyrazole-3-carboxamide
31 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3- 556 557
methyl-phenyl]-4-ethoxy-1-(4-fluoro-2-
methyl-phenyl)pyrazole-3-carboxamide
Example 32 N-[3-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (N2) Step 1: 3-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]aniline (N1)
N1 was prepared from 6,7-dimethoxyquinolin-4-ol and 2-chloro-1-fluoro-4-nitrobenzene following the general procedure reported in Preparative Example 1 Step 1-2. 1H NMR (400 MHz, d6-DMSO, 300K) δ 3.92 (s, 6H), 5.45 (br s, 2H), 6.28 (d, J=5.3 Hz, 1H), 6.61 (dd, J=8.7 Hz, J=2.6 Hz, 1H), 6.78 (d, J=2.6 Hz, 1H), 7.07 (d, J=8.7 Hz, 1H), 7.36 (s, 1H), 7.50 (s, 1H), 8.42 (d, J=5.3 Hz, 1H). MS (ES) C17H16ClN2O3 requires: 330. Found: 331 (M+H)+.
Step 2: N-[3-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (N2)
N2 was prepared from N1 and D4 following the general procedure reported in Preparative Example 16 Step 5. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.37 (t, J=7.0 Hz, 3H), 3.94 (s, 6H), 4.09 (q, J=7.0 Hz, 2H), 6.37 (d, J=5.2 Hz, 1H), 7.42 (m, 4H), 7.53 (s, 1H), 7.87 (dd, J=8.7 Hz, J=2.5 Hz, 1H), 8.00 (m, 2H), 8.21 (d, J=2.5 Hz, 1H), 8.46 (m, 2H), 10.16 (s, 1H). MS (ES) C29H24ClFN4O6 requires: 562. Found: 563 (M+H)+.
The Examples in the following table were prepared according to the procedure described in the previous Example 32.
Exam- [M +
ple Name Mwt H]+
33 N-[3-chloro-4-[(6,7-dimethoxy-4- 576 577
quinolyl)oxy]phenyl]-1-(4-fluorophenyl)-4-
isopropoxy-pyrazole-3-carboxamide
34 N-[3-chloro-4-[(6,7-dimethoxy-4- 588 589
quinolyl)oxy]phenyl]-4-(cyclopropylmethoxy)-
1-(4-fluorophenyl)pyrazole-3-carboxamide
35 N-[3-chloro-4-[(6,7-dimethoxy-4- 576 577
quinolyl)oxy]phenyl]-4-ethoxy-1-(4-fluoro-2-
methyl-phenyl)pyrazole-3-carboxamide
Example 36 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxamide (O3) Step 1: Ethyl 4-[2-ethoxyvinyl]-1-(4-fluorophenyl)pyrazole-3-carboxylate (O1)
To a solution of D1 (500 mg, 2.0 mmol, 1.0 eq.) and 2,6-lutidine (0.3 mL, 2.8 mmol, 1.4 eq.) in dry DCM (10 mL) at 0° C. was added trifluoromethanesulfonic anhydride (1M in DCM, 2.4 mL, 2.4 mmol, 1.2 eq.). After 45 min the mixture was diluted with DCM and washed twice with aq. NaHCO3-solution. After drying over MgSO4 the solvent was removed in vacuo.
The crude material was resolved in dry DMF (15 mL) under N2-atmosphere. Than cis-tributyl[2-ethoxyethenyl]stannane (1083 mg, 3 mmol, 1.5 eq.) and tetrakis(triphenylphosphine)-palladium (123 mg, 0.2 mmol, 0.1 eq.) were added and the mixture was heated for 5 h at 90° C. EtOAC was added and the organic phase was washed, three times with aq. NaHCO3-solution. The organic phase was dried over MgSO4 and solvents were removed in vacuo. The crude material was used without further purification. MS (ES) C16H17IFN2O3 requires: 304. Found: 305 (M+H)+ and 327 (M+Na)+.
Step 2: 4-(2-dimethylaminoethyl)-1-(4-fluorophenyl)pyrazole-3-carboxylic acid (O2)
A solution of O1 (2 mmol) in TFA/DCM (1/1 mixture, 15 mL) was stirred for 2 h at RT. The solvents were removed in vacuo. The crude material was resolved in dry EtOH (5 mL) and dimethylamine in EtOH (5.6N, 1.07 mL, 6 mmol, 3.0 eq.) was added. After stirring for 2 h, sodium cyanoborohydride (376 mg, 6 mmol, 3.0 eq.) was added and the mixture was stirred further for 12 h. After adding water the solvents were removed in vacuo. The crude material was solved in EtOAc and washed twice with aq. NaHCO3-solution, dried over MgSO4 and evaporated in vacuo. The crude material was purified using an Isolute® SPE column SCX, loading the reaction mixture as a MeOH-solution and than eluting the desired compound with 2N NH3 in MeOH yielding ethyl 4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxylate. MS (ES) C16H20FN3O2 requires: 305. Found: 306 (M+H)+.
The crude material and sodium hydroxide (160 mg, 4.0 mmol, 2.0 eq.) was stirred in dioxane/water (1/1, 8 mL) for 12 h at RT. The solvents were removed in vacuo and the residue was purified by reverse phase RP-HPLC (column: C18), using H2O and ACN as eluents. The desired fractions were lyophilized to yield the title compound O2 (198 mg, 0.71 mmol, 36%) as a white powder. MS (ES) C14H16FN3O2 requires: 277. Found: 278 (M+H)+.
Step 3: N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxamide (O3)
To a solution of A2 (50 mg, 0.16 mmol, 1.0 eq), O2 (44 mg, 0.16 mmol, 1.0 eq.) and DIPEA (62 mg, 0.48 mmol, 3.0 eq.) in dry DMF (4 mL) was added HATU (121 mg, 0.32 mmol, 2.0 eq.). The mixture was stirred for 12 h at 60° C. Then the mixture was diluted with EtOAc and washed three times with aq. NaHCO3-solution. The organic phase was dried over MgSO4 and evaporated in vacuo. The residue was purified by reverse phase RP-HPLC (column: C18), using H2O and ACN as eluents. The desired fractions were lyophilized to yield the desired compound O3 with impurities. A subsequent purification by chromatography on silica gel (DCM/MeOH=20:1) yielded the product O3 (15 mg, 0.026 mmol, 16%) as a white solid. 1H NMR (400 MHz, d6-DMSO, 300K) δ 2.34 (s, 6H), 2.72 (m, 2H), 2.98 (t, J=7.4 Hz, 2H), 3.94 (s, 6H), 6.47 (d, J=5.3 Hz, 1H), 7.40 (s, 1H), 7.44 (m, 3H), 7.53 (s, 1H), 7.77 (d, J=8.8 Hz, 1H), 8.03 (m, 3H), 8.48 (d, J=5.3 Hz, 1H), 8.51 (s, 1H), 10.44 (s, 1H). MS (ES) C31H29F2N5O4 requires: 573. Found: 574 (M+H)+.
Example 37 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-[2-(2-dimethylaminoethyl)-4-fluoro-phenyl]-4-ethoxy-pyrazole-3-carboxamide (P7) Step 1: ethyl 1-(2-bromo-4-fluoro-phenyl)-4-hydroxy-pyrazole-3-carboxylate (P1)
To a solution of 2-bromo-4-fluoroaniline (10 g, 52.6 mmol, 1.0 eq.) in DCM/HOAc (1/1, 160 mL, 0.3M) at 0° C. was added dropwise a precooled solution of sodium nitrite (4.1 g, 57.9 mmol, 1.1 eq.) in conc. sulfuric acid (20 mL). After stirring for 30 min at 0° C. a mixture of ethyl 4-chloroacetoacetate (14.6 mL, 17.8 g, 108 mmol, 1.2 eq.) in HOAc (40 mL) and H2O (80 mL) was added within 5 min. After further 15 min at 0° C. a solution of sodium acetate (72 g, 0.878 mol, 16.7 eq.) in H2O (140 mL) was added slowly. The mixture stirred for 30 min at 0° C. and than 12 h at RT. DCM (200 mL) was added and the organic phase was separated. The aq. phase was extracted with DCM (3×100 mL). The combined organic phase was washed with water, phosphate buffer and subsequent with brine. The organic layer was dried over Na2SO4 and concentrated under reduced pressure to give the product ethyl 2-(2-bromo-4-fluoro-phenyl)azo-4-chloro-3-oxo-butanoate as a red solid. MS (ES) C12H11BrClFN2O3 requires: 365. Found: 365/367 (M+H)+.
Without further purification the crude material was dissolved in dry ethanol (130 mL) and after adding potassium acetate (7.1 g, 71 mmol, 1.4 eq.) the mixture was refluxed for 20 min. The reaction mixture was diluted with EtOAc and washed three times with water. The combined aq. phase was extracted with EtOAc. The combined organic phase was then washed with phosphate buffer and brine. The organic layer was dried over Na2SO4 and concentrated under reduced pressure. The desired product P1 was obtained as a yellow solid (18.19 g, 81%) and was used without further purification in the subsequent step. 1H NMR (400 MHz, CDCl3, 300K) δ 1.44 (t, J=7.1 Hz, 3H), 4.47 (q, J=7.1 Hz, 2H), 7.13 (ddd, J=9.0 Hz, J=7.5 Hz, J=2.8 Hz, 1H), 7.41 (s, 1H), 7.42 (dd, J=7.5 Hz, J=2.8 Hz, 1H), 7.48 (dd, J=9.0 Hz, J=5.5 Hz, 1H). MS (ES) C12H10BrFN2O3 requires: 329. Found: 329/331 (M+H)+ and 351/353 (M+Na)+.
Step 2: ethyl 1-(2-bromo-4-fluoro-phenyl)-4-ethoxy-pyrazole-3-carboxylate (P2)
To a mixture of P1 (4.3 g, 13.1 mmol, 1.0 eq.) and K2CO3 (2.4 g, 17.3 mmol, 1.3 eq.) in dry DMF (55 mL) was added at RT iodoethane (1.38 mL, 2.7 g, 17.3 mmol, 1.3 eq.). After stirring for 12 h at RT the mixture was cooled to 0° C. MeOH (5 mL) was added, the mixture was diluted with DCM (200 mL) and washed with water and phosphate buffer.
The organic layer was dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel (DCM/MeOH=100:0 to 5:1) to yield the desired product P2 (4.1 g, 86%) as a yellow solid. 1H NMR (400 MHz, CDCl3, 300K) δ 1.40 (t, J=7.1 Hz, 3H), 1.47 (t, J=7.0 Hz, 3H), 4.06 (q, J=7.0 Hz, 2H), 4.43 (q, J=7.1 Hz, 2H), 7.13 (ddd, J=8.8 Hz, J=7.5 Hz, J=2.8 Hz, 1H), 7.41 (s, 1H), 7.42 (dd, J=8.8 Hz, J=2.8 Hz, 1H), 7.52 (dd, J=8.8 Hz, J=5.3 Hz, 1H). MS (ES) C14H14BrFN2O3 requires: 357. Found: 357/359 (M+H)+.
Step 3: ethyl 4-ethoxy-1-[2-[(Z)-2-ethoxyvinyl]-4-fluoro-phenyl]pyrazole-3-carboxylate (P3)
A mixture of P2 (1 g, 2.8 mmol, 1.0 eq.), cis-tributyl[2-ethoxyethenyl]stannane (1.3 g, 3.1 mmol, 1.1 eq.) in DMF (9 mL) was degassed with a stream of N2 for 15 min. Then Pd(PPh3)4 (170 mg, 0.15 mmol, 0.05 eq.) was added and the reaction mixture was heated to 100° C. for 45 min in the microwave oven. The mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on silica gel (cHex/EtOAc=50:1 to 3:1) to yield the desired product P3 (820 mg, 84%) as a yellow oil. 1H NMR (400 MHz, CDCl3, 300K) δ 1.35 (t, J=7.1 Hz, 3H), 1.38 (t, J=7.1 Hz, 3H), 1.44 (t, J=7.0 Hz, 3H), 4.00 (m, 4H), 4.40 (q, J=7.1 Hz, 2H), 4.81 (d, J=7.3 Hz, 1H), 6.23 (d, J=7.3 Hz, 1H), 6.88 (m, 1H), 7.26 (m, 2H), 7.88 (dd, J=10.6 Hz, J=2.8 Hz, 1H). MS (ES) C19H21FN2O4 requires: 348. Found: 349 (M+H)+.
Step 4: ethyl 4-ethoxy-1-[4-fluoro-2-(2-oxoethyl)phenyl]pyrazole-3-carboxylate (P4)
P3 (820 mg, 2.3 mmol, 1.0 eq.) was stirred in TFA/DCM (1/2, 7.5 mL) at RT for 40 h. The mixture was concentrated under reduced pressure to yield the desired product P4 as an yellow oil. The crude material was used without further purification. MS (ES) C16H17FN2O4 requires: 320. Found: 321 (M+H)+.
Step 5: ethyl 1-[2-(2-dimethylaminoethyl)-4-fluoro-phenyl]-4-ethoxy-pyrazole-3-carboxylate (P5)
A mixture of the crude product P4 (2.3 mmol, 1.0 eq.) and a solution of dimethylamine in MeOH (5.6M, 3 ml, 7 eq.) was stirred at RT for 2 h. After addition of sodium cyanoborohydride (215 mg, 3.4 mmol, 1.5 eq.) the mixture was stirred for 15 h at RT. Water was added and the aq. phase was extracted with EtOAc. The combined org. phase was washed with aq. sat. NaHCO3-solution and dried over Na2SO4. The solvent was removed in vacuo and the crude was purified using an Isolute® SPE column SCX, loading the reaction mixture as a MeOH solution and than eluting the desired compound with 2N NH3 in MeOH. The title compound P5 was isolated after evaporation of the solvent under reduced pressure as a yellow oil (138 mg, 0.4 mmol, 17%). MS (ES) C19H24FN3O3 requires: 349. Found: 350 (M+H)+.
Step 6: 1-[2-(2-dimethylaminoethyl)-4-fluoro-phenyl]-4-ethoxy-pyrazole-3-carboxylic acid (P6)
P6 was prepared from P5 following the general procedure reported in Preparative Example 16 Step 3. The residue was purified by reversed-phase flash chromatography (H2O/MeOH=100:0 to 1:10) to yield the desired product P6 (112 mg, 88%) as a white solid. MS (ES) C16H20FN3O3 requires: 321. Found: 322 (M+H)+.
Step 7: N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-1-(2-(2-(dimethylamino)ethyl)-4-fluorophenyl)-4-ethoxy-1H-pyrazole-3-carboxamide hydrochloride (P7)
Carboxylic acid P6 (117 mg, 0.36 mmol, 1.0 eq.) was heated in thionyl chloride (3 mL) for 4 h under reflux. Solvent was removed in vacuo and the crude material was resolved in dry toluene and evaporated under reduced pressure again.
The crude material was solved in dry pyridine (3 mL) and A2 (115 mg, 0.36 mmol, 1.0 eq.) was added. The mixture was stirred at RT for 12 h. Water was added and the mixture was evaporated in vacuo. The residue was purified by reverse phase RP-HPLC (column: C18), using H2O and ACN as eluents. The desired fractions were lyophilized. The white solid (70 mg) was solved in water and ACN and than 1N HCl (0.13 mL) was added. The mixture was lyophilized to yield the title compound P7 (74 mg, 0.113 mmol, 32%) as a white powder. 1H NMR (400 MHz, MeOD, 300K) δ 1.57 (t, J=7.0 Hz, 3H), 2.97 (s, 6H), 3.08 (t, J=7.6 Hz, 2H), 3.55 (t, J=7.6 Hz, 2H), 4.04 (s, 3H), 4.05 (s, 3H), 4.28 (q, J=7.0 Hz, 2H), 6.66 (d, J=5.8 Hz, 1H), 7.25 (dt, J=8.6 Hz, J=2.8 Hz, 1H), 7.35 (dd, J=9.2 Hz, J=2.8 Hz, 1H), 7.41 (s, 1H), 7.45 (t, J=8.6 Hz, 1H), 7.53 (d, J=8.9 Hz, 1H), 7.60 (dd, J=8.9 Hz, J=5.0 Hz, 1H), 7.71 (s, 1H), 8.04 (m, 1H), 8.06 (s, 1H), 8.51 (d, J=5.8 Hz, 1H). MS (ES) C33H33F2N5O5 requires: 617. Found: 618 (M+H)+.
Example 38 N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-2-phenyl-thiazole-4-carboxamide (Q1)
Q1 was prepared from 3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]aniline and 2-phenyl-1,3-thiazole-4-carbonyl chloride following the general procedure reported in Preparative Example 1 Step 3. 1H NMR (400 MHz, d4-MeOD, 300K) δ 2.17 (m, 2H), 2.73 (m, 4H), 2.81 (t, J=7.4 Hz, 2H), 3.77 (t, J=4.7 Hz, 4H), 3.98 (s, 3H), 4.24 (t, J=6.0 Hz, 2H), 6.50 (d, J=5.4 Hz, 1H), 7.33 (s, 1H), 7.35 (t, J=8.8 Hz, 1H), 7.50 (m, 4H), 7.62 (s, 1H), 7.66 (d, J=8.8 Hz, 1H), 8.01 (dd, J=12.6 Hz, J=2.5 Hz, 1H), 8.07 (m, 2H), 8.32 (s, 1H), 8.39 (d, J=5.4 Hz, 1H). MS (ES) C33H31FN4O5S requires: 614. Found: 615 (M+H)+.
Example 39 4-bromo-N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-methyl-pyrazole-3-carboxamide (Q2)
Q2 was prepared from 3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]aniline and 4-bromo-1-methyl-1H-pyrazole-3-carbonyl chloride following the general procedure reported in Preparative Example 1 Step 3. 1H NMR (400 MHz, d4-MeOD, 300K) δ 2.20 (m, 2H), 2.73 (m, 4H), 2.81 (t, J=7.4 Hz, 2H), 3.80 (t, J=4.7 Hz, 4H), 4.02 (s, 3H), 4.05 (s, 3H), 4.29 (t, J=6.1 Hz, 2H), 6.54 (dd, J=5.4 Hz, J=1.0 Hz, 1H), 7.37 (t, J=9.0 Hz, 1H), 7.38 (s, 1H), 7.61 (d, J=8.8 Hz, 1H), 7.68 (s, 1H), 7.86 (s, 1H), 7.95 (dd, J=12.9 Hz, J=2.4 Hz, 1H), 8.45 (d, J=5.4 Hz, 1H). MS (ES) C28H29BrFN5O5 requires: 614. Found: 614/616 (M+H)+.
Example 40 N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-methyl-pyrazole-3-carboxamide (Q3)
Q3 was prepared from 3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]aniline and 1-methyl-1H-pyrazole-3-carbonyl chloride following the general procedure reported in Preparative Example 1 Step 3. 1H NMR (400 MHz, d4-MeOD, 300K) δ 2.10 (m, 2H), 2.52 (m, 4H), 2.62 (t, J=7.5 Hz, 2H), 3.70 (t, J=4.7 Hz, 4H), 3.99 (s, 3H), 4.00 (s, 3H), 4.22 (t, J=6.2 Hz, 2H), 6.49 (d, J=5.4 Hz, 1H), 6.83 (d, J=2.3 Hz, 1H), 7.33 (m, 2H), 7.58 (d, J=8.8 Hz, 1H), 7.62 (s, 1H), 7.67 (d, J=2.4 Hz, 1H), 7.94 (dd, J=12.7 Hz, J=2.4 Hz, 1H), 8.40 (d, J=5.4 Hz, 1H). MS (ES) C28H30FN5O5 requires: 535. Found: 536 (M+H)+.
Example 41 1-tert-butyl-N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-5-methyl-pyrazole-3-carboxamide (Q4)
Q4 was prepared from 3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]aniline and 1-methyl-5-phenyl-1H-pyrazole-3-carbonyl chloride following the general procedure reported in Preparative Example 1 Step 3. MS (ES) C32H38FN5O5 requires: 591. Found: 592 (M+H)+.
Example 42 N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1,5-dimethyl-pyrazole-3-carboxamide (Q5)
Q5 was prepared from 3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]aniline and 1,5-dimethyl-1H-pyrazole-3-carbonyl chloride following the general procedure reported in Preparative Example 1 Step 3. MS (ES) C29H32FN5O5 requires: 549. Found: 550 (M+H)+.
Example 43 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide (Q6)
Q6 was prepared from 3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]aniline and J4 following the general procedure reported in Preparative Example 1 Step 3. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.36 (t J=7.0 Hz, 3H), 1.96 (m, 2H), 2.25 (s, 3H), 2.38 (m, 4H), 2.46 (t, J=7.0 Hz, 2H), 3.57 (t, J=4.5 Hz, 4H), 3.94 (s, 3H), 4.04 (q, J=7.0 Hz, 2H), 4.19 (t, J=6.4 Hz, 2H), 6.44 (d, J=5.1 Hz, 1H), 7.21 (dt, J=8.6 Hz, J=2.9 Hz, 1H), 7.31 (dt, J=9.7 Hz, J=2.9 Hz, 1H), 7.39 (s, 1H), 7.41 (t, J=9.0 Hz, 1H), 7.51 (m, 2H), 7.69 (d, J=8.6 Hz, 1H), 8.02 (s, 1H), 8.02 (dd, J=13.3 Hz, J=2.3 Hz, 1H), 8.45 (d, J=5.2 Hz, 1H), 10.14 (s, 1H). MS (ES) C36H37F2N5O6 requires: 673. Found: 674 (M+H)+.
Example 44 N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxamide (Q7)
Q7 was prepared from 3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]aniline and E3 following the general procedure reported in Preparative Example 1 Step 3. 1H NMR (400 MHz, d6-DMSO, 300K) δ 2.01 (m, 2H), 2.51 (m, 6H), 3.61 (m, 4H), 3.86 (s, 3H), 3.94 (s, 3H), 4.20 (t, J=6.2 Hz, 2H), 6.46 (d, J=5.3 Hz, 1H), 7.43 (m, 4H), 7.53 (s, 1H), 7.72 (t, J=9.1 Hz, 1H), 8.01 (m, 3H), 8.47 (d, J=5.3 Hz, 1H), 8.49 (s, 1H), 10.19 (s, 1H). MS (ES) C34H33F2N6O6 requires: 645. Found: 646 (M+H)+.
Example 45 N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carboxamide (Q8)
Q8 was prepared from 3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]aniline and 12 following the general procedure reported in Preparative Example 1 Step 3. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.34 (d, J=6.0 Hz, 6H), 1.97 (m, 2H), 2.38 (m, 4H), 2.47 (m, 2H), 3.57 (t, J=4.6 Hz, 4H), 3.94 (s, 3H), 4.19 (t, J=6.3 Hz, 2H), 4.43 (sept, J=6.0 Hz, 1H), 6.46 (d, J=5.2 Hz, 1H), 7.42 (m, 4H), 7.59 (s, 1H), 7.68 (t, J=9.1 Hz, 1H), 8.01 (m, 3H), 8.46 (d, J=5.2 Hz, 1H), 8.49 (s, 1H), 10.15 (s, 1H). MS (ES) C36H37F2N6O6 requires: 673. Found: 674 (M+H)+.
The Examples in the following table were prepared according to the procedure described in the previous Example 45.
Exam- [M +
ple Name Mwt H]+
46 4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6- 685 686
methoxy-7-(3-morpholinopropoxy)-4-
quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
47 1-(2-chloro-4-fluoro-phenyl)-4-ethoxy-N-[3- 694 695
fluoro-4-[[6-methoxy-7-(3-
morpholinopropoxy)-4-
quinolyl]oxy]phenyl]pyrazole-3-carboxamide
48 4-(2-dimethylaminoethoxy)-N-[3-fluoro-4-[[6- 702 703
methoxy-7-(3-morpholinopropoxy)-4-
quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
49 1-(2-bromo-4-fluoro-phenyl)-4-ethoxy-N-[3- 738 738/740
fluoro-4-[[6-methoxy-7-(3-
morpholinopropoxy)-4-
quinolyl]oxy]phenyl]pyrazole-3-carboxamide
50 N-[3-fluoro-4-[[6-methoxy-7-(3- 689 690
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-
1-(4-fluorophenyl)-4-(2-
methoxyethoxy)pyrazole-3-carboxamide
51 4-benzyloxy-N-[3-fluoro-4-[[6-methoxy-7-(3- 721 722
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-
1-(4-fluorophenyl)pyrazole-3-carboxamide
52 N-[3-fluoro-4-[[6-methoxy-7-(3- 660 661
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-
1-(4-fluorophenyl)-4-nitro-pyrazole-3-
carboxamide
53 4-amino-N-[3-fluoro-4-[[6-methoxy-7-(3- 630 631
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-
1-(4-fluorophenyl)pyrazole-3-carboxamide
Example 54 N-[4-[[7-(3-aminopropoxy)-6-methoxy-4-quinolyl]oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (R3) Step 1: tert-butyl N-[3-[[4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-7-quinolyl]oxy]propyl]carbamate (R1)
To a solution of 4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-ol (511 mg, 1.55 mmol, 1.0 eq.) and potassium carbonate (428 mg, 3.1 mmol, 2.0 eq.) in dry DMF (10 mL) was added tert-butyl(3-bromopropyl)carbamate (480 mg, 2.01 mmol, 1.3 eq.). The mixture was stirred for 3 h at 90° C. and then cooled to RT. EtOAc was added and the organic phase was washed three times with water. The organic phase was dried over MgSO4 and solvents were removed in vacuo. The desired product R1 was obtained as brown oil and was used without further purification in the next step. MS (ES) C24H26FN3O7 requires: 487. Found: 488 (M+H)+.
Step 2: tert-butyl N-[3-[[4-(4-amino-2-fluoro-phenoxy)-6-methoxy-7-quinolyl]oxy]propyl]carbamate (R2)
A suspension of R1 (1.55 mmol, 1.0 eq.) and Pd/C (10% w/w, 75 mg) in MeOH (30 mL) was stirred under hydrogen atmosphere (1 atm) at RT for 5 h. The suspension was filtered through a pad of Celite®. The solvent was removed in vacuo. The product R2 was obtained as yellow solid (708 mg, 1.55 mmol, 100%). The crude material was used without further purification. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.37 (s, 9H), 1.92 (quint., J=6.4 Hz, 2H), 3.13 (quart., J=6.4 Hz, 2H), 3.93 (s, 3H), 4.14 (t, J=6.4 Hz, 2H), 5.46 (br s, 2H), 6.36 (d, J=5.3 Hz, 1H), 6.45 (dd, J=8.7 Hz, J=2.4 Hz, 1H), 6.53 (dd, J=13.1 Hz, J=2.4 Hz, 1H), 6.88 (m, 1H), 7.05 (t, J=8.9 Hz, 1H), 7.34 (s, 1H), 7.49 (s, 1H), 8.43 (d, J=5.3 Hz, 1H). MS (ES) C24H28FN3O5 requires: 457. Found: 458 (M+H)+.
Step 3: N-[4-[[7-(3-aminopropoxy)-6-methoxy-4-quinolyl]oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide (R3)
Tert-butyl N-[3-[[4-[4-[[4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carbonyl]amino]-2-fluoro-phenoxy]-6-methoxy-7-quinolyl]oxy]propyl]carbamate was prepared from R2 and D4 following the general procedure reported in Preparative Example 1 Step 3.
Then the crude material was stirred in TFA/DCM (1/1) for 3 h at RT. The reaction mixture was concentrated under reduced pressure and the residue was purified by reverse phase RP-HPLC (column: C18), using H2O and MeOH as eluents. The desired fractions were lyophilized to yield the title compound R3 as a white powder. 1H NMR (400 MHz, d4-MeOD, 300K) δ 1.59 (t, J=7.0 Hz, 3H), 2.29 (m, 2H), 3.27 (t, J=6.8 Hz, 2H), 4.03 (s, 3H), 4.19 (q, J=7.0 Hz, 2H), 4.35 (t, J=5.6 Hz, 2H), 6.55 (d, J=5.3 Hz, 1H), 7.24 (t, J=8.7 Hz, 2H), 7.36 (t, J=9.0 Hz, 1H), 7.38 (s, 1H), 7.55 (d, J=9.0 Hz, 1H), 7.68 (s, 1H), 7.88 (m, 2H), 7.99 (dd, J=12.6 Hz, J=2.4 Hz, 1H), 8.16 (s, 1H), 8.44 (d, J=5.3 Hz, 1H). MS (ES) C31H29F2N5O5 requires: 589. Found: 590 (M+H)+.
The Examples in the following table were prepared according to the procedure described in the previous Example 54.
Exam- [M +
ple Name Mwt H]+
55 N-[4-[[7-(3-aminopropoxy)-6-methoxy-4- 603 604
quinolyl]oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-
fluoro-2-methyl-phenyl)pyrazole-3-
carboxamide
56 N-[4-[[7-(3-aminopropoxy)-6-methoxy-4- 590 591
quinolyl]oxy]-3-fluoro-phenyl]-5-ethoxy-2-(4-
fluorophenyl)oxazole-4-carboxamide
Example 57 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide (S2) Step 1: 3-fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-quinolyl]oxy]aniline (S1)
S1 was prepared from 4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-ol and 1-(3-chloropropyl)-4-methylpiperazine following the general procedure reported in Preparative Example 54 Step 1-2. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.95 (quint., J=6.8 Hz, 2H), 2.14 (s, 3H), 2.22-2.47 (m, 10H), 3.94 (s, 3H), 4.17 (t, J=6.5 Hz, 2H), 5.48 (br.s, 2H), 6.38 (d, J=5.2 Hz, 1H), 6.46 (dd, J=8.7 Hz, J=2.4 Hz, 1H), 6.55 (dd, J=13.2 Hz, J=2.4 Hz, 1H), 7.07 (t, J=9.0 Hz, 1H), 7.36 (s, 1H), 7.50 (s, 1H), 8.44 (d, J=5.2 Hz, 1H). MS (ES) C24H29FN4O3 requires: 440. Found: 441 (M+H)+.
Step 2: 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide (S2)
S2 was prepared from S1 and J4 following the general procedure reported in Preparative Example 1 Step 3. The crude product was purified by flash chromatography on silica gel (DCM/MeOH=100:0 to 5:1) to yield the desired product S2 (60 mg, 0.087 mmol, 77%) as a white solid. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.36 (t, J=7.0 Hz, 3H), 1.95 (t, J=7.3 Hz, 2H), 2.17 (m, 4H), 2.25 (m, 4H), 2.30-2.50 (m, 8H), 3.94 (s, 3H), 4.05 (q, J=7.0 Hz, 2H), 4.17 (t, J=6.4 Hz, 2H), 6.44 (d, J=5.2 Hz, 1H), 7.21 (dt, J=8.6 Hz, J=2.5 Hz, 1H), 7.31 (dd, J=9.8 Hz, J=2.5 Hz, 1H), 7.37 (s, 1H), 7.41 (t, J=9.0 Hz, 1H), 7.50 (m, 2H), 7.69 (d, J=9.0 Hz, 1H), 8.01 (dd, J=13.1 Hz, J=2.5 Hz, 1H), 8.02 (s, 1H), 8.46 (d, J=5.2 Hz, 1H), 10.14 (s, 1H). MS (ES) C37H40F2N6O6 requires: 686. Found: 687 (M+H)+.
The Examples in the following table were prepared according to the procedure described in the previous Example 57.
Exam- [M +
ple Name Mwt H]+
58 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-[3-(4- 672 673
methylpiperazin-1-yl)propoxy]-4-
quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
59 N-[3-fluoro-4-[[6-methoxy-7-[3-(4- 658 659
methylpiperazin-1-yl)propoxy]-4-
quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-
methoxy-pyrazole-3-carboxamide
60 1-(2-chloro-4-fluoro-phenyl)-4-ethoxy-N-[3- 706 707
fluoro-4-[[6-methoxy-7-[3-(4-
methylpiperazin-1-yl)propoxy]-4-
quinolyl]oxy]phenyl]pyrazole-3-carboxamide
61 4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6- 698 699
methoxy-7-[3-(4-methylpiperazin-1-
yl)propoxy]-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
62 N-[3-fluoro-4-[[6-methoxy-7-[3-(4- 686 687
methylpiperazin-1-yl)propoxy]-4-
quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-
isopropoxy-pyrazole-3-carboxamide
63 5-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-[3-(4- 673 674
methylpiperazin-1-yl)propoxy]-4-
quinolyl]oxy]phenyl]-2-(4-
fluorophenyl)oxazole-4-carboxamide
Example 64 4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide trifluoroacetic acid salt (T2) Step 1: tert-butyl 4-[3-[[4-(4-amino-2-fluoro-phenoxy)-6-methoxy-7-quinolyl]oxy]propyl]piperazine-1-carboxylate (T1)
T1 was prepared from 4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-ol and tert-butyl 4-(3-chloropropyl)piperazine-1-carboxylate following the general procedure reported in Preparative Example 54 Step 1-2. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.38 (s, 9H), 1.96 (m, 2H), 2.23 (m, 4H), 2.47 (m, 2H), 3.30 (m, 4H), 3.92 (s, 3H), 4.17 (t, J=6.3 Hz, 2H), 5.46 (br s, 2H), 6.37 (d, J=5.2 Hz, 1H), 6.45 (dd, J=8.9 Hz, J=1.8 Hz, 1H), 6.54 (dd, J=13.1 Hz, J=2.4 Hz, 1H), 7.05 (t, J=8.9 Hz, 1H), 7.35 (s, 1H), 7.49 (s, 1H), 8.42 (d, J=5.2 Hz, 1H). MS (ES) C29H35FN4O5 requires: 526. Found: 527 (M+H)+.
Step 2: 4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide trifluoroacetic acid salt (T2)
Tert-butyl 4-[3-[[4-[4-[[4-(cyclopropylmethoxy)-1-(4-fluorophenyl)pyrazole-3-carbonyl]-amino]-2-fluoro-phenoxy]-6-methoxy-7-quinolyl]oxy]propyl]piperazine-1-carboxylate was prepared from T1 and F3 following the general procedure reported in Preparative Example 1 Step 3. The crude material was stirred in TFA/DCM (1/1) for 3 h at RT. The reaction mixture was concentrated under reduced pressure and the residue was purified by reverse phase RP-HPLC (column: C18), using H2O (0.1% TFA) and MeOH (0.1% TFA) as eluents. The desired fractions were lyophilized to yield the title compound T2 as a white powder. 1H NMR (400 MHz, d6-DMSO, 300K) δ 0.35 (m, 2H), 0.58 (m, 2H), 1.30 (m, 1H), 1.94 (m, 2H), 2.32 (m, 2H), 2.41 (t, J=7.2 Hz, 2H), 2.71 (m, 4H), 3.87 (d, J=7.1 Hz, 2H), 3.93 (s, 3H), 4.17 (t, J=6.4 Hz, 2H), 6.45 (d, J=5.3 Hz, 1H), 7.39 (m, 4H), 7.45 (t, J=9.1 Hz, 1H), 7.52 (s, 1H), 7.68 (d, J=8.8 Hz, 1H), 8.00 (m, 4H), 8.45 (d, J=5.3 Hz, 1H), 8.46 (s, 1H), 10.18 (s, 1H). MS (ES) C37H38F2N6O6 requires: 684. Found: 685 (M+H)+.
The Examples in the following table were prepared according to the procedure described in the previous Example 64.
Exam- [M +
ple Name Mwt H]+
65 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(3- 658 659
piperazin-1-ylpropoxy)-4-
quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
66 N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1- 644 645
ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)-4-methoxy-pyrazole-3-
carboxamide
67 N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1- 672 673
ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)-4-isopropoxy-pyrazole-3-
carboxamide
68 1-(2-chloro-4-fluoro-phenyl)-4-ethoxy-N-[3- 692 693
fluoro-4-[[6-methoxy-7-(3-piperazin-1-
ylpropoxy)-4-quinolyl]oxy]phenyl]pyrazole-3-
carboxamide
69 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(3- 672 673
piperazin-1-ylpropoxy)-4-
quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-
phenyl)pyrazole-3-carboxamide
70 N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1- 688 689
ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)-4-(2-methoxyethoxy)pyrazole-
3-carboxamide
71 N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1- 727 728
ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)-4-[(1-methylpyrrolidin-3-
yl)methoxy]pyrazole-3-carboxamide
72 N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1- 613 614
ylpropoxy)-4-quinolyl]oxy]phenyl]-2-phenyl-
thiazole-4-carboxamide trifluoroacetic acid
salt
Example 73 N-[3-fluoro-4-[[6-methoxy-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxamide (U2) Step 1: tert-butyl 4-[[4-(4-amino-2-fluoro-phenoxy)-6-methoxy-7-quinolyl]oxymethyl]piperidine-1-carboxylate (U1)
U1 was prepared from 4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-ol and tert-butyl 4-(bromomethyl)piperidine-1-carboxylate following the general procedure reported in Preparative Example 54 Step 1-2. 1H NMR (400 MHz, CDCl3, 300K) δ 1.22 (m, 2H), 1.40 (s, 9H), 1.82 (d, J=12.7 Hz, 2H), 2.10 (m, 1H), 2.69 (t, J=12.3 Hz, 2H), 3.77 (m, 2H), 3.96 (s, 3H), 3.97 (m, 2H), 4.10 (m, 2H), 6.31 (d, J=5.2 Hz, 1H), 6.46 (m, 2H), 6.96 (t, J=8.7 Hz, 1H), 7.31 (s, 1H), 7.51 (s, 1H), 8.40 (d, J=5.2 Hz, 1H). MS (ES) C27H32FN3O5 requires: 497. Found: 498 (M+H)+.
Step 2: N-[3-fluoro-4-[[6-methoxy-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxamide (U2)
Tert-butyl 4-[[4-[2-fluoro-4-[[1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carbonyl]amino]-phenoxy]-6-methoxy-7-quinolyl]oxymethyl]piperidine-1-carboxylate was prepared from U1 and E3 following the general procedure reported in Preparative Example 1 Step 3. The crude material was stirred in TFA/DCM (1/1) for 3 h at RT. The reaction mixture was concentrated under reduced pressure and the residue was purified by reverse phase RP-HPLC (column: C18), using H2O and MeOH as eluents. The desired fractions were lyophilized to yield the title compound U2 as a white powder. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.50 (q, J=12.3 Hz, 2H), 1.97 (d, J=13.0 Hz, 2H), 2.18 (m, 1H), 2.95 (m, 2H), 3.33 (m, 2H), 3.85 (s, 3H), 3.95 (s, 3H), 4.07 (d, J=6.2 Hz, 2H), 6.48 (d, J=5.2 Hz, 1H), 7.41 (m, 4H), 7.54 (s, 1H), 7.72 (d, J=8.7 Hz, 1H), 8.00 (m, 3H), 8.47 (d, J=5.2 Hz, 1H), 8.50 (s, 1H), 10.26 (s, 1H). MS (ES) C33H31F2N5O5 requires: 615. Found: 616 (M+H)+.
The Examples in the following table were prepared according to the procedure described in the previous Example 73.
Exam- [M +
ple Name Mwt H]+
74 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(4- 643 644
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-
(4-fluoro-2-methyl-phenyl)pyrazole-3-
carboxamide
75 4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6- 655 656
methoxy-7-(4-piperidylmethoxy)-4-
quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
76 4-bromo-N-[3-fluoro-4-[[6-methoxy-7-(4- 664 664/666
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-
(4-fluorophenyl)pyrazole-3-carboxamide
77 N-[3-fluoro-4-[[6-methoxy-7-(4- 709 710
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-
(4-fluorophenyl)-4-[(4-
fluorophenyl)methoxy]pyrazole-3-
carboxamide
78 1-tert-butyl-N-[3-fluoro-4-[[6-methoxy-7-(4- 561 562
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-5-
methyl-pyrazole-3-carboxamide
79 N-[3-fluoro-4-[[6-methoxy-7-(4- 661 662
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-4-
nitro-1-[3-(1-piperidyl)propyl]pyrazole-3-
carboxamide
80 N-[3-fluoro-4-[[6-methoxy-7-(4- 582 583
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-5-
methyl-2-phenyl-oxazole-4-carboxamide
81 N-[3-fluoro-4-[[6-methoxy-7-(4- 584 585
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-2-
phenyl-thiazole-4-carboxamide
trifluoroacetic acid salt
Example 82 4-ethoxy-N-[4-[[7[(1-ethyl-4-piperidyl)methoxy]-6-methoxy-4-quinolyl]oxy]-3-fluoro-phenyl]-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide (V1)
Example 74 (39 mg, 0.06 mmol, 1.0 eq.) and acetaldehyde (5 mg, 0.12 mmol, 2.0 eq.) in dry MeOH (5 mL) was stirred for 2 h at RT. After adding sodium cyanoborohydride (6 mg, 0.09 mmol, 1.5 eq.) the mixture was stirred for 12 h. The mixture was diluted with EtOAc and the organic phase was washed twice with aq.NaHO3-solution. The organic phase was dried and solvents were removed in vacuo. The residue was purified by reverse phase RP-HPLC (column: C18), using H2O and MeOH as eluents. The desired fractions were lyophilized to yield the title compound V01 as a white powder. MS (ES) C37H39F2N5O5 requires: 671. Found: 672 (M+H)+.
The Example in the following table was prepared according to the procedure described in the previous Example 82.
Exam- [M +
ple Name Mwt H]+
83 4-ethoxy-N-[3-fluoro-4-[[7-[(1-isobutyl-4- 699 700
piperidyl)methoxy]-6-methoxy-4-
quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-
phenyl)pyrazole-3-carboxamide
Example 84 N-[5-[(6,7-dimethoxy-4-quinolyl)oxy]-2-pyridyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide trifluoroacetic acid salt (W3) Step 1: 6,7-dimethoxy-4-[(6-nitro-3-pyridyl)oxy]quinoline (W1)
A mixture of 6,7-dimethoxyquinolin-4-ol (2.02 g, 9.8 mmol, 1.0 eq.), 5-fluoro-2-nitro-pyridine (1.96 g, 13.78 mmol, 1.4 eq.) and cesium carbonate (4.8 g, 14.7 mmol, 1.5 eq.) in dry DMF (10 mL) was heated for 1 h at 80° C. in a microwave oven. After cooling to RT the mixture was diluted with water and extracted with DCM. The combined organic phase was dried over Na2SO4 and evaporated in vacuo. The crude product was purified by flash chromatography on silica gel (DCM/MeOH=100:0 to 10:1) to yield the desired product W1 (1.28 g, 40%) as a yellow solid. 1H NMR (400 MHz, d6-DMSO, 300K) δ 3.88 (s, 3H), 3.94 (s, 3H), 6.92 (d, J=5.2 Hz, 1H), 7.41 (s, 1H), 7.45 (s, 1H), 7.98 (dd, J=2.7 Hz, J=9.0 Hz, 1H), 8.40 (d, J=9.0 Hz, 1H), 8.60 (d, J=5.2 Hz, 1H), 8.66 (d, J=2.7 Hz, 1H). MS (ES) C16H13N3O5 requires: 327. Found: 328 (M+H)+.
Step 2: 5-[(6,7-dimethoxy-4-quinolyl)oxy]pyridin-2-amine (W2)
W1 (1.28 g, 3.91 mmol) in EtOH (40 mL) was reduced in an H-Cube® hydrogenation reactor (Pd/C cartridge, H2=100 bar, T=60° C., flow=0.7 mL/min). After evaporation of the solvent the crude material was purified by flash chromatography on silica gel (DCM/MeOH=100:0 to 5:1) to yield the desired product W2 (0.48 g, 41%) as a white solid. 1H NMR (400 MHz, d6-DMSO, 300K) δ 3.92 (s, 6H), 6.03 (br s, 2H), 6.40 (d, J=5.2 Hz, 1H), 6.55 (d, J=8.9 Hz, 1H), 7.35 (m, 2H), 7.49 (s, 1H), 7.88 (d, J=2.9 Hz, 1H), 8.43 (d, J=5.2 Hz, 1H). MS (ES) C16H15N3O3 requires: 297. Found: 298 (M+H)+.
Step 3: N-[5-[(6,7-dimethoxy-4-quinolyl)oxy]-2-pyridyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide trifluoroacetic acid salt (W3)
W3 was prepared from W2 and D4 following the general procedure reported in Preparative Example 1 Step 3. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.42 (t, J=7.0 Hz, 3H), 4.02 (s, 3H), 4.03 (s, 3H), 4.18 (q, J=7.0 Hz, 2H), 7.03 (d, J=6.5 Hz, 1H), 7.40 (t, J=8.9 Hz, 1H), 7.58 (s, 1H), 7.76 (s, 1H), 7.98 (m, 3H), 8.43 (d, J=8.9 Hz, 1H), 8.52 (d, J=3.0 Hz, 1H), 8.56 (s, 1H), 8.82 (d, J=6.6 Hz, 1H), 9.97 (s, 1H). MS (ES) C28H24FN5O5 requires: 529. Found: 530 (M+H)+.
The Examples in the following table were prepared according to the procedure described in the previous Example 84.
Exam- [M +
ple Name Mwt H]+
85 N-[5-[(6,7-dimethoxy-4-quinolyl)oxy]-2- 543 544
pyridyl]-4-ethoxy-1-(4-fluoro-2-methyl-
phenyl)pyrazole-3-carboxamide
86 1-(2-chloro-4-fluoro-phenyl)-N-[5-[(6,7- 563 564
dimethoxy-4-quinolyl)oxy]-2-pyridyl]-4-
ethoxy-pyrazole-3-carboxamide
87 N-[5-[(6,7-dimethoxy-4-quinolyl)oxy]-2- 556 557
pyridyl]-4-(2-dimethylaminoethyl)-1-(4-
fluorophenyl)pyrazole-3-carboxamide
Example 88 Tert-butyl 4-(((4-((6-(4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamido)pyridin-3-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)piperidine-1-carboxylate (X1)
X1 was prepared from tert-butyl 4-(((4-((6-aminopyridin-3-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)piperidine-1-carboxylate and J4 following the general procedure reported in Preparative Example 16 Step 5. 1H NMR (400 MHz, d4-MeOH, 300K) δ 1.32 (m, 2H), 1.46 (s, 9H), 1.53 (t, J=7.0 Hz, 3H), 1.90 (m, 2H), 2.12 (m, 1H), 2.27 (s, 3H), 2.84 (m, 2H), 4.00 (s, 3H), 4.03 (m, 2H), 4.14 (m, 2H), 4.22 (q, J=7.00 Hz, 3H), 6.59 (d, J=5.4 Hz, 1H), 7.08 (dt, J=2.5 Hz, J=8.2 Hz, 1H), 7.15 (dd, J=2.5 Hz, J=9.3 Hz, 1H), 7.32 (s, 1H), 7.42 (m, 1H), 7.63 (s, 1H), 7.76 (m, 1H), 7.84 (s, 1H), 8.31 (m, 1H), 8.45 (m, 2H). MS (ES) C36H43FN6O7 requires: 726. Found: 727 (M+H)+.
Example 89 N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1-(4-methoxy-2-methylphenyl)-1H-pyrazole-3-carboxamide (X2)
Following the general procedure reported in Preparative Example 16 Step 5 X2 was prepared from W2 and 4-ethoxy-1-(4-methoxy-2-methylphenyl)-1H-pyrazole-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.41 (t, J=7.0 Hz, 3H), 2.21 (s, 3H), 3.81 (s, 3H), 3.93 (s, 3H), 3.94 (s, 3H), 4.15 (q, J=7.0 Hz, 2H), 6.54 (d, J=5.2 Hz, 1H), 6.91 (dd, J=8.7 Hz, J=2.8 Hz, 1H), 6.98 (d, J=2.8 Hz, 1H), 7.36 (d, J=8.7 Hz, 1H), 7.41 (s, 1H), 7.53 (s, 1H), 7.85 (dd, J=2.9 Hz, J=9.0 Hz, 1H), 8.04 (s, 1H), 8.35 (d, J=9.0 Hz, 1H), 8.39 (d, J=2.9 Hz, 1H), 8.49 (d, J=5.2 Hz, 1H), 9.68 (s, 1H). MS (ES) C30H26N6O6 requires: 555. Found: 556 (M+H)+.
Example 90 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(3-nitrophenyl)-1H-pyrazole-3-carboxamide (X3)
Following the general procedure reported in Preparative Example 16 Step 5 X3 was prepared from A2 and 4-ethoxy-1-(3-nitrophenyl)-1H-pyrazole-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4. MS (ES) C29H24N5O7 requires: 573. Found: 574 (M+H)+.
Example 91 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-methoxy-2-methylphenyl)-1H-pyrazole-3-carboxamid (X4)
Following the general procedure reported in Preparative Example 16 Step 5×4 was prepared from A2 and 4-ethoxy-1-(4-methoxy-2-methylphenyl)-1H-pyrazole-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.36 (t, J=7.0 Hz, 3H), 2.20 (s, 3H), 3.80 (s, 3H), 3.94 (s, 6H), 4.05 (q, J=7.0 Hz, 2H), 6.46 (d, J=5.2 Hz, 1H), 6.90 (dd, J=2.9 Hz, J=8.8 Hz, 1H), 6.98 (d, J=2.7 Hz, 1H), 7.36 (d, J=8.8 Hz, 1H), 7.40 (s, 1H), 7.43 (d, J=9.0 Hz, 1H), 7.53 (s, 1H), 7.71 (d, J=9.0 Hz, 1H), 7.95 (s, 1H), 8.03 (dd, J=2.4 Hz, J=13.3 Hz, 1H), 8.47 (d, J=5.2 Hz, 1H), 10.10 (s, 1H). MS (ES) C31H29FN4O6 requires: 572. Found: 573 (M+H)+.
Example 92 N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1-(3-nitrophenyl)-1H-pyrazole-3-carboxamide (X5)
Following the general procedure reported in Preparative Example 16 Step 5×5 was prepared from W2 and 4-ethoxy-1-(3-nitrophenyl)-1H-pyrazole-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4. MS (ES) C28H24N6O7 requires: 556. Found: 557 (M+H)+.
Example 93 1-(2-(benzyloxy)-4-fluorophenyl)-N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1H-pyrazole-3-carboxamide (X6)
Following the general procedure reported in Preparative Example 16 Step 5 X6 was prepared from W2 and 1-(2-(benzyloxy)-4-fluorophenyl)-4-ethoxy-1H-pyrazole-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4. 1H NMR (400 MHz, CDCl3, 300K) δ 1.45 (t, J=7.0 Hz, 3H), 4.01 (s, 3H), 4.07 (s, 3H), 5.14 (s, 2H), 6.48 (d, J=5.3 Hz, 1H), 6.83 (m, 1H), 7.26 (m, 1H), 7.40 (m, 5H), 7.46 (s, 1H), 7.56 (s, 1H), 7.60 (dd, J=2.9 Hz, J=9.0 Hz, 1H), 7.76 (s, 1H), 7.85 (m, 1H), 8.26 (d, J=2.9 Hz, 1H), 8.52 (d, J=5.3 Hz, 1H), 8.59 (d, J=9.0 Hz, 1H), 9.53 (s, 1H). MS (ES) C35H30FN5O6 requires: 635. Found: 636 (M+H)+.
Example 94 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methoxyphenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide (X7)
Following the general procedure reported in Preparative Example 16 Step 5 X7 was prepared from J4 and 4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methoxyaniline, which was prepared similar to Preparative Example 1 step 1-2. 1H NMR (400 MHz, CDCl3, 300K) δ 1.58 (t, J=7.0 Hz, 3H), 2.27 (s, 3H), 3.91 (s, 3H), 4.05 (s, 3H), 4.06 (s, 3H), 4.15 (q, J=7.0 Hz, 2H), 6.52 (d, J=5.3 Hz, 1H), 6.77 (d, J=2.5 Hz, 1H), 6.85 (dd, J=2.5 Hz, J=8.8 Hz, 1H), 7.00 (m, 2H), 7.32 (s, 1H), 7.34 (dd, J=5.3 Hz, J=8.8 Hz, 1H), 7.44 (s, 1H), 7.58 (s, 1H), 8.50 (d, J=5.3 Hz, 1H), 8.76 (d, J=8.8 Hz, 1H), 9.50 (s, 1H). MS (ES) C31H29FN4O6 requires: 572. Found: 573 (M+H)+.
Example 95 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methylphenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide (X8)
Following the general procedure reported in Preparative Example 16 Step 5×8 was prepared from J4 and 4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methylaniline, which was prepared similar to Preparative Example 1 step 1-2. 1H NMR (400 MHz, CDCl3, 300K) δ 1.56 (t, J=7.0 Hz, 3H), 2.28 (s, 3H), 2.39 (s, 3H), 4.05 (s, 6H), 4.18 (q, J=7.0 Hz, 2H), 6.51 (d, J=5.3 Hz, 1H), 7.02 (m, 3H), 7.09 (dd, J=2.7 Hz, J=8.8 Hz, 1H), 7.35 (m, 2H), 7.44 (s, 1H), 7.57 (s, 1H), 8.41 (d, J=8.8 Hz, 1H), 8.49 (d, J=5.3 Hz, 1H), 8.78 (s, 1H). MS (ES) C31H29FN4O5 requires: 556. Found: 557 (M+H)+.
Example 96 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-3-methoxyphenyl)-1H-pyrazole-3-carboxamide (X9)
Following the general procedure reported in Preparative Example 16 Step 5 X9 was prepared from A2 and 4-ethoxy-1-(4-fluoro-3-methoxyphenyl)-1H-pyrazole-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4. 1H NMR (400 MHz, d5-DMSO, 300K) δ 1.39 (t, J=7.0 Hz, 3H), 3.94 (s, 6H), 3.96 (s, 3H), 4.10 (q, J=7.0 Hz, 2H), 6.48 (d, J=5.2 Hz, 1H), 7.40 (m, 2H), 7.46 (t, J=9.0 Hz, 1H), 7.52 (m, 2H), 7.70 (m, 2H), 8.03 (dd, J=2.4 Hz, J=13.2 Hz, 1H), 8.48 (d, J=5.2 Hz, 1H), 8.52 (s, 1H), 10.19 (s, 1H). MS (ES) C30H26F2N4O6 requires: 576. Found: 577 (M+H)+.
Example 97 N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1-(4-fluoro-3-methoxyphenyl)-1H-pyrazole-3-carboxamide (X10)
Following the general procedure reported in Preparative Example 16 Step 5 X10 was prepared from W2 and 4-ethoxy-1-(4-fluoro-3-methoxyphenyl)-1H-pyrazole-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.43 (t, J=7.0 Hz, 3H), 3.97 (s, 3H), 4.02 (s, 6H), 4.19 (q, J=7.0 Hz, 2H), 6.99 (d, J=6.5 Hz, 1H), 7.39 (dd, J=8.9 Hz, J=10.9 Hz, 1H), 7.49 (m, 1H), 7.68 (dd, J=2.5 Hz, J=7.5 Hz, 1H), 7.72 (s, 1H), 7.75 (s, 1H), 8.01 (dd, J=2.9 Hz, J=9.0 Hz, 1H), 8.42 (d, J=9.0 Hz, 1H), 8.52 (d, J=2.9 Hz, 1H), 8.60 (s, 1H), 8.80 (d, J=6.5 Hz, 1H), 9.97 (s, 1H). MS (ES) C29H26FN5O6 requires: 559. Found: 560 (M+H)+.
Example 98 N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1-(4-nitrophenyl)-1H-pyrazole-3-carboxamide (X11)
Following the general procedure reported in Preparative Example 16 Step 5 X11 was prepared from W2 and 4-ethoxy-1-(4-nitrophenyl)-1H-pyrazole-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.43 (t, J=7.0 Hz, 3H), 3.93 (s, 3H), 3.94 (s, 3H), 4.20 (q, J=7.0 Hz, 2H), 6.56 (d, J=5.2 Hz, 1H), 7.40 (s, 1H), 7.53 (s, 1H), 7.87 (dd, J=2.9 Hz, J=9.1 Hz, 1H), 8.22 (d, J=9.1 Hz, 2H), 8.34 (d, J=9.1 Hz, 1H), 8.41 (m, 3H), 8.48 (d, J=5.3 Hz, 1H), 8.75 (s, 1H), 10.04 (s, 1H). MS (ES) C28H24N6O7 requires: 556. Found: 557 (M+H)+.
Example 99 1-(4-aminophenyl)-N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1H-pyrazole-3-carboxamide (X12)
A suspension of X11 (357 mg, 0.64 mmol), and Pd/C (10% w/w, 35 mg) in a mixture of aq. HCl-solution (6N, 1.5 mL). DCM (20 mL) and MeOH (40 mL) was stirred under hydrogen atmosphere (1 atm) at RT for 2 h. The mixture was diluted with DCM (100 mL) and aq. NaHCO3-solution (50 mL). The org. phase was separated and the aq. phase was extracted twice with DCM (50 mL). The combined org. phase was dried over Na2SO4 and concentrated under reduced pressure. The residue was solved in MeCN (20 mL) and H2O (5 mL) and lyophilized yielding X12 (322 mg, 95%) as a beige solid. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.42 (t, J=7.0 Hz, 3H), 3.94 (s, 3H), 3.95 (s, 3H), 4.17 (q, J=7.0 Hz, 2H), 5.35 (s, 2H), 6.55 (d, J=5.2 Hz, 1H), 6.66 (d, J=8.8 Hz; 2H), 7.41 (s, 1H), 7.54 (m, 3H), 7.86 (dd, J=2.9 Hz, J=8.9 Hz, 1H), 8.30 (s, 1H), 8.37 (m, 2H), 8.49 (d, J=5.3 Hz, 1H), 9.71 (s, 1H). MS (ES) C28H26N6O6 requires: 526. Found: 527 (M+H)+.
Example 100 N-(5-((6-methoxy-7-(piperidin-4-ylmethoxy)quinolin-4-yl)oxy)pyridin-2-yl)-4-(2-methoxyphenyl)thiazole-2-carboxamide (X13)
Following the general procedure reported in Preparative Example 16 Step 5 X13 was prepared from tert-butyl 4-(((4-((6-aminopyridin-3-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)piperidine-1-carboxylate and 4-(2-methoxyphenyl)thiazole-2-carbonyl chloride, which was prepared similar to Preparative Example 16 step 4 from commercially available 4-(2-methoxyphenyl)thiazole-2-carboxylic acid. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.40 (m, 2H), 1.87 (d, J=12.6 Hz, 2H), 2.07 (m, 1H), 2.76 (t, J=11.8 Hz, 2H), 3.18 (d, J=12.6 Hz, 2H), 3.93 (s, 3H), 3.95 (s, 3H), 4.02 (d, J=6.4 Hz, 2H), 6.57 (d, J=5.2 Hz, 1H), 7.09 (t, J=7.6 Hz, 1H), 7.18 (d, J=8.4 Hz, 1H), 7.39 (m, 2H), 7.53 (s, 1H), 7.90 (dd, J=2.8 Hz, J=9.0 Hz, 1H), 8.29 (d, J=9.0 Hz, 1H), 8.49 (m, 4H). MS (ES) C32H31N6O6S requires: 597. Found: 598 (M+H)+.
Example 101 N-(5-((6-methoxy-7-(piperidin-4-ylmethoxy)quinolin-4-yl)oxy)pyridin-2-yl)-4-phenylthiazole-2-carboxamide (X14)
A mixture of tert-butyl 4-(((4-((6-aminopyridin-3-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)piperidine-1-carboxylate (70 mg, 0.14 mmol), 4-phenylthiazole-2-carboxylic acid (46 mg, 0.21 mmol), DIPEA (56 mg, 0.43 mmol) and HATU (110 mg, 0.29 mmol) in dry DMF (5 mL) was stirred for 72 h at 55° C. The solution was diluted with EtOAc (150 mL) and washed twice with aq.NaHCO3-solution and once with brine. The residue was dissolved in 50% TFA in DCM (5 mL) and stirred for 2 h at RT. The mixture was concentrated under reduced pressure. The residue was purified by reverse phase RP-HPLC (column: C18), using H2O and ACN as eluents. The desired fractions were lyophilized to yield the title compound X14 (25 mg, 30%) as a white powder. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.25 (m, 2H), 1.76 (d, J=12.0 Hz, 2H), 1.95 (m, 1H), 2.55 (t, J=11.0 Hz, 2H), 3.00 (d, J=12.0 Hz, 2H), 3.94 (s, 3H), 3.99 (d, J=6.3 Hz, 2H), 6.58 (d, J=5.2 Hz, 1H), 7.41 (m, 2H), 7.51 (m, 3H), 7.90 (dd, J=2.9 Hz, J=9.0 Hz, 1H), 8.17 (d, J=7.4 Hz, 2H), 8.29 (d, J=9.0 Hz, 1H), 8.48 (d, J=2.9 Hz, 1H), 8.50 (d, J=5.2 Hz, 1H), 8.55 (s, 1H). MS (ES) C3H29N5O4S requires: 567. Found: 568 (M+H)+.
Example 102 4-bromo-N-(5-((6-methoxy-7-(piperidin-4-ylmethoxy)quinolin-4-yl)oxy)pyridin-2-yl)thiazole-2-carboxamide (X15)
Following the general procedure reported in Preparative Example 16 Step 5 X15 was prepared from tert-butyl 4-(((4-((6-aminopyridin-3-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)piperidine-1-carboxylate and 4-bromothiazole-2-carbonyl chloride, which was prepared similar to Preparative Example 16 step 4 from commercially available 4-bromothiazole-2-carboxylic acid. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.53 (m, 2H), 1.98 (d, J=12.5 Hz, 2H), 2.18 (m, 1H), 2.95 (m, 2H), 3.33 (m, 2H), 3.94 (s, 3H), 4.08 (d, J=6.3 Hz, 2H), 6.58 (d, J=5.2 Hz, 1H), 7.45 (s, 1H), 7.54 (m, 1H), 7.87 (dd, J=2.9 Hz, J=9.0 Hz, 1H), 8.19 (d, J=9.0 Hz, 1H), 8.31 (s, 1H), 8.45 (d, J=2.9 Hz, 1H), 8.50 (d, J=5.2 Hz, 1H), 10.61 (br s, 1H). MS (ES) C25H24BrN5O4S requires: 570. Found: 570/572 (M−1-H)+.
Example 103 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methoxyphenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide (X16)
Following the general procedure reported in Preparative Example 16 Step 5 X16 was prepared from J4 and 4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methoxyaniline, which was prepared similar to Preparative Example 1 step 1-2. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.58 (t, J=7.0 Hz, 3H), 2.27 (s, 3H), 3.91 (s, 3H), 4.05 (s, 3H), 4.06 (s, 3H), 4.15 (q, J=7.0 Hz, 2H), 6.53 (d, J=5.3 Hz, 1H), 6.77 (d, J=2.5 Hz, 1H), 6.85 (dd, J=2.5 Hz, J=8.8 Hz, 1H), 7.00 (m, 2H), 7.32 (s, 1H), 7.35 (dd, J=8.6 Hz, J=5.3 Hz, 1H), 7.44 (s, 1H), 7.58 (s, 1H), 8.50 (d, J=5.3 Hz, 1H), 8.76 (d, J=8.8 Hz, 1H), 9.50 (s, 1H). MS (ES) C31H29FN4O6 requires: 572. Found: 573 (M+H)+.
Example 104 N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1-(4-fluoro-2-hydroxyphenyl)-1H-pyrazole-3-carboxamide (X18)
A suspension of X6 (60 mg, 0.09 mmol) and Pd/C (10% w/w, 6 mg) in EtOH (50 mL) was stirred under hydrogen atmosphere (1 atm) at RT for 15 h. The suspension was filtered through a pad of Celite®. The solvent was removed in vacuo. The residue was purified by reverse phase RP-HPLC (column: C18), using H2O and ACN as eluents. The desired fractions were lyophilized to yield the title compound X18 (1.2 mg, 2%) as a white solid. 1H NMR (400 MHz, CDCl3, 300K) δ 1.61 (t, J=7.0 Hz, 3H), 4.06 (s, 3H), 4.07 (s, 3H), 4.26 (q, J=7.0 Hz, 2H), 6.48 (d, J=5.2 Hz, 1H), 6.68 (dt, J=2.6 Hz, J=8.4 Hz, 1H), 6.87 (dd, J=2.3 Hz, J=9.8 Hz, 1H), 7.31 (dd, J=5.7 Hz, J=9.0 Hz, 1H), 7.44 (s, 1H), 7.56 (s, 1H), 7.61 (dd, J=2.8 Hz, J=9.0 Hz, 1H), 7.68 (s, 1H), 8.28 (d, J=2.8 Hz, 1H), 8.53 (m, 2H), 9.49 (s, 1H). MS (ES) C28H24FN6O6 requires: 545. Found: 546 (M+H)+.
Example 105 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(pyridin-3-yl)-1H-pyrazole-3-carboxamide (X19)
Following the general procedure reported in Preparative Example 16 Step 5 X19 was prepared from A2 and 4-ethoxy-1-(pyridin-3-yl)-1H-pyrazole-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.39 (t, J=7.0 Hz, 3H), 3.96 (s, 6H), 4.10 (q, J=7.0 Hz, 2H), 6.56 (d, J=5.5 Hz, 1H), 7.43 (s, 1H), 7.49 (t, J=9.0 Hz, 1H), 7.57 (s, 1H), 7.60 (dd, J=4.7 Hz, J=8.4 Hz, 1H), 7.73 (d, J=9.0 Hz, 1H), 8.04 (dd, J=2.4 Hz, J=13.2 Hz, 1H), 8.35 (d, J=8.4 Hz, 1H), 8.54 (d, J=5.5 Hz, 1H), 8.57 (dd, J=1.4 Hz, J=4.7 Hz, 1H), 8.59 (s, 1H), 9.24 (s, 1H), 10.25 (s, 1H). MS (ES) C28H24FN6O6 requires: 529. Found: 530 (M+H)+.
Example 106 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1′-methyl-1′H-[1,3′-bipyrazole]-3-carboxamide (X20)
Following the general procedure reported in Preparative Example 16 Step 5 X20 was prepared from A2 and 4-ethoxy-1′-methyl-1′H-[1,3′-bipyrazole]-3-carbonyl chloride, which was prepared similar to Preparative Example 16 step 1-4. 1H NMR (400 MHz, d6-DMSO, 300K) δ 1.36 (t, J=7.0 Hz, 3H), 3.85 (s, 3H), 4.01 (s, 3H), 4.02 (s, 3H), 4.06 (q, J=7.0 Hz, 2H), 6.57 (d, J=2.1 Hz, 1H), 6.88 (d, J=6.2 Hz, 1H), 7.52 (s, 1H), 7.56 (m, 2H), 7.71 (s, 1H), 7.76 (d, J=8.9 Hz, 1H), 8.08 (dd, J=2.1 Hz, J=13.1 Hz, 1H), 8.17 (s, 1H), 8.75 (d, J=6.2 Hz, 1H), 10.34 (s, 1H). MS (ES) C27H25FN6O5 requires: 532. Found: 533 (M+H)+.
Biological Assays
The exemplified compounds described herein were tested for activity and were found to have an IC50 value less than 10 uM, particularly less than 500 nM, in one of the following assays:
1. Enzymatic Axl Assay:
The IMAP FP Sreening Express Kit (Molecular Devices) was employed for the detection of Axl activity in vitro. In brief, a mix of FITC-labeled substrate peptide (400 nM final concentration; 5FITC-KKKKEEIYFFFG-NH2, Seq ID No. 01) and recombinant Axl kinase (30 nM final concentration; Proqinase) was preincubated with a compound according to formula (I) at the suitable concentrations. Reaction was started by addition of ATP (Adenosine-5′-triphosphate, Sigma Aldrich) to a final concentration of 22 μM. Except proteins and substrates the reaction buffer conditions were 20 mM HEPES (2-(4-(2-Hydroxyethyl)-1-piperazine)-ethanesulfonic acid) pH 8.0, 1 mM DTT (Dithiothreitol), 10 mM MgCl2 and 0.01% Brij35 (all Sigma Aldrich). After incubation of 1 hour the reaction was stopped by addition of IMAP binding buffer, containing the large M(III)-based nanoparticles, who bind to the phosphorylated fluorescent substrat. This reduces the rotational speed of the bound substrate increasing its polarization signal. Finally, the fluorescence polarization was determined using an EnVision Multilabelreader 2104 (Perkin Elmer).
2. Axl Binding Assay:
The principle behind this assay is based upon the binding and displacement of an Alexa Fluor 647-labeled tracer to the kinase of interest. Binding of the tracer to the kinase is detected using an EU-labeled anti-tag antibody. Simultaneous binding of both the tracer and antibody to the kinase gives rise to a FRET-signal. Binding of an inhibitor to the kinase competes for binding with the tracer, resulting in a loss of FRET-signal. At first a compound according to formula (I) was diluted in 20 mM Hepes pH 8.0, 1 mM DTT, 10 mM MgCl2 and 0.01% Brij35. Next Axl kinase (5 nM final concentration; Proqinase), kinase tracer (15 nM final concentration; Invitrogen) and LanthaScreen Eu-Anti-GST antibody (2 nM final concentration; Invitrogen) was mixed with suitable compound dilutions and incubated for 1 hour. FRET-signal was quantified employing an EnVision Multilabelreader 2104 (Perkin Elmer).
3. Cellular Axl Phosphorylation Assay:
HEK293 embryonal kidney fibroblasts were transfected in 96 wells with a plasmid containing Axl cDNA. As transfection reagent Superfect (Qiagen) was used. Transfection of the sole vector backbone served as negative control of Axl expression. After overnight incubation the cellular supernatant was replaced with fresh medium. On the following day the Axl-expressing cells were incubated for 1 hour with a compound according to formula (I) at the suitable concentrations. Cells were lysed with buffer and lysates were investigated for Axl expression and phosphorylation employing antibodies H-124 (Santa Cruz) and AF2228 (R&D), respectively. The mesoscale technology was used for quantification.
Table 2 shows activity data in the Axl binding assay and cellular Axl phosphorylation assay for selected compounds of the invention. Inhibition is indicated as IC50 with the following key: A=IC50 less than 0.5 uM; B=IC50 greater than 0.5 uM, but less than 5.0 uM; C=IC50 greater than 5.0 uM; -=not measured
TABLE 2
Axl Cellular Axl
Exam- binding phosphoryl-
ple Nomenclature assay ation assay
1 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- B B
phenyl]-1,5-dimethyl-pyrazole-3-carboxamide
2 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- B —
phenyl]-2-[4-(trifluoromethyl)phenyl]thiazole-4-
carboxamide
3 4-bromo-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]- B B
3-fluoro-phenyl]-1-methyl-pyrazole-3-
carboxamide
4 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- B B
phenyl]-1-methyl-pyrazole-3-carboxamide
5 1-tert-butyl-N-[4-[(6,7-dimethoxy-4- A A
quinolyl)oxy]-3-fluoro-phenyl]-5-methyl-
pyrazole-3-carboxamide
6 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- B —
phenyl]thiazole-2-carboxamide
8 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- B —
phenyl]-1-methyl-indazole-3-carboxamide
9 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- B —
phenyl]-5-methyl-isoxazole-3-carboxamide
10 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- B B
phenyl]-2-phenyl-thiazole-4-carboxamide
13 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- B A
phenyl]-1-propyl-pyrazole-3-carboxamide
15 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- B A
phenyl]-1-(2,2,2-
trifluoroethoxymethyl)pyrazole-3-carboxamide
16 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- A A
phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-
carboxamide
17 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- A A
phenyl]-1-(4-fluorophenyl)-4-methoxy-
pyrazole-3-carboxamide
18 4-(cyclopropylmethoxy)-N-[4-[(6,7-dimethoxy- A A
4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
19 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- A A
phenyl]-4-(2-dimethylaminoethoxy)-1-(4-
fluorophenyl)pyrazole-3-carboxamide
20 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- B B
phenyl]-4-(2-dimethylaminoethoxy)-1-(4-
fluorophenyl)pyrazole-3-carboxamide
21 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- A A
phenyl]-1-(4-fluorophenyl)-4-isopropoxy-
pyrazole-3-carboxamide
22 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- A A
phenyl]-4-ethoxy-1-(4-fluoro-2-methyl-
phenyl)pyrazole-3-carboxamide
23 1-(2-chloro-4-fluoro-phenyl)-N-[4-[(6,7- A A
dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-
ethoxy-pyrazole-3-carboxamide
24 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4- A A
ethoxy-1-(4-fluorophenyl)pyrazole-3-
carboxamide
25 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-1- A A
(4-fluorophenyl)-4-isopropoxy-pyrazole-3-
carboxamide
26 4-(cyclopropylmethoxy)-N-[4-[(6,7-dimethoxy- A A
4-quinolyl)oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
27 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4- A A
ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-
carboxamide
28 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-methyl- A A
phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-
carboxamide
29 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-methyl- A A
phenyl]-1-(4-fluorophenyl)-4-isopropoxy-
pyrazole-3-carboxamide
30 4-(cyclopropylmethoxy)-N-[4-[(6,7-dimethoxy- A A
4-quinolyl)oxy]-3-methyl-phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
31 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-methyl- A A
phenyl]-4-ethoxy-1-(4-fluoro-2-methyl-
phenyl)pyrazole-3-carboxamide
32 N-[3-chloro-4-[(6,7-dimethoxy-4- A A
quinolyl)oxy]phenyl]-4-ethoxy-1-(4-
fluorophenyl)pyrazole-3-carboxamide
33 N-[3-chloro-4-[(6,7-dimethoxy-4- A A
quinolyl)oxy]phenyl]-1-(4-fluorophenyl)-4-
isopropoxy-pyrazole-3-carboxamide
34 N-[3-chloro-4-[(6,7-dimethoxy-4- A A
quinolyl)oxy]phenyl]-4-(cyclopropylmethoxy)-1-
(4-fluorophenyl)pyrazole-3-carboxamide
35 N-[3-chloro-4-[(6,7-dimethoxy-4- A A
quinolyl)oxy]phenyl]-4-ethoxy-1-(4-fluoro-2-
methyl-phenyl)pyrazole-3-carboxamide
36 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3- A A
fluorophenyl)-4-(2-(dimethylamino)ethyl)-1-(4-
fluorophenyl)-1H-pyrazole-3-carboxamide
37 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro- A A
phenyl]-1-[2-(2-dimethylaminoethyl)-4-fluoro-
phenyl]-4-ethoxy-pyrazole-3-carboxamide
38 N-[3-fluoro-4-[[6-methoxy-7-(3- A A
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-2-
phenyl-thiazole-4-carboxamide
39 4-bromo-N-[3-fluoro-4-[[6-methoxy-7-(3- B A
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-
methyl-pyrazole-3-carboxamide
40 N-[3-fluoro-4-[[6-methoxy-7-(3- B A
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-
methyl-pyrazole-3-carboxamide
41 1-tert-butyl-N-[3-fluoro-4-[[6-methoxy-7-(3- A A
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-5-
methyl-pyrazole-3-carboxamide
42 N-[3-fluoro-4-[[6-methoxy-7-(3- A A
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-
1,5-dimethyl-pyrazole-3-carboxamide
43 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(3- A A
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-
(4-fluoro-2-methyl-phenyl)pyrazole-3-
carboxamide
44 N-[3-fluoro-4-[[6-methoxy-7-(3- A A
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-
(4-fluorophenyl)-4-methoxy-pyrazole-3-
carboxamide
45 N-[3-fluoro-4-[[6-methoxy-7-(3- A A
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-
(4-fluorophenyl)-4-isopropoxy-pyrazole-3-
carboxamide
46 4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6- A A
methoxy-7-(3-morpholinopropoxy)-4-
quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
47 1-(2-chloro-4-fluoro-phenyl)-4-ethoxy-N-[3- A A
fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-
4-quinolyl]oxy]phenyl]pyrazole-3-carboxamide
48 4-(2-dimethylaminoethoxy)-N-[3-fluoro-4-[[6- A A
methoxy-7-(3-morpholinopropoxy)-4-
quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
49 1-(2-bromo-4-fluoro-phenyl)-4-ethoxy-N-[3- A A
fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-
4-quinolyl]oxy]phenyl]pyrazole-3-carboxamide
50 N-[3-fluoro-4-[[6-methoxy-7-(3- A A
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-
(4-fluorophenyl)-4-(2-methoxyethoxy)pyrazole-
3-carboxamide
51 4-benzyloxy-N-[3-fluoro-4-[[6-methoxy-7-(3- A A
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-
(4-fluorophenyl)pyrazole-3-carboxamide
52 N-[3-fluoro-4-[[6-methoxy-7-(3- A A
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-
(4-fluorophenyl)-4-nitro-pyrazole-3-
carboxamide
53 4-amino-N-[3-fluoro-4-[[6-methoxy-7-(3- A A
morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-
(4-fluorophenyl)pyrazole-3-carboxamide
54 N-[4-[[7-(3-aminopropoxy)-6-methoxy-4- A A
quinolyl]oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-
fluorophenyl)pyrazole-3-carboxamide
55 N-[4-[[7-(3-aminopropoxy)-6-methoxy-4- A A
quinolyl]oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-
fluoro-2-methyl-phenyl)pyrazole-3-
carboxamide
56 N-[4-[[7-(3-aminopropoxy)-6-methoxy-4- A A
quinolyl]oxy]-3-fluoro-phenyl]-5-ethoxy-2-(4-
fluorophenyl)oxazole-4-carboxamide
57 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-[3-(4- A A
methylpiperazin-1-yl)propoxy]-4-
quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-
phenyl)pyrazole-3-carboxamide
58 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-[3-(4- A A
methylpiperazin-1-yl)propoxy]-4-
quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
59 N-[3-fluoro-4-[[6-methoxy-7-[3-(4- A A
methylpiperazin-1-yl)propoxy]-4-
quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-
methoxy-pyrazole-3-carboxamide
60 1-(2-chloro-4-fluoro-phenyl)-4-ethoxy-N-[3- A A
fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-
yl)propoxy]-4-quinolyl]oxy]phenyl]pyrazole-3-
carboxamide
61 4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6- A A
methoxy-7-[3-(4-methylpiperazin-1-
yl)propoxy]-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
62 N-[3-fluoro-4-[[6-methoxy-7-[3-(4- A A
methylpiperazin-1-yl)propoxy]-4-
quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-
isopropoxy-pyrazole-3-carboxamide
63 5-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-[3- A A
(4-methylpiperazin-1-yl)propoxy]-4-
quinolyl]oxy]phenyl]-2-(4-
fluorophenyl)oxazole-4-carboxamide
64 4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6- A A
methoxy-7-(3-piperazin-1-yl propoxy)-4-
quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
trifluoroacetic acid salt
65 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(3- A A
piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-
1-(4-fluorophenyl)pyrazole-3-carboxamide
66 N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1- A A
ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)-4-methoxy-pyrazole-3-
carboxamide
67 N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1- A A
ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)-4-isopropoxy-pyrazole-3-
carboxamide
68 1-(2-chloro-4-fluoro-phenyl)-4-ethoxy-N-[3- A A
fluoro-4-[[6-methoxy-7-(3-piperazin-1-
ylpropoxy)-4-quinolyl]oxy]phenyl]pyrazole-3-
carboxamide
69 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(3- A A
piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-
1-(4-fluoro-2-methyl-phenyl)pyrazole-3-
carboxamide
70 N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1- A A
ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)-4-(2-methoxyethoxy)pyrazole-3-
carboxamide
71 N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1- A B
ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)-4-[(1-methylpyrrolidin-3-
yl)methoxy]pyrazole-3-carboxamide
72 N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1- A A
ylpropoxy)-4-quinolyl]oxy]phenyl]-2-phenyl-
thiazole-4-carboxamide
73 N-[3-fluoro-4-[[6-methoxy-7-(4- A A
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)-4-methoxy-pyrazole-3-
carboxamide
74 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(4- A A
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-(4-
fluoro-2-methyl-phenyl)pyrazole-3-
carboxamide
75 4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6- A A
methoxy-7-(4-piperidylmethoxy)-4-
quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
76 4-bromo-N-[3-fluoro-4-[[6-methoxy-7-(4- A A
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)pyrazole-3-carboxamide
77 N-[3-fluoro-4-[[6-methoxy-7-(4- A A
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-(4-
fluorophenyl)-4-[(4-
fluorophenyl)methoxy]pyrazole-3-carboxamide
78 1-tert-butyl-N-[3-fluoro-4-[[6-methoxy-7-(4- A A
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-5-
methyl-pyrazole-3-carboxamide
80 N-[3-fluoro-4-[[6-methoxy-7-(4- A A
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-5-
methyl-2-phenyl-oxazole-4-carboxamide
81 N-[3-fluoro-4-[[6-methoxy-7-(4- A B
piperidylmethoxy)-4-quinolyl]oxy]phenyl]-2-
phenyl-thiazole-4-carboxamide
82 4-ethoxy-N-[4-[[7-[(1-ethyl-4- A A
piperidyl)methoxy]-6-methoxy-4-quinolyl]oxy]-
3-fluoro-phenyl]-1-(4-fluoro-2-methyl-
phenyl)pyrazole-3-carboxamide
83 4-ethoxy-N-[3-fluoro-4-[[7-[(1-isobutyl-4- A A
piperidyl)methoxy]-6-methoxy-4-
quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-
phenyl)pyrazole-3-carboxamide
84 N-[5-[(6,7-dimethoxy-4-quinolyl)oxy]-2-pyridyl]- A A
4-ethoxy-1-(4-fluorophenyl)pyrazole-3-
carboxamide
85 N-[5-[(6,7-dimethoxy-4-quinolyl)oxy]-2-pyridyl]- A A
4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-
3-carboxamide
86 1-(2-chloro-4-fluoro-phenyl)-N-[5-[(6,7- A A
dimethoxy-4-quinolyl)oxy]-2-pyridyl]-4-ethoxy-
pyrazole-3-carboxamide
87 N-[5-[(6,7-dimethoxy-4-quinolyl)oxy]-2-pyridyl]- B A
4-(2-dimethylaminoethyl)-1-(4-
fluorophenyl)pyrazole-3-carboxamide
89 N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin- A A
2-yl)-4-ethoxy-1-(4-methoxy-2-methylphenyl)-
1H-pyrazole-3-carboxamide
90 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3- A A
fluorophenyl)-4-ethoxy-1-(3-nitrophenyl)-1H-
pyrazole-3-carboxamide
91 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3- A A
fluorophenyl)-4-ethoxy-1-(4-methoxy-2-
methylphenyl)-1H-pyrazole-3-carboxamide
92 N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin- A A
2-yl)-4-ethoxy-1-(3-nitrophenyl)-1H-pyrazole-3-
carboxamide
94 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2- A A
methoxyphenyl)-4-ethoxy-1-(4-fluoro-2-
methylphenyl)-1H-pyrazole-3-carboxamide
95 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2- A B
methylphenyl)-4-ethoxy-1-(4-fluoro-2-
methylphenyl)-1H-pyrazole-3-carboxamide
96 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3- A A
fluorophenyl)-4-ethoxy-1-(4-fluoro-3-
methoxyphenyl)-1H-pyrazole-3-carboxamide
97 N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin- A A
2-yl)-4-ethoxy-1-(4-fluoro-3-methoxyphenyl)-
1H-pyrazole-3-carboxamide
98 N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin- B A
2-yl)-4-ethoxy-1-(4-nitrophenyl)-1H-pyrazole-3-
carboxamide
99 1-(4-aminophenyl)-N-(5-((6,7- A A
dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-
ethoxy-1H-pyrazole-3-carboxamide
100 N-(5-((6-methoxy-7-(piperidin-4- B —
ylmethoxy)quinolin-4-yl)oxy)pyridin-2-yl)-4-(2-
methoxyphenyl)thiazole-2-carboxamide
101 N-(5-((6-methoxy-7-(piperidin-4- A A
ylmethoxy)quinolin-4-yl)oxy)pyridin-2-yl)-4-
phenylthiazole-2-carboxamide
102 4-bromo-N-(5-((6-methoxy-7-(piperidin-4- A A
ylmethoxy)quinolin-4-yl)oxy)pyridin-2-
yl)thiazole-2-carboxamide
103 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2- A A
methoxyphenyl)-4-ethoxy-1-(4-fluoro-2-
methylphenyl)-1H-pyrazole-3-carboxamide
104 N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin- A A
2-yl)-4-ethoxy-1-(4-fluoro-2-hydroxyphenyl)-
1H-pyrazole-3-carboxamide
105 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3- A A
fluorophenyl)-4-ethoxy-1-(pyridin-3-yl)-1H-
pyrazole-3-carboxamide
106 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3- A —
fluorophenyl)-4-ethoxy-1′-methyl-1′H-[1,3′-
bipyrazole]-3-carboxamide
Ref1 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)- >10 μM —
3-fluorophenyl)-1-phenyl-5-
(trifluoromethyl)-1H-pyrazole-4-
carboxamide
Ref2 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)- >10 μM —
3-fluorophenyl)-5-phenylisoxazole-3-
carboxamide
Ref3 N-(4-((6,7-dimethoxyquinolin-4- >10 μM —
yl)oxy)phenyl)furan-2-carboxamide
Ref4 N-(4-((6,7-dimethoxyquinolin-4- 7042 nM —
yl)oxy)phenyl)thiophene-3-carboxamide
Ref5 N-(4-((6,7-dimethoxyquinolin-4- >10 μM —
yl)oxy)phenyl)isonicotinamide
Ref6 N-(4-((6,7-dimethoxyquinolin-4- 8293 nM —
yl)oxy)phenyl)thiophene-2-carboxamide
Ref7 N-(4-((6,7-dimethoxyquinolin-4- 9302 nM —
yl)oxy)phenyl)picolinamide
SOURCE FOR REFERENCE EXAMPLES REF1 TO REF7
  • Ref1: Example 20 on page 106/107 of WO2008035209A2 (D01 in the ESR)
  • Ref2: Example 21 on page 106/107 of WO2008035209A2
  • Ref3: Compound 64, Example 53 on page 47 of EP0860433A1 (D02 in the ESR)
  • Ref4: Compound 65, Example 54 on page 47 of EP0860433A1
  • Ref5: Compound 71, Example 60 on page 49 of EP0860433A1
  • Ref6: Compound 72, Example 61 on page 49 of EP0860433A1
  • Ref7: Compound 77, Example 61 on page 50 of EP0860433A1
It is obvious from Table 2 that all Reference Examples (Ref1-Ref7) exhibit worse Axl binding assay data which are in the range of 10 μM and higher. In contrast to the seven Reference Examples the compounds of the present invention are in average ten to hundred times more effective in the Axl binding assay.
It seems that the substitution pattern and the position of the hetero atoms and especially the position of the nitrogen atom in the substituent D is important for the better activity of the inventive compounds. Comparing compound 21 of WO2008035209A2 with example 9 of the present invention, both compounds are markedly similar. However compound 21 of WO2008035209A2 shows in the Axl binding assay a worse value of larger than 10 μM while example 9 shows 3.389 μM.
It can be concluded that the position of the heteroatoms and the phenyl substitution in the isoxazole ring (ring D) is not suitable in comparison to example 9 of the present invention. Thus it seems to be important that a nitrogen atom is present in substituent D in direct vicinity to the carbon atom which is attached to the amide group. Thus the isoxazole residue as substituent D should be linked through the 3-yl-carbon atom to the amide group and not through the 4-yl-carbon atom or the 5-yl-carbon atom as done in compound 21 of WO2008035209A2. From Example 80 (Axl binding assay 0.184 uM) of the present invention it can be followed that the oxazole group as substituent D should be linked to the amide group through 2-yl-carbon atom or the 4-yl-carbon atom but not through the 5-yl-carbon atom.
The same conclusion can be drawn from the comparison of compound 20 of WO2008035209A2 with example 17 of the present invention which are again very similar and differ only in the substitution pattern of substituent D. Example 17 wherein the pyrazole residue is linked to the amide group through the 3-yl-carbon atom shows in the Axl binding assay a value of 0.172 μM, while compound 20 of WO2008035209A2, wherein the pyrazole residue is linked to the amide group through the 4-yl-carbon atom shows with >10 μM a much more worse binding/inhibition in the Axl binding assay.
Thus it can be concluded that the compounds disclosed in WO2008035209A2 which are very similar to the compounds of the present invention exhibit the wrong substitution pattern especially in regard to substituent D and thus have lower activity and potency as anti-cancer drug for Axl receptor tyrosine kinase induced disorders as proved by the Axl binding assay.
In regard to the compounds 64, 65, 71, 72 and 77 as disclosed in EP0860433A1 which was cited as D02 in the European Search Report it can be stated that all these compounds are not potent in the Axl binding assay, since they exhibit values of about 10 μM and higher which is in average 10 to 100 times less potent than the compounds of the present invention. Since these compounds 64, 65, 71, 72 and 77 as disclosed in EP0860433A1 differ in comparision to the inventive compounds mainly in the substituent D it can be concluded that furane, thiophene and pyridine substituents as ring D are not suitable substituents in order to obtain highly potent inhibitors of the Axl receptor tyrosine kinase. Thus it seems important that substituent D is a five-membered heterocyclic ring and not a six-membered heterocyclic ring and that it is moreover important that the substituent D contains at least one nitrogen and still more preferably two nitrogen atoms.
However, in regard to the most similar compounds 64, 65, 71, 72 and 77 disclosed in EP0860433A1 it can be stated that they do not have the right substitution pattern especially at substituent D and that the compounds of the present invention are much more potent as demonstrated by the data of the Axl binding assay.
Thus the compounds of the present invention are superior in regard to the compounds of EP0860433A1 as well as of WO2008035209A2.
WO2007146824A2 was cited as D03 in the European Search Report (ESR). D03 does not cite any novelty destroying compounds for the present invention and does even not cite any similar compound. In WO2007146824A2 not a single compound is disclosed which has a 5-membered nitrogen heterocycle as substituent D so that the compounds of WO2007146824A2 are regarded as less relevant. Even compounds such as compounds 134, 172, 175, 176, 177, 178, 195 or 196 are only insignificantly similar to the compounds of the present invention.
Furthermore we have observed that the quinolines without such carboxy-substituted residue D of the present invention shows very weak to no activity in the Axl binding assay (Table 3). Through the introduction of a carboxy-substituted residue D described in this invention very potent inhibitors of the Axl kinase were invented. This further stresses the importance of the carboxy-substituted residue D of the present invention for obtaining potent inhibitors of the Axl kinase.
TABLE 3
Axl binding
Nomenclature Structure assay
4-((6,7-dimethoxyquinolin-4- yl)oxy)-3-fluoroaniline
Figure US08999982-20150407-C00153
 		>10000 nM
4-((6,7-dimethoxyquinolin-4- yl)oxy)aniline
Figure US08999982-20150407-C00154
 		>10000 nM
4-((6,7-dimethoxyquinolin-4- yl)oxy)-3-methylaniline
Figure US08999982-20150407-C00155
 		>10000 nM
3-chloro-4-((6,7- dimethoxyquinolin-4- yl)oxy)aniline
Figure US08999982-20150407-C00156
 		>10000 nM
5-((6,7-dimethoxyquinolin-4- yl)oxy)pyridin-2-amine
Figure US08999982-20150407-C00157
 		>10000 nM
4-((6,7-dimethoxyquinolin-4- yl)oxy)-2-methoxyaniline
Figure US08999982-20150407-C00158
 		>10000 nM
4-((6,7-dimethoxyquinolin-4- yl)oxy)-2-methylaniline
Figure US08999982-20150407-C00159
 		>10000 nM
3-fluoro-4-((6-methoxy-7-(3- morpholinopropoxy)quinolin- 4-yl)oxy)aniline
Figure US08999982-20150407-C00160
 		8503 nM
tert-butyl 4-(((4-(4-amino-2- fluorophenoxy)-6- methoxyquinolin-7- yl)oxy)methyl)piperidine-1- carboxylate
Figure US08999982-20150407-C00161
 		>10000 nM
Example 22 of the present invention was tested in an oncology in vivo model (orthotopic breast cancer model for metastasis):
Female BALB/c mice which developed tumours from 4T1 mouse breast tumour cells, (orthotopically inoculated into the third mammary fat pad) were selected for the study. The mice were randomised, based on tumour volume into four groups on Day 0 of the study. The mice in each group received treatment with either Vehicle Control (PEG400:H2O (70:30, v/v)), Example 22 (32 or 106.5 mg/kg) or Cisplatin (4 mg/kg). The Vehicle Control and Example 22 were administered orally, twice daily (12 hours apart) for 15 days (Day 0-14) in a dosing volume of 5 mL/kg. Cisplatin was administered intravenously on Day 0, 7 and 14 in a dosing volume of 10 mL/kg. Remaining liver tissue from untreated and treated mice, and the liver from mice treated with Cisplatin was preserved in 10% neutral buffered formalin and embedded in paraffin. Liver sections were stained with haematoxylin and eosin, and micro-metastases were quantified. The number of liver metastasis was reduced significantly to roughly 50% by Example 22 (dosing 106.5 mg/kg) without any side effects.

Claims (15)

The invention claimed is:
1. Compounds having the general formula (I)
Figure US08999982-20150407-C00162
wherein
A represents C—R10, N;
B represents C—R11, N;
D represents one of the following heterocycles
Figure US08999982-20150407-C00163
R1, R4, R88, R92, R100 are selected independently of each other from —H, —F, —Cl, —Br, —I, —OH, —NH2, —NHR19, —NR19R20, —OCH3, —OC2H5, —OC3H7, —OCH(CH3)2, —OC(CH3)3, —OC4H9, —NO2, —CHO, —COCH3, —COC2H5, —O-cyclo-C3H5, —OCH2-cyclo-C3H5, —O—C2H4-cyclo-C3H5, —OPh, —COC3H7, —COCH(CH3)2, —COC(CH3)3, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —OOC—CH3, —OOC—C2H5, —OOC—C3H7, —OOC—CH(CH3)2, —OOC—C(CH3)3, —NHCH3, —NHC2H5, —NHC3H7, —NHCH(CH3)2, —NHC(CH3)3, —N(CH3)2, —N(C2H5)2, —N(C3H7)2, —N[CH(CH3)2]2, —N[C(CH3)3]2, —OCF3, —OC2F5, —CH2F, —CHF2, —CF3, —CH2CI, —CH2Br, —CH2I, —CH2—CH2F, —CH2—CHF2, —CH2—CF3, —CH2—CH2CI, —CH2—CH2Br, —CH2—CH2I, cyclo-C3H5, —CH2-cyclo-C3H5, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CH═CH2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —CH═CH—C2H5, —CH2—C(CH3)═CH2, —CH(CH3)—CH═CH, —CH═C(CH3)2, —C(CH3)═CH—CH3, —CH═CH—CH═CH2, —C3H6—CH═CH2, —C2H4—CH═CH—CH3, —CH2—CH═CH—C2H5, —CH═CH—C3H7, —CH2—CH═CH—CH═CH2, —CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C2H4—C(CH3)═CH2, —CH2—CH(CH3)—CH═CH2, —CH(CH3)—CH2—CH═CH2, —CH2—CH═C(CH3)2, —CH2—C(CH3)═CH—CH3, —CH(CH3)—CH═CH—CH3, —CH═CH—CH(CH3)2, —CH═C(CH3)—C2H5, —C(CH3)═CH—C2H5, —C(CH3)═C(CH3)2, —C(CH3)2—CH═CH2, —CH(CH3)—C(CH3)═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C4H5—CH═CH2, —C3H6—CH═CH—CH3, —C2H4—CH═CH—C2H5, —CH2—CH═CH—C3H7, —CH═CH—C4H9, —C3H6—C(CH3)═CH2, —C2H4—CH(CH3)—CH═CH2, —CH2—CH(CH3)—CH2—CH═CH2, —CH(CH3)—C2H4—CH═CH2, —C2H4—CH═C(CH3)2, —C2H4—C(CH3)═CH—CH3, —CH2—CH(CH3)—CH═CH—CH3, —CH(CH3)—CH2—CH═CH—CH3, —CH2—CH═CH—CH(CH3)2, —CH2—CH═C(CH3)—C2H5, —CH2—C(CH3)═CH—C2H5, —CH(CH3)—CH═CH—C2H5, —CH═CH—CH2—CH(CH3)2, —CH═CH—CH(CH3)—C2H5, —CH═C(CH3)—C3H7, —C(CH3)═CH—C3H7, —CH2—CH(CH3)—C(CH3)═CH2, —CH(CH3)—CH2—C(CH3)═CH2, —CH(CH3)—CH(CH3)—CH═CH2, —CH2—C(CH3)2—CH═CH2, —C(CH3)2—CH2—CH═CH2, —CH2—C(CH3)═C(CH3)2, —CH(CH3)—CH═C(CH3)2, —C(CH3)2—CH═CH—CH3, —CH(CH3)—C(CH3)═CH—CH3, —CH═C(CH3)—CH(CH3)2, —C(CH3)═CH—CH(CH3)2, —C(CH3)═C(CH3)—C2H5, —CH═CH—C(CH3)3, —C(CH3)2—C(CH3)═CH2, —CH(C2H5)—C(CH3)═CH2, —C(CH3)(C2H5)—CH═CH2, —CH(CH3)—C(C2H5)═CH2, —CH2—C(C3H7)═CH2, —CH2—C(C2H5)═CH—CH3, —CH(C2H5)—CH═CH—CH3, —C(C4H9)═CH2, —C(C3H7)═CH—CH3, —C(C2H5)═CH—C2H5, —C(C2H5)═C(CH3)2, —C[C(CH3)3]═CH2, —C[CH(CH3)(C2H5)]═CH2, —C[CH2—CH(CH3)2]═CH2, —C2H4—CH═CH—CH═CH2, —CH2—CH═CH—CH2—CH═CH2, —CH═CH—C2H4—CH—CH2, CH2—CH—CH═CH—CH═CH3, —CH═CH—CH2—CH═CH—CH3, —CH═CH—CH═CH—C2H5, —CH2—CH═CH—C(CH3)═CH2, —CH2—CH═C(CH3)—CH═CH2, —CH2—C(CH3)═CH—CH═CH2, —CH(CH3)—CH═CH—CH═CH2, —CH═CH—CH2—C(CH3)═CH2, —CH═CH—CH(CH3)—CH═CH2, —CH═C(CH3)—CH2—CH═CH2, —C(CH3)═CH—CH2—CH═CH2, —CH═CH—CH═C(CH3)2, —CH═CH—C(CH3)═CH—CH3, —CH═C(CH3)—CH═CH—CH3, —C(CH3)═CH—CH═CH—CH3, —CH═C(CH3)—C(CH3)═CH2, —C(CH3)═CH—C(CH3)═CH2, —C(CH3)═C(CH3)—CH═CH2, CH—CH═CH—CH═CH—CH2, —C≡CH, —C≡C—CH3, —CH2—C≡CH, —C2H4—C≡CH, —CH2—C≡C—CH3, —C≡C—C2H5, —C3H6—C≡CH, —C2H4—C═C—CH3, —CH2—C═C—C2H5, —C≡C—C3H7, —CH(CH3)—C≡CH, —CH2—CH(CH3)—C≡CH, —CH(CH3)—CH2—C≡CH, —CH(CH3)—C≡C—CH3, —C4H8—C≡CH, —C3H6—C≡C—CH3, —C2H4—C═C—C2H5, —CH2—C═C—C3H7, —C≡C—C4H9, —C2H4—CH(CH3)—C═CH, —CH2—CH(CH3)—CH2—C≡CH, —CH(CH3)—C2H4—C≡CH, —CH2—CH(CH3)—C≡C—CH3, —CH(CH3)—CH2—C═C—CH3, —CH(CH3)—C≡C—C2H5, —CH2—C═C—CH(CH3)2, —C═C—CH(CH3)—C2H5, —C≡C—CH2—CH(CH3)2, —C═C—C(CH3)3, —CH(C2H5)—C═C—CH3, —C(CH3)2—C═C—CH3, —CH(C2H5)—CH2—C≡CH, —CH2—CH(C2H5)—C≡CH, —C(CH3)2—CH2—C≡CH, —CH2—C(CH3)2—C≡CH, —CH(CH3)—CH(CH3)—C≡CH, —CH(C3H7)—C≡CH, —C(CH3)(C2H5)—C≡CH, —C═C—C≡CH, —CH2—C═C—C≡CH, —C═C—C═C—CH3, —CH(C≡CH)2, —C2H4—C≡C—C≡CH, —CH2—C═C—CH2—C≡CH, —C═C—C2H4—C≡CH, —CH2—C≡C—C≡C—CH3, —C═C—CH2—C≡C—CH3, —C≡C—C═C—C2H5, —C≡C—CH(CH3)—C≡CH, —CH(CH3)—C≡C—C≡CH, —CH(C≡CH)—CH2—C≡CH, —C(C≡CH)2—CH3, —CH2—CH(C≡CH)2, —CH(C≡CH)—C≡C—CH3; R21, R35, R36;
R2 and R3 are selected independently of each other from —R88, —R37, —R38, —R54, —O—R54, —R55, —O—R55, —R56, —O—R56, —R57, —O—R57, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl or C1-6alkoxy groups represented by R88 are optionally mono- or polysubstituted by —OH, —F, —Cl, —Br, —I, —O—R71, R72, —R138, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16R17, —SO2—NR16R17, —SOm—R16R17, —CR16R17H, —NR16R17;
or R2 and/or R3 are selected independently of each other from —O—R18, —O—CR73R74—R18, —O—CR73R74—CR75R76—R18, —O—CR73R74—CR75R76—CR77R78—R18, —O—CR73R74—CR75R76—CR77R78—CR79R80—R18, —O—CR73R74—CR75R76—CR77R78—CR79R80—CR81R82—R18, —O—CR73R74—CR75R76—CR77R78—CR79R80—CR81R82—CR83R84—R18,
R73-R84 independently of each other represent —H, —OH, —F, —Cl, —Br, —I, —R85;
R18 represents —H, —OH, —F, —Cl, —Br, —I, —O—R86, —R87, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16R17, —SO2—NR16R17, —SOm—R16R17, —CR16R17H, —NR16R17;
m=0, 1, 2;
R5 and R6, which may be the same or different, represent —H, —OH, —F, —Cl, —Br, —I, —CN, —NO2, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, cyclo-C3H5, —CH2-cyclo-C3H5, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CH═CH2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —CH═CH—C2H5, —CH2—C(CH3)═CH2, —CH(CH3)—CH═CH, —CH═C(CH3)2, —C(CH3)═CH—CH3, —CH═CH—CH═CH2, —C3H6—CH═CH2, —C2H4—CH═CH—CH3, —CH2—CH═CH—C2H5, —CH═CH—C3H7, —CH2—CH═CH—CH═CH2, —CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C2H4—C(CH3)═CH2, —CH2—CH(CH3)—CH═CH2, —CH(CH3)—CH2—CH═CH2, —CH2—CH═C(CH3)2, —CH2—C(CH3)═CH—CH3, —CH(CH3)—CH═CH—CH3, —CH═CH—CH(CH3)2, —CH═C(CH3)—C2H5, —C(CH3)═CH—C2H5, —C(CH3)═C(CH3)2, —C(CH3)2—CH═CH2, —CH(CH3)—C(CH3)═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C4H5—CH═CH2, —C3H6—CH═CH—CH3, —C2H4—CH═CH—C2H5, —CH2—CH═CH—C3H7, —CH═CH—C4H9, —C3H6—C(CH3)═CH2, —C2H4—CH(CH3)—CH═CH2, —CH2—CH(CH3)—CH2—CH═CH2, —CH(CH3)—C2H4—CH═CH2, —C2H4—CH═C(CH3)2, —C2H4—C(CH3)═CH—CH3, —CH2—CH(CH3)—CH═CH—CH3, —CH(CH3)—CH2—CH═CH—CH3, —CH2—CH═CH—CH(CH3)2, —CH2—CH═C(CH3)—C2H5, —CH2—C(CH3)═CH—C2H5, —CH(CH3)—CH═CH—C2H5, —CH═CH—CH2—CH(CH3)2, —CH═CH—CH(CH3)—C2H5, —CH═C(CH3)—C3H7, —C(CH3)═CH—C3H7, —CH2—CH(CH3)—C(CH3)═CH2, —CH(CH3)—CH2—C(CH3)═CH2, —CH(CH3)—CH(CH3)—CH═CH2, —CH2—C(CH3)2—CH═CH2, —C(CH3)2—CH2—CH═CH2, —CH2—C(CH3)═C(CH3)2, —CH(CH3)—CH═C(CH3)2, —C(CH3)2—CH═CH—CH3, —CH(CH3)—C(CH3)═CH—CH3, —CH═C(CH3)—CH(CH3)2, —C(CH3)═CH—CH(CH3)2, —C(CH3)═C(CH3)—C2H5, —CH═CH—C(CH3)3, —C(CH3)2—C(CH3)═CH2, —CH(C2H5)—C(CH3)═CH2, —C(CH3)(C2H5)—CH═CH2, —CH(CH3)—C(C2H5)═CH2, —CH2—C(C3H7)═CH2, —CH2—C(C2H5)═CH—CH3, —CH(C2H5)—CH═CH—CH3, —C(C4H9)═CH2, —C(C3H7)═CH—CH3, —C(C2H5)═CH—C2H5, —C(C2H5)═C(CH3)2, —C[C(CH3)3]═CH2, —C[CH(CH3)(C2H5)]═CH2, —C[CH2—CH(CH3)2]═CH2, —C2H4—CH═CH—CH═CH2, —CH2—CH═CH—CH2—CH═CH2, —CH═CH—C2H4—CH═CH2, —CH2—CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH—CH3, —CH═CH—CH═CH—C2H5, —CH2—CH═CH—C(CH3)═CH2, —CH2—CH═C(CH3)—CH═CH2, —CH2—C(CH3)═CH—CH═CH2, —CH(CH3)—CH═CH—CH═CH2, —CH═CH—CH2—C(CH3)═CH2, —CH═CH—CH(CH3)—CH═CH2, —CH═C(CH3)—CH2—CH═CH2, —C(CH3)═CH—CH2—CH═CH2, —CH═CH—CH═C(CH3)2, —CH═CH—C(CH3)═CH—CH3, —CH═C(CH3)—CH═CH—CH3, —C(CH3)═CH—CH═CH—CH3, —CH═C(CH3)—C(CH3)═CH2, —C(CH3)═CH—C(CH3)═CH2, —C(CH3)═C(CH3)—CH═CH2, —CH═CH—CH═CH—CH═CH2, —C≡CH, —C≡C—CH3, —CH2—C≡CH, —C2H4—C≡CH, —CH2—C≡C—CH3, —C≡C—C2H5, —C2H4—C≡C—CH3, —CH2—C≡C—C2H5, —C≡C—C3H7, —CH(CH3)—C≡CH, —CH2—CH(CH3)—C≡CH, —CH(CH3)—CH2—C≡CH, —CH(CH3)—C≡C—CH3, —C4H5—C≡CH, —C3H6—C≡C—CH3, —C2H4—C≡C—C2H5, —CH2—C≡C—C3H7, —C≡C—C4H9, —C2H4—CH(CH3)—C≡CH, —CH2—CH(CH3)—CH2—C≡CH, —CH(CH3)—C2H4—C≡CH, —CH2—CH(CH3)—C≡C—CH3, —CH(CH3)—CH2—C≡C—CH3, —CH(CH3)—C≡C—C2H5, —CH2—C≡C—CH(CH3)2, —C≡C—CH(CH3)—C2H5, —C≡C—CH2—CH(CH3)2, —C≡C—C(CH3)3, —CH(C2H5)—C≡C—CH3, —C(CH3)2—C≡C—CH3, —CH(C2H5)—CH2—C≡CH, —CH2—CH(C2H5)—C≡CH, —C(CH3)2—CH2—C≡CH, —CH2—C(CH3)2—C≡CH, —CH(CH3)—CH(CH3)—C≡CH, —CH(C3H7)—C≡CH, —C(CH3)(C2H5)—C≡CH, —C≡C—C≡CH, —CH2—C≡C—C≡CH, —C≡C—C≡C—CH3, —CH(C≡CH)2, —C2H4—C≡C—C≡CH, —CH2—C≡C—CH2—C≡CH, —C≡C—C2H4—C≡CH, —CH2—C≡C—C≡C—CH3, —C≡C—CH2—C≡C—CH3, —C≡C—C≡C—C2H5, —C≡C—CH(CH3)—C≡CH, —CH(CH3)—C≡C—C≡CH, —CH(C≡CH)—CH2—C≡CH, —C(C≡CH)2—CH3, —CH2—CH(C≡CH)2, —CH(C≡CH)—C≡C—CH3, —O—R89;
R7, R8, R1° and R11, which may be the same or different, represent —H, —F, —Cl, —Br, —I, —CN, —NO2, —CH3, —C2H5, —C3H7, —CH(CH3)2, cyclo-C3H5, —CH2-cyclo-C3H5, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CH═CH2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —CH═CH—C2H5, —CH2—C(CH3)═CH2, —CH(CH3)—CH═CH, —CH═C(CH3)2, —C(CH3)═CH—CH3, —CH═CH—CH═CH2, —C3H6—CH═CH2, —C2H4—CH═CH—CH3, —CH2—CH═CH—C2H5, —CH═CH—C3H7, —CH2—CH═CH—CH═CH2, —CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C2H4—C(CH3)═CH2, —CH2—CH(CH3)—CH═CH2, —CH(CH3)—CH2—CH═CH2, —CH2—CH═C(CH3)2, —CH2—C(CH3)═CH—CH3, —CH(CH3)—CH═CH—CH3, —CH═CH—CH(CH3)2, —CH═C(CH3)—C2H5, —C(CH3)═CH—C2H5, —C(CH3)═C(CH3)2, —C(CH3)2—CH═CH2, —CH(CH3)—C(CH3)═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C4H8—CH═CH2, —C3H6—CH═CH—CH3, —C2H4—CH═CH—C2H5, —CH2—CH═CH—C3H7, —CH═CH—C4H9, —C3H6—C(CH3)═CH2, —C2H4—CH(CH3)—CH═CH2, —CH2—CH(CH3)—CH2—CH═CH2, —CH(CH3)—C2H4—CH═CH2, —C2H4—CH═C(CH3)2, —C2H4—C(CH3)═CH—CH3, —CH2—CH(CH3)—CH═CH—CH3, —CH(CH3)—CH2—CH═CH—CH3, —CH2—CH═CH—CH(CH3)2, —CH2—CH═C(CH3)—C2H5, —CH2—C(CH3)═CH—C2H5, —CH(CH3)—CH═CH—C2H5, —CH═CH—CH2—CH(CH3)2, —CH═CH—CH(CH3)—C2H5, —CH═C(CH3)—C3H7, —C(CH3)═CH—C3H7, —CH2—CH(CH3)—C(CH3)═CH2, —CH(CH3)—CH2—C(CH3)═CH2, —CH(CH3)—CH(CH3)—CH═CH2, —CH2—C(CH3)2—CH═CH2, —C(CH3)2—CH2—CH═CH2, —CH2—C(CH3)═C(CH3)2, —CH(CH3)—CH═C(CH3)2, —C(CH3)2—CH═CH—CH3, —CH(CH3)—C(CH3)═CH—CH3, —CH═C(CH3)—CH(CH3)2, —C(CH3)═CH—CH(CH3)2, —C(CH3)═C(CH3)—C2H5, —CH═CH—C(CH3)3, —C(CH3)2—C(CH3)═CH2, —CH(C2H5)—C(CH3)═CH2, —C(CH3)(C2H5)—CH═CH2, —CH(CH3)—C(C2H5)═CH2, —CH2—C(C3H7)═CH2, —CH2—C(C2H5)═CH—CH3, —CH(C2H5)—CH═CH—CH3, —C(C4H9)═CH2, —C(C3H7)═CH—CH3, —C(C2H5)═CH—C2H5, —C(C2H5)═C(CH3)2, —C[C(CH3)3]═CH2, —C[CH(CH3)(C2H5)]═CH2, —C[CH2—CH(CH3)2]═CH2, —C2H4—CH═CH—CH═CH2, —CH2—CH═CH—CH2—CH═CH2, —CH═CH—C2H4—CH═CH2, —CH2—CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH—CH3, —CH═CH—CH═CH—C2H5, —CH2—CH═CH—C(CH3)═CH2, —CH2—CH═C(CH3)—CH═CH2, —CH2—C(CH3)═CH—CH═CH2, —CH(CH3)—CH═CH—CH═CH2, —CH═CH—CH2—C(CH3)═CH2, —CH═CH—CH(CH3)—CH═CH2, —CH═C(CH3)—CH2—CH═CH2, —C(CH3)═CH—CH2—CH═CH2, —CH═CH—CH═C(CH3)2, —CH═CH—C(CH3)═CH—CH3, —CH═C(CH3)—CH═CH—CH3, —C(CH3)═CH—CH═CH—CH3, —CH═C(CH3)—C(CH3)═CH2, —C(CH3)═CH—C(CH3)═CH2, —C(CH3)═C(CH3)—CH═CH2, —CH═CH—CH═CH—CH═CH2, —C≡CH, —C≡C—CH3, —CH2—C≡CH, —C2H4—C≡CH, —CH2—C≡C—CH3, —C≡C—C2H5, —C3H6—C≡CH, —C2H4—C≡C—CH3, —CH2—C≡C—C2H5, —C≡C—C3H7, —CH(CH3)—C≡CH, —CH2—CH(CH3)—C≡CH, —CH(CH3)—CH2—C≡CH, —CH(CH3)—C≡C—CH3, —C4H8—C≡CH, —C3H6—C≡C—CH3, —C2H4—C≡C—C2H5, —CH2—C≡C—C3H7, —C≡C—C4H9, —C2H4—CH(CH3)—C≡CH, —CH2—CH(CH3)—CH2—C≡CH, —CH(CH3)—C2H4—C≡CH, —CH2—CH(CH3)—C≡C—CH3, —CH(CH3)—CH2—C≡C—CH3, —CH(CH3)—C≡C—C2H5, —CH2—C≡C—CH(CH3)2, —C≡C—CH(CH3)—C2H5, —C≡C—CH2—CH(CH3)2, —C≡C—C(CH3)3, —CH(C2H5)—C≡C—CH3, —C(CH3)2—C≡C—CH3, —CH(C2H5)—CH2—C≡CH, —CH2—CH(C2H5)—C≡CH, —C(CH3)2—CH2—C≡CH, —CH2—C(CH3)2—C≡CH, —CH(CH3)—CH(CH3)—C≡CH, —CH(C3H7)—C≡CH, —C(CH3)(C2H5)—C≡CH, —C≡C—C≡CH, —CH2—C≡C—C≡CH, —C≡C—C≡C—CH3, —CH(C≡CH)2, —C2H4—C≡C—C≡CH, —CH2—C≡C—CH2—C≡CH, —C≡C—C2H4—C≡CH, —CH2—C≡C—C≡C—CH3, —C≡C—CH2—C≡C—CH3, —C≡C—C≡C—C2H5, —C≡C—CH(CH3)—C≡CH, —CH(CH3)—C≡C—C≡CH, —CH(C≡CH)—CH2—C≡CH, —C(C≡CH)2—CH3, —CH2—CH(C≡CH)2, —CH(C≡CH)—C≡C—CH3, —O—R90, —O—R111, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl and C1-6alkoxy groups are optionally mono- or polysubstituted by —OH, —F, —Cl, —Br, —I;
R9represents —H, —R91;
R12 represent —R92, —CN, —R93, —R94, —OR94, phenyl, naphtalinyl, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl or C1-6alkoxy groups represented by R92 are optionally mono- or polysubstituted by —OH, —F, —Cl, —Br, —I, —O—R95, R96, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16R17, —SO2—NR16R17, —SOm—R16R17, —CR16R17H, —NR16R17; and wherein the saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring systems represented by R137 are optionally mono- or polysubstituted by —OH, —F, —Cl, —Br, —I, —R96;
R13 is selected from —H, —OH, —F, —Cl, —Br, —I, —NO2, —CH3, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —C5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—CH(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3, —CH═CH2, —CH2—CH═CH2, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —CH═CH—C2H5, —CH2—C(CH3)═CH2, —CH(CH3)—CH═CH, —CH═C(CH3)2, —C(CH3)═CH—CH3, —CH═CH—CH═CH2, —C3H6—CH═CH2, —C2H4—CH═CH—CH3, —CH2—CH═CH—C2H5, —CH═CH—C3H7, —CH2—CH═CH—CH═CH2, —CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C2H4—C(CH3)═CH2, —CH2—CH(CH3)—CH═CH2, —CH(CH3)—CH2—CH═CH2, —CH2—CH═C(CH3)2, —CH2—C(CH3)═CH—CH3, —CH(CH3)—CH═CH—CH3, —CH═CH—CH(CH3)2, —CH═C(CH3)—C2H5, —C(CH3)═CH—C2H5, —C(CH3)═C(CH3)2, —C(CH3)2—CH═CH2, —CH(CH3)—C(CH3)═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C4H8—CH═CH2, —C3H6—CH═CH—CH3, —C2H4—CH═CH—C2H5, —CH2—CH═CH—C3H7, —CH═CH—C4H9, —C3H6—C(CH3)═CH2, —C2H4—CH(CH3)—CH═CH2, —CH2—CH(CH3)—CH2—CH═CH2, —CH(CH3)—C2H4—CH═CH2, —C2H4—CH═C(CH3)2, —C2H4—C(CH3)═CH—CH3, —CH2—CH(CH3)—CH═CH—CH3, —CH(CH3)—CH2—CH═CH—CH3, —CH2—CH═CH—CH(CH3)2, —CH2—CH═C(CH3)—C2H5, —CH2—C(CH3)═CH—C2H5, —CH(CH3)—CH═CH—C2H5, —CH═CH—CH2—CH(CH3)2, —CH═CH—CH(CH3)—C2H5, —CH═C(CH3)—C3H7, —C(CH3)═CH—C3H7, —CH2—CH(CH3)—C(CH3)═CH2, —CH(CH3)—CH2—C(CH3)═CH2, —CH(CH3)—CH(CH3)—CH═CH2, —CH2—C(CH3)2—CH═CH2, —C(CH3)2—CH2—CH═CH2, —CH2—C(CH3)═C(CH3)2, —CH(CH3)—CH═C(CH3)2, —C(CH3)2—CH═CH—CH3, —CH(CH3)—C(CH3)═CH—CH3, —CH═C(CH3)—CH(CH3)2, —C(CH3)═CH—CH(CH3)2, —C(CH3)═C(CH3)—C2H5, —CH═CH—C(CH3)3, —C(CH3)2—C(CH3)═CH2, —CH(C2H5)—C(CH3)═CH2, —C(CH3)(C2H5)—CH═CH2, —CH(CH3)—C(C2H5)═CH2, —CH2—C(C3H7)═CH2, —CH2—C(C2H5)═CH—CH3, —CH(C2H5)—CH═CH—CH3, —C(C4H9)═CH2, —C(C3H7)═CH—CH3, —C(C2H5)═CH—C2H5, —C(C2H5)═C(CH3)2, —C[C(CH3)3]═CH2, —C[CH(CH3)(C2H5)]═CH2, —C[CH2—CH(CH3)2]═CH27—C2H4—CH═CH—CH═CH2, —CH2—CH═CH—CH2—CH═CH2, —CH═CH—C2H4—CH—CH2, CH2—CH—CH═CH—CH═CH3, CH—CH═CH2—CH—CH═CH3, —CH═CH—CH═CH—C2H5, —CH2—CH═CH—C(CH3)═CH2, —CH2—CH═C(CH3)—CH═CH2, —CH2—C(CH3)═CH—CH═CH2, —CH(CH3)—CH═CH—CH═CH2, —CH═CH—CH2—C(CH3)═CH2, —CH═CH—CH(CH3)—CH═CH2, —CH═C(CH3)—CH2—CH═CH2, —C(CH3)═CH—CH2—CH═CH2, —CH═CH—CH═C(CH3)2, —CH═CH—C(CH3)═CH—CH3, —CH═C(CH3)—CH═CH—CH3, —C(CH3)═CH—CH═CH—CH3, —CH═C(CH3)—C(CH3)═CH2, —C(CH3)═CH—C(CH3)═CH2, —C(CH3)═C(CH3)—CH═CH2, —CH═CH—CH═CH—CH═CH2, —C≡CH, —C≡C—CH3, —CH2—C≡CH, —C2H4—C≡CH, —CH2—C≡C—CH3, —C≡C—C2H5, —C3H6—C≡CH, —C2H4—C≡C—CH3, —CH2—C≡C—C2H5, —C≡C—C3H7, —CH(CH3)—C≡CH, —CH2—CH(CH3)—C≡CH, —CH(CH3)—CH2—C≡CH, —CH(CH3)—C≡C—CH3, —C4H8—C≡CH, —C3H6—C≡C—CH3, —C2H4—C≡C—C2H5, —CH2—C≡C—C3H7, —C≡C—C4H9, —C2H4—CH(CH3)—C≡CH, —CH2—CH(CH3)—CH2—C≡CH, —CH(CH3)—C2H4—C≡CH, —CH2—CH(CH3)—C≡C—CH3, —CH(CH3)—CH2—C≡C—CH3, —CH(CH3)—C≡C—C2H5, —CH2—C≡C—CH(CH3)2, —C≡C—CH(CH3)—C2H5, —C≡C—CH2—CH(CH3)2, —C≡C—C(CH3)3, —CH(C2H5)—C≡C—CH3, —C(CH3)2—C≡C—CH3, —CH(C2H5)—CH2—C≡CH, —CH2—CH(C2H5)—C≡CH, —C(CH3)2—CH2—C≡CH, —CH2—C(CH3)2—C≡CH, —CH(CH3)—CH(CH3)—C≡CH, —CH(C3H7)—C≡CH, —C(CH3)(C2H6)—C≡CH, —C≡C—C≡CH, —CH2—C≡C—C≡CH, —C≡C—C≡C—CH3, —CH(C≡CH)2, —C2H4—C≡C—C≡CH, —CH2—C≡C—CH2—C≡CH, —C≡C—C2H4—C≡CH, —CH2—C≡C—C≡C—CH3, —C≡C—CH2—C≡C—CH3, —C≡C—C≡C—C2H5, —C≡C—CH(CH3)—C≡CH, —CH(CH3)—C≡C—C≡CH, —CH(C≡CH)—CH2—C≡CH, —CH2—CH(C≡CH)2, —CH(C≡CH)—C≡C—CH3, cyclo-C3H5, —O—R97, —R98, —R99;
when R12 and R13 represent alkenylene groups, R12 and R13 may combine to form a condensed aromatic ring together with the atoms of residue D to which R12 and R13 are attached in order to form a bicyclic group with residue D;
R14 represents
(i) —H, —OH, —F, —Cl, —Br, —I, —NO2, —CN, —NH2;
(ii) —R100, —R101, —R102, —O—R102, —R103, —O—R103, —R136, wherein the C1-6alkyl, C2-6alkenyl, C2-6alkynyl and C1-6alkoxy groups represented by R100 and the ether groups represented by —R136 are optionally mono- or polysubstituted by —OH, —F, —Cl, —Br, —I, —O—R104, —R105, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16R17, —SO2—NR16R17, —SOm—R16R17, —CR16R17H, —NR16R17;
(iii) —R113, wherein the saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system represented by —R113 is optionally mono- or polysubstituted by —F, —Cl, —Br, —I, —OH, —NO2, —NH2, —C2H4—N(CH3)2, —CN, —CF3, ═O, —R16, —R17, —R106, —O—R107, —R108, —R109, a saturated or unsaturated three- to eight-membered carbocyclic or heterocyclic group, wherein the C1-6alkyl groups represented by R106, the C1-6alkenyl groups represented by R108, the C2-6alkynyl groups represented by R109, the C1-6alkoxy groups represented by —O—R107 are optionally mono- or polysubstituted by —OH, —F, —Cl, —Br, —I, —O—R104, —R105, —COOH, —COOCH3, —COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16R17, —SO2—NR16R17, —SOm—R16R17, —CR16R17H, —NR16R17;
R16 and R17, which may be the same or different, represent —H, —R112, optionally substituted by —OH, —F, —Cl, —Br, —I, —NH2, —CN;
or alternatively R16 and R17 may combine with the nitrogen atom attached thereto to form a saturated or unsaturated five to eight-membered heterocyclic group selected from —R114; which is optionally mono- or polysubstituted by —OH, ═O, —R116, —R117, —R118, —O—R119, —R120, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system selected from —R115; wherein the C1-6alkyl group represented by R116, Cmalkenyl group represented by R117, Cmalkynyl group represented by R118 are optionally substituted by —OH, —R122, or a saturated or unsaturated three- to twelve-membered carbocylic or heterocyclic ring system selected from —R121;
amino group in which one or two hydrogen atoms on the amino group are optionally substituted by —R123, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system selected from —R124, and the C1-6alkyl group represented by R123 is optionally substituted by —OH, —R125, or a saturated or unsaturated three- to twelve-membered carbocylic or heterocyclic ring system selected from —R126;
or a saturated or unsaturated three- to twelve-membered carbocyclic ring system selected from —R127; optionally substituted by —OH, ═O, —R128, —R129, —R130, —O—R131, —R132, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system selected from —R133, wherein the C1-6alkyl group represented by R128, C2-6alkenyl group represented by R129 and C2-6alkynyl group represented by R135 are optionally substituted by —OH, —R134, or a saturated or unsaturated three- to twelve-membered carbocyclic or heterocyclic ring system selected from —R135;
when the carbocyclic or heterocyclic group is substituted by C1-6alkyl groups, two alkyl groups may combine together to form an alkylene chain; and the carbocyclic or heterocyclic group may be condensed with another saturated or unsaturated five to seven-membered carbocyclic or heterocyclic group to form a bicyclic group;
R19, R20, R71, R85, R86, R89, R90, R91, R95, R97, R104, R106, R107, R110, R111, R112, R116, R119, R122, R123, R125, R128, R131 and R134 independently of each other represent —CH3, —H, —CF3, -Ph, —CH2-Ph, —C2H5, —C3H7, —CH(CH3)2, —C4H9, —CH2—CH(CH3)2, —CH(CH3)—C2H5, —C(CH3)3, —O5H11, —CH(CH3)—C3H7, —CH2—CH(CH3)—C2H5, —CH(CH3)—CH(CH3)2, —C(CH3)2—C2H5, —CH2—C(CH3)3, —CH(C2H5)2, —C2H4—C(CH3)2, —C6H13, —C3H6—CH(CH3)2, —C2H4—CH(CH3)—C2H5, —CH(CH3)—C4H9, —CH2—CH(CH3)—C3H7, —CH(CH3)—CH2—CH(CH3)2, —CH(CH3)—CH(CH3)—C2H5, —CH2—CH(CH3)—CH(CH3)2, —CH2—C(CH3)2—C2H5, —C(CH3)2—C3H7, —C(CH3)2—CH(CH3)2, —C2H4—C(CH3)3, —CH(CH3)—C(CH3)3;
R21 and R98 represent independently of each other —CR22R23R24, —CR23R24—CR25R26R22—CR23R24—CR25R26—CR27R28R22, —CR23R24—CR25R26—CR27R28—CR29R30R22, —CR23R24—CR25R26—CR27R28—CR29R30—CR31R32R22, —CR23R24—CR25R26— CR27R28—CR29R30—CR31R32—CR33R34R22;
R22-R34 independently of each other represent —H, —F, —Cl, —Br, —I, —CH3, —CF3, —OCH3, —OCF3, —C2H5, —C3H7;
R35 and R99 represent independently of each other —O—CR22R23R24, —O—CR23R24—CR25R26R22, —O—CR23R24—CR25R26—CR27R28R22, O—CR23R24—CR25R26—CR27R28—CR29R30R22, —O—CR23R24—CR25R26—CR27R28—CR29R30—CR31R32R22, —O—CR23R24—CR25R26—CR27R28—CR29R30—CR31R32—CR33R34R22;
R36, R72, R87, R96, R105, R120, R132 and R136 represent independently of each other —CR23R24—XH, —X—CR22R23R24, —X—CR23R24—CR25R26R22, —CR23R24—X—CR25R26R22, —CR23R24—CR25R26—XH, —X—CR23R24—CR25R26—CR27R28R22, —CR23R24—X—CR25R26—CR27R28R22, —CR23R24—CR25R26—X—CR27R28R22, —CR23R24—CR25R26—CR27R28—XH, —X—CR23R24—CR25R26—CR27R28—CR29R30R22, —CR23R24—X—CR28R28—CR27R28—CR29R30R22, —CR23R24—CR28R28—X—CR27R28—CR29R30R22, —CR23R24—CR25R26—CR27R28—X—CR29R30R22, —CR23R24—CR25R26—CR27R28—CR29R30—XH, —X—CR23R24—CR25R26—CR27R28—CR29R30—CR31R32R22, —CR23R24—X—CR25R26—CR27R28—CR29R30—CR31R32R22, —CR23R24—CR25R26—X—CR27R28—CR29R30—CR31R32R22—CR23R24—CR25R26—CR27R28—X—CR29R30—CR31R32R22, —CR23R24—CR25R26—CR27R28—CR29R30—X—CR31R32R22, —CR23R24—CR25R26—CR27R28—CR29R30—CR31R32—XH, —X—CR23R24—CR25R26—CR27R28—CR29R30—CR31R32—CR33R34R22, —CR23R24—X—CR25R26—CR27R28—CR29R30—CR31R32—CR33R34R22, —CR23R24—CR25R25—X—CR27R28—CR29R30—CR31R32—CR33R34R22, —CR23R24—CR25R26—CR27R28—X—CR29R30—CR31R32—CR33R34R22, —CR23R24—CR25R26—CR27R28—CR29R30—X—CR31R32—CR33R34R22, —CR23R24—CR25R26—CR27R28—CR29R30—CR31R32—X—CR33R34R22, —CR23R24—CR25R26—CR27R28—CR29R39—CR31R32—CR33R34—XH;
X represents —O—, —CO—, —O—CO—
R37, R38, R93 and R101 represent independently of each other —CR40R41—YH, —Y—CR39R40—R41, —Y—CR40—R41—CR42R43R39, —CR40R41—Y—CR42R43R39, —CR40R41—CR42R43—YH, —Y—CR40R41—CR42R43—CR44R45R39, —CR40R41—Y—CR42R43—CR44R45R39, —CR40R41—CR42R43—Y—CR44R45R39, —CR40R41—CR42R43—CR44R45—YH, —Y—CR40R41—CR42R43—CR44R45—CR46R47R39, —CR40R41—Y—CR42R43—CR44R45—CR46R47R39, —CR40R41—CR42R43—Y—CR44R45—CR46R47R39, —CR40R41—CR42R43—CR44R45—Y—CR46R46R39, —CR40R42—CR42R43—CR44R45—CR46R47—YH, —Y—CR40R41—CR42R43—CR44R45—CR46R47—CR48R49R39, —CR40R41—Y—CR42R43—CR44R45—CR46R47—CR48R49R39, —CR40R41—CR42R43—Y—CR44R45—CR46R47—CR48R49R39, —CR40R41—CR42R43—CR44R45—Y—CR46R47—CR48R49R39, —CR40R41—CR42R43—CR44R45—CR46R47—Y—CR48R49R39, —CR40R41—CR42R43—CR44R45—CR46R47—CR48R49—YH, —Y—CR40R41—CR42R43—CR44R45—CR46R47—CR46R49—CR50R51R39, —CR40R41—Y—CR42R43—CR44R45—CR46R47—CR48R49—CR50R51R39, —CR40R41—CR42R43—Y—CR44R45—CR46R47—CR48R49—CR50R51R39, CR40R41—CR42R43—CR44R45—Y—CR46R47—CR48R49—CR50R51R39, —CR40R41—CR42R43—CR44R45—CR46R47—Y—CR48R49—CR50R51R39, CR40R41—CR42R43—CR44R45—CR46R47—CR48R49—Y—CR50R51R39—CR4° R41—CR42R43—CR44R45—CR46R47—CR48R49—CR50R51—YH;
R39-R53 represent independently of each other —H, —CH3, —C2H5, —C3H7;
Y represents —NR52—CO—, —CO—NR53—;
R54, R55 and R102 represent independently of each other
Figure US08999982-20150407-C00164
Figure US08999982-20150407-C00165
Figure US08999982-20150407-C00166
R56, R57, R94 and R103 represent independently of each other —CR58R16R17, —CR69R60, —CR16R17CR61R62R58, —CR59R60—CR61R62R58, —R60R16R17R58, —CR16R17—CR61R62—CR63R64R58, —R59R60—CR61R62—CR63R64R58, —CR59R60—CR16R17—CR63R64R58, —CR59R60—CR61R62—CR16R17R58, R16R17—CR61R62—CR63R64—CR65R66R58, —CR59R60—CR61R62—CR63R64—CR65R66R58, —CR59R60—CR16R17—CR63R64—CR66R67R58, —CR59R60—CR61R62—CR16R17—CR65R66R58, —CR59R60—CR61R62—CR63R64—CR16R17R58, —R17—CR61R62—CR63R64—CR65R66—CR67R68R58, —CR69R60—CR61R62—CR63R64—CR65R66—CR67R68R58, —CR59R60—CR16R17—CR63R64—CR65R66—CR67R68R58, —CR59R60—CR61R62—CR16R17—CR65R66—CR67R68R69, —CR59R60—CR61R62—CR63R64—CR16R17—CR67R68R58, —CR59R60—CR61R62—CR63R64—CR65R66—CR16R17R58, —CR16R17—CR61R62—CR63R64—CR65R66—CR67R68—CR69R70R58, —CR59R60—CR16R17—CR63R64—CR65R66—CR67R68—CR69R76R58, —CR59R66—CR61R62—CR16R17—CR65R66—CR67R65—CR69R70R55, —CR59R60—CR61R62—CR63R64—CR16R17—CR67R68—CR69R70R55, —CR59R60—CR61R62—CR63R64—CR66R66—CR16R17—CR69R76R68, —CR59R66—CR61R62—CR63R64—CR65R66—CR67R68—CR16R17R58,
R58-R70 represent independently of each other —H, —NH2, —OH, —F, —Cl, —Br, —I, —R71, —O—R71, —R72, —O—R95, —R96, —O—R104, —R105, —COOH, —COOCH3,
—COOC2H5, —COOC3H7, —COOCH(CH3)2, —COOC(CH3)3, —(C═O)—NR16R17, —SO2—NR16R17, —SOm—R16R17, —CR16R17H, —NR16R17;
R107, R117 and R129 represent independently of each other —CH═CH2, —CH2—CH═CH2, —H, —C(CH3)═CH2, —CH═CH—CH3, —C2H4—CH═CH2, —CH2—CH═CH—CH3, —CH═CH—C2H5, —CH2—C(CH3)═CH2, —CH(CH3)—CH═CH, —CH═C(CH3)2, —C(CH3)═CH—CH3, —CH═CH—CH═CH2, —C3H6—CH═CH2, —C2H4—CH═CH—CH3, —CH2—CH═CH—C2H5, —CH═CH—C3H7, —CH2—CH═CH—CH═CH2, —CH═CH—CH═CH—CH3, —CH═CH—CH2—CH═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C2H4—C(CH3)═CH2, —CH2—CH(CH3)—CH═CH2, —CH(CH3)—CH2—CH═CH2, —CH2—CH═C(CH3)2, —CH2—C(CH3)═CH—CH3, —CH(CH3)—CH═CH—CH3, —CH═CH—CH(CH3)2, —CH═C(CH3)—C2H5, —C(CH3)═CH—C2H5, —C(CH3)═C(CH3)2, —C(CH3)2—CH═CH2, —CH(CH3)—C(CH3)═CH2, —C(CH3)═CH—CH═CH2, —CH═C(CH3)—CH═CH2, —CH═CH—C(CH3)═CH2, —C4H8—CH═CH2, —C3H6—CH═CH—CH3, —C2H4—CH═CH—C2H5, —CH2—CH═CH—C3H7, —CH═CH—C4H9, —C3H6—C(CH3)═CH2, —C2H4—CH(CH3)—CH═CH2, —CH2—CH(CH3)—CH2—CH═CH2, —CH(CH3)—C2H4—CH═CH2, —C2H4—CH═C(CH3)2, —C2H4—C(CH3)═CH—CH3, —CH2—CH(CH3)—CH═CH—CH3, —CH(CH3)—CH2—CH═CH—CH3, —CH2—CH═CH—CH(CH3)2, —CH2—CH═C(CH3)—C2H5, —CH2—C(CH3)═CH—C2H5, —CH(CH3)—CH═CH—C2H5, —CH═CH—CH2—CH(CH3)2, —CH═CH—CH(CH3)—C2H5, —CH═C(CH3)—C3H7, —C(CH3)═CH—C3H7, —CH2—CH(CH3)—C(CH3)═CH2, —CH(CH3)—CH2—C(CH3)═CH2, —CH(CH3)—CH(CH3)—CH═CH2, —CH2—C(CH3)2—CH═CH2, —C(CH3)2—CH2—CH═CH2, —CH2—C(CH3)═C(CH3)2, —CH(CH3)—CH═C(CH3)2, —C(CH3)2—CH═CH—CH3, —CH(CH3)—C(CH3)═CH—CH3, —CH═C(CH3)—CH(CH3)2, —C(CH3)═CH—CH(CH3)2, —C(CH3)═C(CH3)—C2H5, —CH═CH—C(CH3)3, —C(CH3)2—C(CH3)═CH2, —CH(C2H5)—C(CH3)═CH2, —C(CH3)(C2H5)—CH═CH2, —CH(CH3)—C(C2H5)═CH2, —CH2—C(C3H7)═CH2, —CH2—C(C2H5)═CH—CH3, —CH(C2H5)—CH═CH—CH3, —C(C4H9)═CH2, —C(C3H7)═CH—CH3, —C(C2H5)═CH—C2H5, —C(C2H5)═C(CH3)2, —C[C(CH3)3]═CH2, —C[CH(CH3)(C2H5)]═CH2, —C[CH2—CH(CH3)2]═CH2, —C2H4—CH═CH—CH═CH2, —CH2—CH═CH—CH2—CH═CH2, —CH═CH—C2H4—CH═CH2, CH2—CH—CH═CH—CH═CH3, —CH═CH—CH2—CH═CH—CH3, —CH═CH—CH═CH—C2H5, —CH2—CH═CH—C(CH3)═CH2, —CH2—CH═C(CH3)—CH═CH2, —CH2—C(CH3)═CH—CH═CH2, —CH(CH3)—CH═CH—CH═CH2, —CH═CH—CH2—C(CH3)═CH2, —CH═CH—CH(CH3)—CH═CH2, —CH═C(CH3)—CH2—CH═CH2, —C(CH3)═CH—CH2—CH═CH2, —CH═CH—CH═C(CH3)2, —CH═CH—C(CH3)═CH—CH3, —CH═C(CH3)—CH═CH—CH3, —C(CH3)═CH—CH═CH—CH3, —CH═C(CH3)—C(CH3)═CH2, —C(CH3)═CH—C(CH3)═CH2, —C(CH3)═C(CH3)—CH═CH2, —CH═CH—CH═CH—CH═CH2;
R109, R118 and R130 represent independently of each other —H, —C≡CH, —C≡C—CH3, —CH2—C≡CH, —C2H4—C≡CH, —CH2—C≡C—CH3, —C≡C—C2H5, —C3H6—C≡CH, —C2H4—C≡C—CH3, —CH2—C≡C—C2H5, —C≡C—C3H7, —CH(CH3)—C≡CH, —CH2—CH(CH3)—C≡CH, —CH(CH3)—CH2—C≡CH, —CH(CH3)—C≡C—CH3, —C4H8—C≡CH, —C3H6—C≡C—CH3, —C2H4—C≡C—CH5, —CH2—C≡C—C3H7, —C≡C—C4H9, —C2H4—CH(CH3)—C≡CH, —CH2—CH(CH3)—CH2—C≡CH, —CH(CH3)—C2H4—C≡CH, —CH2—CH(CH3)—C≡C—CH3, —CH(CH3)—CH2—C≡C—CH3, —CH(CH3)—C≡C—C2H5, —CH2—C≡C—CH(CH3)2, —C≡C—CH(CH3)—C2H5, —C≡C—CH2—CH(CH3)2, —C≡C—C(CH3)3, —CH(C2H5)—C≡C—CH3, —C(CH3)2—C≡C—CH3, —CH(C2H5)—CH2—C≡CH, —CH2—CH(C2H5)—C≡CH, —C(CH3)2—CH2—C≡CH, —CH2—C(CH3)2—C≡CH, —CH(CH3)—CH(CH3)—C≡CH, —CH(C3H7)—C≡CH, —C(CH3)(C2H5)—C≡CH, —C≡C—C≡CH, —CH2—C≡C—C≡CH, —C≡C—C≡C—CH3, —CH(C≡CH)2, —C2H4—C≡C—C≡CH, —CH2—C≡C—CH2—C≡CH, —C≡C—C2H4—C≡CH, —CH2—C≡C—C≡C—CH3, —C≡C—CH2—C≡C—CH3, —C≡C—C≡C—C2H5, —C≡C—CH(CH3)—C≡CH, —CH(CH3)—C≡C—C≡CH, —CH(C≡CH)—CH2—C≡CH, —C(C≡CH)2—CH3, —CH2—CH(C≡CH)2, —CH(C≡CH)—C≡C—CH3;
R113, R115, R121, R124, R126, R127, R133, R135, R137 and R138 independently of each other represent
Figure US08999982-20150407-C00167
Figure US08999982-20150407-C00168
Figure US08999982-20150407-C00169
Figure US08999982-20150407-C00170
Figure US08999982-20150407-C00171
Figure US08999982-20150407-C00172
Figure US08999982-20150407-C00173
Figure US08999982-20150407-C00174
R114 represents
Figure US08999982-20150407-C00175
and enantiomers, stereoisomeric forms, mixtures of enantiomers, diastereomers, mixtures of diastereomers, prodrugs, hydrates, solvates, acid salt forms, tautomers, and racemates of the above mentioned compounds and pharmaceutically acceptable salts thereof.
2. The compounds according to claim 1, wherein the residue D represents one of the following heterocycles,
Figure US08999982-20150407-C00176
and the substituents R12-R14 have the meanings as defined in formula (I).
3. The compounds according to claim 1, wherein R1, R4, R5 and R6 are selected from hydrogen or C1-6alkyl, particularly from hydrogen.
4. The compounds according to any of claims 1 to 3, having the general formula (Ia)
Figure US08999982-20150407-C00177
5. The compounds according to any of claims 1 to 3, having the general formula (Ib) or the general formula (Ic)
Figure US08999982-20150407-C00178
6. The compounds according to any of claims 1 to 3, wherein R9 is a hydrogen atom.
7. The compound according to claim 1, wherein the compound is selected from the group of compounds comprising
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1,5-dimethyl-pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-2-[4-(trifluoromethyl)phenyl]thiazole-4-carboxamide
4-bromo-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-methyl-pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-methyl-pyrazole-3-carboxamide
1-tert-butyl-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-5-methyl-pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]thiazole-2-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-2-methyl-thiazole-4-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-methyl-indazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-5-methyl-isoxazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-2-phenyl-thiazole-4-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-methyl-imidazole-2-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-methyl-imidazole-4-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-propyl-pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-[3-(1-piperidyl)propyl]pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(2,2,2-trifluoroethoxymethyl)pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxamide
4-(cyclopropylmethoxy)-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-(2-dimethylaminoethoxy)-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-(2-dimethylaminoethoxy)-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide
1-(2-chloro-4-fluoro-phenyl)-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carboxamide
4-(cyclopropylmethoxy)-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-methyl-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-methyl-phenyl]-1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carboxamide
4-(cyclopropylmethoxy)-N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-methyl-phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-methyl-phenyl]-4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide
N-[3-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[3-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carboxamide
N-[3-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4-(cyclopropylmethoxy)-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[3-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide
N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1-[2-(2-dimethylaminoethyl)-4-fluoro-phenyl]-4-ethoxy-pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-2-phenyl-thiazole-4-carboxamide
4-bromo-N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-methyl-pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-methyl-pyrazole-3-carboxamide
1-tert-butyl-N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-5-methyl-pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1,5-dimethyl-pyrazole-3-carboxamide 4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carboxamide
4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide
1-(2-chloro-4-fluoro-phenyl)-4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]pyrazole-3-carboxamide
4-(2-dimethylaminoethoxy)-N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide
1-(2-bromo-4-fluoro-phenyl)-4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-(2-methoxyethoxyl)pyrazole-3-carboxamide
4-benzyloxy-N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-nitro-pyrazole-3-carboxamide
4-amino-N-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[4-[[7-(3-aminopropoxy)-6-methoxy-4-quinolyl]oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[4-[[7-(3-aminopropoxy)-6-methoxy-4-quinolyl]oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide
N-[4-[[7-(3-aminopropoxy)-6-methoxy-4-quinolyl]oxy]-3-fluoro-phenyl]-5-ethoxy-2-(4-fluorophenyl)oxazole-4-carboxamide
4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide
4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxamide
1-(2-chloro-4-fluoro-phenyl)-4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-quinolyl]oxy]phenyl]pyrazole-3-carboxamide
4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carboxamide
5-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]-4-quinolyl]oxy]phenyl]-2-(4-fluorophenyl)oxazole-4-carboxamide
4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide trifluoroacetic acid salt
4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-isopropoxy-pyrazole-3-carboxamide
1-(2-chloro-4-fluoro-phenyl)-4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]pyrazole-3-carboxamide
4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-(2-methoxyethoxyl)pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-[(1-methylpyrrolidin-3-yl)methoxy]pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(3-piperazin-1-ylpropoxy)-4-quinolyl]oxy]phenyl]-2-phenyl-thiazole-4-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-methoxy-pyrazole-3-carboxamide
4-ethoxy-N-[3-fluoro-4-[[6-methoxy-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide
4-(cyclopropylmethoxy)-N-[3-fluoro-4-[[6-methoxy-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide
4-bromo-N-[3-fluoro-4-[[6-methoxy-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl]-1-(4-fluorophenyl)-4-[(4-fluorophenyl)methoxy]pyrazole-3-carboxamide
1-tert-butyl-N-[3-fluoro-4-[[6-methoxy-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl]-5-methyl-pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl]-4-nitro-1-[3-(1-piperidyl)propyl]pyrazole-3-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl]-5-methyl-2-phenyl-oxazole-4-carboxamide
N-[3-fluoro-4-[[6-methoxy-7-(4-piperidylmethoxy)-4-quinolyl]oxy]phenyl]-2-phenyl-thiazole-4-carboxamide
4-ethoxy-N-[4-[[7-[(1-ethyl-4-piperidyl)methoxy]-6-methoxy-4-quinolyl]oxy]-3-fluoro-phenyl]-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide
4-ethoxy-N-[3-fluoro-4-[[7-((1-isobutyl-4-piperidyl)methoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide
N-[5-[(6,7-dimethoxy-4-quinolyl)oxy]-2-pyridyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide
N-[5-[(6,7-dimethoxy-4-quinolyl)oxy]-2-pyridyl]-4-ethoxy-1-(4-fluoro-2-methyl-phenyl)pyrazole-3-carboxamide
1-(2-chloro-4-fluoro-phenyl)-N-[5-[(6,7-dimethoxy-4-quinolyl)oxy]-2-pyridyl]-4-ethoxy-pyrazole-3-carboxamide
N-[5-[(6,7-dimethoxy-4-quinolyl)oxy]-2-pyridyl]-4-(2-dimethylaminoethyl)-1-(4-fluorophenyl)pyrazole-3-carboxamide
tert-butyl 4-(((4-((6-(4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamido)pyridin-3-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)piperidine-1-carboxylate
N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1-(4-methoxy-2-methylphenyl)-1H-pyrazole-3-carboxamide
N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(3-nitrophenyl)-1H-pyrazole-3-carboxamide
N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-methoxy-2-methylphenyl)-1H-pyrazole-3-carboxamide
N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1-(3-nitrophenyl)-1H-pyrazole-3-carboxamide
1-(2-(benzyloxy)-4-fluorophenyl)-N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1H-pyrazole-3-carboxamide
N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methoxyphenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide
N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methylphenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide
N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-3-methoxyphenyl)-1H-pyrazole-3-carboxamide
N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1-(4-fluoro-3-methoxyphenyl)-1H-pyrazole-3-carboxamide
N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1-(4-nitrophenyl)-1H-pyrazole-3-carboxamide
1-(4-aminophenyl)-N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1H-pyrazole-3-carboxamide
N-(5-((6-methoxy-7-(piperidin-4-ylmethoxy)quinolin-4-yl)oxy)pyridin-2-yl)-4-(2-methoxyphenyl)thiazole-2-carboxamide
N-(5-((6-methoxy-7-(piperidin-4-ylmethoxy)quinolin-4-yl)oxy)pyridin-2-yl)-4-phenylthiazole-2-carboxamide
4-bromo-N-(5-((6-methoxy-7-(piperidin-4-ylmethoxy)quinolin-4-yl)oxy)pyridin-2-yl)thiazole-2-carboxamide
N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methoxyphenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide
N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-4-ethoxy-1-(4-fluoro-2-hydroxyphenyl)-1H-pyrazole-3-carboxamide
N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(pyridin-3-yl)-1H-pyrazole-3-carboxamide
N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1′-methyl-1′H-[1,3′-bipyrazole]-3-carboxamide.
8. A compound according to claim 1 for use as pharmaceutically active agent.
9. The compound of claim 8 as efficient inhibitors of TAM family RTKs.
10. The compound of claim 8 as suitable pharmaceutically active agents for the treatment of disorders associated with, accompanied by and/or caused by TAM family RTKs hyperfunction.
11. The compound of claim 9 for the treatment of Axl receptor tyrosine induced disorders.
12. The compound of claim 11, wherein the Axl receptor tyrosine kinase induced disorders are selected from a group comprising hyperproliferative disorders.
13. The compound of claim 12, wherein the Axl receptor tyrosine kinase induced disorders are selected from the group comprising cancer and primary tumor metastases.
14. The compound of claim 13, wherein the Axl receptor tyrosine kinase induced disorders are selected from adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, desmoid tumor, bladder cancer, bronchial carcinoma, breast cancer, Burkitt's lymphoma, corpus cancer, CUP-syndrome, colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors, gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, cervix, glioblastomas, gynecologic tumors, ear tumors, nose tumors and throat tumors, hematologic neoplasias, hairy cell leukemia, urethral cancer, skin cancer, skin testis cancer, brain tumors, brain metastases, testicle cancer, hypophysis tumor, carcinoids, Kaposi's sarcoma, laryngeal cancer, germ cell tumor, bone cancer, colorectal carcinoma, head and neck tumors, colon carcinoma, craniopharyngiomas, oral cancer, cancer of the central nervous system, liver cancer, liver metastases, leukemia, eyelid tumor, lung cancer, lymph node cancer, lymphomas, stomach cancer, malignant melanoma, malignant neoplasia, malignant tumors of the gastrointestinal tract, breast carcinoma, rectal cancer, medulloblastomas, melanoma, meningiomas, Hodgkin's disease, mycosis fungoides, nasal cancer, neurinoma, neuroblastoma, kidney cancer, renal cell carcinomas, non-Hodgkin's lymphomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcomas, ovarial carcinoma, pancreatic carcinoma, penile cancer, plasmocytoma, prostate cancer, pharyngeal cancer, rectal carcinoma, retinoblastoma, vaginal cancer, thyroid carcinoma, Schneeberger disease, esophageal cancer, spinalioms, T-cell lymphoma, thymoma, tube carcinoma, eye tumors, urethral cancer, urologic tumors, urothelial carcinoma, vulva cancer, wart appearance, soft tissue tumors, soft tissue sarcoma, Wilm's tumor, cervical carcinoma and tongue cancer.
15. Pharmaceutical composition comprising at least one compound according to claim 1 as an active ingredient, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.
US13/819,560 2010-08-28 2011-08-26 Pharmaceutically active compounds as Axl inhibitors Active US8999982B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/819,560 US8999982B2 (en) 2010-08-28 2011-08-26 Pharmaceutically active compounds as Axl inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP10075374 2010-08-28
EP10075374A EP2423208A1 (en) 2010-08-28 2010-08-28 Pharmaceutically active compounds as Axl inhibitors
EP10075374.8 2010-08-28
US34495910P 2010-11-29 2010-11-29
PCT/EP2011/004451 WO2012028332A1 (en) 2010-08-28 2011-08-26 Pharmaceutically active compounds as axl inhibitors
US13/819,560 US8999982B2 (en) 2010-08-28 2011-08-26 Pharmaceutically active compounds as Axl inhibitors

Publications (2)

Publication Number Publication Date
US20140018365A1 US20140018365A1 (en) 2014-01-16
US8999982B2 true US8999982B2 (en) 2015-04-07

Family

ID=43269622

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/819,560 Active US8999982B2 (en) 2010-08-28 2011-08-26 Pharmaceutically active compounds as Axl inhibitors

Country Status (17)

Country Link
US (1) US8999982B2 (en)
EP (2) EP2423208A1 (en)
JP (1) JP5843861B2 (en)
KR (1) KR101624296B1 (en)
CN (1) CN103124729B (en)
AU (1) AU2011297889B2 (en)
BR (1) BR112013004368A2 (en)
CA (1) CA2807620C (en)
DK (1) DK2609091T3 (en)
ES (1) ES2530492T3 (en)
HK (1) HK1185879A1 (en)
MX (1) MX2013002289A (en)
MY (1) MY158494A (en)
RU (1) RU2573834C2 (en)
SG (1) SG187597A1 (en)
WO (1) WO2012028332A1 (en)
ZA (1) ZA201300533B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9481668B2 (en) 2013-06-06 2016-11-01 Merck Patent Gmbh Quinoline inhibitor of the macrophage stimulating 1 receptor MSTR1
US20180093968A1 (en) * 2015-04-14 2018-04-05 Qurient Co., Ltd. Quinoline derivatives as tam rtk inhibitors
US10851093B2 (en) * 2018-06-01 2020-12-01 Rigel Pharmaceuticals, Inc. Tyrosine kinase inhibitors
US20210163448A1 (en) * 2018-05-30 2021-06-03 Qurient Co., Ltd. Quinoline derivatives as inhibitors of axl/mer rtk and csf1r

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101546693B1 (en) 2011-02-28 2015-08-24 칼리토르 사이언시즈, 엘엘씨 Substituted quinoline compounds and methods of use
UA114900C2 (en) 2011-11-14 2017-08-28 Ігніта, Інк. Uracil derivatives as axl and c-met kinase inhibitors
WO2013162061A1 (en) * 2012-04-26 2013-10-31 第一三共株式会社 Bicyclic pyrimidine compound
EP3184121A3 (en) 2012-07-25 2017-09-27 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
TWI649308B (en) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 Quinoline derivative
JP6527513B2 (en) 2013-11-20 2019-06-05 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Quinazoline derivatives as TAM family kinase inhibitors
CN105764514B (en) 2013-11-27 2019-07-12 圣诺康生命科学公司 Aminopyrazole derivatives as TAM race kinase inhibitor
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2016104617A1 (en) 2014-12-25 2016-06-30 小野薬品工業株式会社 Quinoline derivative
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
CN106279147A (en) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 A kind of pyrido nitrogen heterocyclic and its production and use
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
CN106467541B (en) 2015-08-18 2019-04-05 暨南大学 Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
WO2017059280A1 (en) * 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
JP6885390B2 (en) 2016-02-26 2021-06-16 小野薬品工業株式会社 A drug for the treatment of cancer, which comprises administering a combination of an Axl inhibitor and an immune checkpoint inhibitor.
EP3423452A4 (en) * 2016-03-01 2019-10-30 University of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
JP7034084B2 (en) * 2016-03-28 2022-03-11 インサイト・コーポレイション Pyrrolotriazine compounds as TAM inhibitors
WO2018028591A1 (en) 2016-08-09 2018-02-15 殷建明 Quinoline derivative and use thereof
CN108069938A (en) * 2016-11-15 2018-05-25 中国药科大学 2,4- disubstituted pyridines and its preparation method and application
AU2018211801B2 (en) 2017-01-26 2021-07-08 Ono Pharmaceutical Co., Ltd. Ethane-sulfonate salt of quinoline derivative
CN110612295B (en) * 2017-05-11 2023-07-14 组合化学工业株式会社 Pyrazole-3-carboxylic acid amide derivative and pest control agent
JP7156287B2 (en) 2017-08-23 2022-10-19 小野薬品工業株式会社 Cancer therapeutic agent containing an Axl inhibitor as an active ingredient
TWI821200B (en) 2017-09-27 2023-11-11 美商英塞特公司 Salts of tam inhibitors
EP3695839A4 (en) 2017-10-13 2021-07-14 ONO Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which contains axl inhibitor as active ingredient
CN109896997A (en) * 2017-12-08 2019-06-18 中国药科大学 The preparation method and its usage of N- anilid class c-Met kinase inhibitor
MX2021000127A (en) 2018-06-29 2021-03-29 Incyte Corp Formulations of an axl/mer inhibitor.
KR20210142154A (en) 2019-03-21 2021-11-24 옹쎄오 DBAIT molecules in combination with kinase inhibitors for the treatment of cancer
AR119069A1 (en) * 2019-06-04 2021-11-24 Exelixis Inc COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS
US20220235064A1 (en) * 2019-08-02 2022-07-28 Wellmarker Bio Co., Ltd. Oxo-pyridine fusion ring derivative and pharmaceutical composition comprising same
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
TW202333709A (en) 2021-12-16 2023-09-01 美商奇奈特生物製藥公司 Inhibitors of met kinase

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017329A1 (en) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
WO2001021596A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
WO2003033472A1 (en) 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
US20040053908A1 (en) 2000-10-20 2004-03-18 Yasuhiro Funahashi Nitrogen-containing aromatic derivatives
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
WO2005070891A2 (en) 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
WO2006004636A2 (en) 2004-06-28 2006-01-12 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2006116713A1 (en) 2005-04-27 2006-11-02 Amgen Inc. Substituted amide derivatives as protein kinase inhibitors
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007099326A1 (en) 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
WO2007146824A2 (en) 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
US20080004273A1 (en) 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
WO2008022013A1 (en) 2006-08-11 2008-02-21 Allergan, Inc. Kinase inhibitors
WO2008150015A1 (en) 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
WO2009108670A1 (en) 2008-02-28 2009-09-03 Merck Serono S.A. Protein kinase inhibitors and use thereof
WO2009127417A1 (en) 2008-04-16 2009-10-22 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as axl kinase inhibitors
JP2011063516A (en) 2009-09-15 2011-03-31 Daiichi Sankyo Co Ltd Amide derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2256654C2 (en) * 1999-01-22 2005-07-20 Кирин Бир Кабусики Кайся Quinoline and quinazoline derivatives
US8163923B2 (en) * 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017329A1 (en) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
WO2001021596A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
US20040053908A1 (en) 2000-10-20 2004-03-18 Yasuhiro Funahashi Nitrogen-containing aromatic derivatives
WO2003033472A1 (en) 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
WO2005070891A2 (en) 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
WO2006004636A2 (en) 2004-06-28 2006-01-12 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2006116713A1 (en) 2005-04-27 2006-11-02 Amgen Inc. Substituted amide derivatives as protein kinase inhibitors
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007099326A1 (en) 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
US20080004273A1 (en) 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
WO2008035209A2 (en) 2006-05-30 2008-03-27 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2007146824A2 (en) 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
US20110053931A1 (en) 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
WO2008022013A1 (en) 2006-08-11 2008-02-21 Allergan, Inc. Kinase inhibitors
WO2008150015A1 (en) 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
WO2009108670A1 (en) 2008-02-28 2009-09-03 Merck Serono S.A. Protein kinase inhibitors and use thereof
WO2009127417A1 (en) 2008-04-16 2009-10-22 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as axl kinase inhibitors
JP2011063516A (en) 2009-09-15 2011-03-31 Daiichi Sankyo Co Ltd Amide derivative

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
International Search Report for PCT/EP2011/004451 mailed on Oct. 5, 2011.
Written Opinion for PCT/EP2011/004451 mailed on Oct. 5, 2011.

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9481668B2 (en) 2013-06-06 2016-11-01 Merck Patent Gmbh Quinoline inhibitor of the macrophage stimulating 1 receptor MSTR1
US20180093968A1 (en) * 2015-04-14 2018-04-05 Qurient Co., Ltd. Quinoline derivatives as tam rtk inhibitors
US10934274B2 (en) * 2015-04-14 2021-03-02 Qurient Co., Ltd. Quinoline derivatives as TAM RTK inhibitors
US20210163448A1 (en) * 2018-05-30 2021-06-03 Qurient Co., Ltd. Quinoline derivatives as inhibitors of axl/mer rtk and csf1r
US10851093B2 (en) * 2018-06-01 2020-12-01 Rigel Pharmaceuticals, Inc. Tyrosine kinase inhibitors
US20210078990A1 (en) * 2018-06-01 2021-03-18 Rigel Pharmaceuticals, Inc. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
KR20130084291A (en) 2013-07-24
EP2609091A1 (en) 2013-07-03
AU2011297889B2 (en) 2015-12-24
CA2807620C (en) 2016-05-17
ES2530492T3 (en) 2015-03-03
WO2012028332A1 (en) 2012-03-08
AU2011297889A8 (en) 2013-06-06
EP2423208A1 (en) 2012-02-29
JP2013536813A (en) 2013-09-26
SG187597A1 (en) 2013-03-28
RU2573834C2 (en) 2016-01-27
ZA201300533B (en) 2014-03-26
CN103124729B (en) 2016-01-20
MY158494A (en) 2016-10-14
US20140018365A1 (en) 2014-01-16
DK2609091T3 (en) 2015-01-12
BR112013004368A2 (en) 2017-06-27
CA2807620A1 (en) 2012-03-08
WO2012028332A8 (en) 2013-03-07
KR101624296B1 (en) 2016-05-25
EP2609091B1 (en) 2014-11-26
RU2013113733A (en) 2014-10-10
CN103124729A (en) 2013-05-29
HK1185879A1 (en) 2014-02-28
MX2013002289A (en) 2013-10-28
AU2011297889A1 (en) 2013-02-21
JP5843861B2 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
US8999982B2 (en) Pharmaceutically active compounds as Axl inhibitors
RU2750727C9 (en) Pharmacologically active compounds as inhibitors of the tam family receptor tyrosine kinase
RU2632900C2 (en) Heterocyclic amines and their application
US9382232B2 (en) Quinoline and cinnoline derivatives and their applications
RU2686323C2 (en) Novel compounds and compositions for inhibition of fasn
US9353062B2 (en) Substituted quinolines as bruton's tyrosine kinases inhibitors
AU2017200232A1 (en) Combination therapy
KR20090120483A (en) Spiro substituted compounds as angiogenesis inhibitors
KR20140016889A (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors
KR102093848B1 (en) Anti-cancer compounds targeting ral gtpases and methods of using the same
JP2014122161A (en) Pyrazole compounds
JP2013067595A (en) Pyrazoloquinolinone derivative, preparation thereof, and therapeutic use thereof
WO2019224774A1 (en) Heterocyclic amides as rip1 kinase inhibitors
US9765072B2 (en) 1H-1,8-naphthyridin-2ones as anti proliferative compounds
IL293388A (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
CN116751162A (en) Quinoline compound, preparation method thereof, pharmaceutical composition and medical application
EA045526B1 (en) BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5

Legal Events

Date Code Title Description
AS Assignment

Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHULTZ-FADEMRECHT, CARSTEN;KLEBL, BERT;CHOIDAS, AXEL;AND OTHERS;REEL/FRAME:029888/0406

Effective date: 20130212

Owner name: LEAD DISCOVERY CENTER GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHULTZ-FADEMRECHT, CARSTEN;KLEBL, BERT;CHOIDAS, AXEL;AND OTHERS;REEL/FRAME:029888/0406

Effective date: 20130212

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8